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vWhat is a Witness seMinar?
The Witness Seminar is a specialized form of oral history, where several 
individuals associated with a particular set of circumstances or events are invited 
to meet together to discuss, debate, and agree or disagree about their memories. 
The meeting is recorded, transcribed and edited for publication. 
This format was first devised and used by the Wellcome Trust’s History of 
Twentieth Century Medicine Group in 1993 to address issues associated with 
the discovery of monoclonal antibodies. We developed this approach after 
holding a conventional seminar, given by a medical historian, on the discovery 
of interferon.  Many members of the invited audience were scientists or 
others involved in that work, and the detailed and revealing discussion session 
afterwards alerted us to the importance of recording ‘communal’ eyewitness 
testimonies. We learned that the Institute for Contemporary British History 
held meetings to examine modern political, diplomatic and economic history, 
which they called Witness Seminars, and this seemed a suitable title for us to 
use also. 
The unexpected success of our first Witness Seminar, as assessed by the 
willingness of the participants to attend, speak frankly, agree and disagree, and 
also by many requests for its transcript, encouraged us to develop the Witness 
Seminar model into a full programme, and since then more than 50 meetings 
have been held and published on a wide array of biomedical topics.1 These 
seminars have proved an ideal way to bring together clinicians, scientists, and 
others interested in contemporary medical history to share their memories. We 
are not seeking a consensus, but are providing the opportunity to hear an array 
of voices, many little known, of individuals who were ‘there at the time’ and 
thus able to question, ratify or disagree with others’ accounts – a form of open 
peer-review. The material records of the meeting also create archival sources for 
present and future use.
The History of Twentieth Century Medicine Group became a part of the 
Wellcome Trust’s Centre for the History of Medicine at UCL in October 
2000 until September 2010. It has been part of the School of History, Queen 
Mary, University of London, since October 2010, as the History of Modern 
Biomedicine Research Group, which the Wellcome Trust funds principally 
1 See pages 143–8 for a full list of Witness Seminars held, details of the published volumes and other related 
publications.
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under a Strategic Award entitled ‘The Makers of Modern Biomedicine’. The 
Witness Seminar format continues to be a major part of that programme, 
although now the subjects are largely focused on areas of strategic importance 
to the Wellcome Trust, including the neurosciences, clinical genetics, and 
medical technology.2
Once an appropriate topic has been agreed, usually after discussion with 
a specialist adviser, suitable participants are identified and invited. As the 
organization of the seminar progresses and the participants’ list is compiled, a 
flexible outline plan for the meeting is devised, with assistance from the meeting’s 
designated chairman/moderator. Each participant is sent an attendance list and 
a copy of this programme before the meeting.  Seminars last for about four 
hours; occasionally full-day meetings have been held. After each meeting the raw 
transcript is sent to every participant, each of whom is asked to check his or her 
own contribution and to provide brief biographical details for an appendix. The 
editors incorporate participants’ minor corrections and turn the transcript into 
readable text, with footnotes, appendices and a bibliography. Extensive research 
and liaison with the participants is conducted to produce the final script, which 
is then sent to every contributor for approval and to assign copyright to the 
Wellcome Trust. Copies of the original, and edited, transcripts and additional 
correspondence generated by the editorial process are all deposited with the 
records of each meeting in the Wellcome Library, London (archival reference 
GC/253) and are available for study.
For all our volumes, we hope that, even if the precise details of the more 
technical sections are not clear to the non-specialist, the sense and significance 
of the events will be understandable to all readers. Our aim is that the volumes 
inform those with a general interest in the history of modern medicine and 
medical science; provide historians with new insights, fresh material for study, 
and further themes for research; and emphasize to the participants that their 
own working lives are of proper and necessary concern to historians.
2 See our Group’s website at http://www.history.qmul.ac.uk/research/modbiomed  (visited 13 August 2013).
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introduCtion
How different it all was…
I am sorry I could not make it to this meeting, which sounds as if it was a great 
occasion, but in spite of all the advances of science, Australia is as far away 
from London as ever. However, I still get great pleasure from spending a lot of 
my time talking to, and mentoring, really bright young researchers working in 
human molecular genetics. It is not easy to convey to them how different things 
were 40-plus years ago, when the field was young. While there is a tradition in 
clinical genetics going back over 100 years (particularly to Garrod in London, as 
well as others), beautifully described by Peter Harper in his recent book A Short 
History of Medical Genetics, there was none in human molecular genetics.1 The 
doyens of biochemistry, like J Norman Davidson (Glasgow),2 characterized 
molecular biology as ‘biochemistry practised without a licence’, and make no 
mistake, he intended to make sure we were forced off the road.3 Perhaps more 
surprising, some of the most senior traditional geneticists, from Lionel Penrose 
(University College London) to John Edwards (Oxford), had no sympathy with 
DNA; they disliked Crick and Watson personally, and made it clear that their 
superior understanding of both statistics and phenotype was the pre-requisite for 
entry into the field. There were exceptions: I remember J B S Haldane (Professor 
of Biometry, University College London) being pro-Crick and Watson, and 
always intellectually open and willing to discuss new ideas with the very young 
undergraduate I was at the time, as was Peter Medawar (also UCL, Professor 
of Zoology until 1962), but not the Professor of Biochemistry, Ernest Baldwin, 
who refused to acknowledge anything that diminished the role of proteins. 
We had so much more time to talk and think…
Recalling these days does, remind me, however, of what is perhaps the biggest 
difference: we all seemed to have so much more time. I went out for a beer 
with the most senior staff, not only Haldane but also John Maynard-Smith, 
David Newth, Anne McLaren, John Paul, Pat Clarke, all manner of super-good 
intellects who had the time and the kindness to talk to us students as if we really 
1 Harper (2008). 
2 For the frequent biographical references made throughout this introduction, the reader is referred to 
standard biographical sources such as Who’s Who, Biographical Memoirs of the Royal Society or specific 
internet searches. 
3 For the quotation, see Campbell (1992). 
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might understand the science they discussed. This was true for clinicians as well; 
long before I met David Weatherall in 1974, I knew John Dacie (Hammersmith), 
Tom Prankerd (UCH) and Sheila Sherlock (Royal Free); once again, they were 
ever-generous with their time, and not only to me. Robin Weiss and Ian Healey 
and Tony Trewarvas and Patsy Ingold were my contemporaries, and they too 
benefited. How sad we are all so busy today; I fear this does not happen now as 
it did then. 
International links…
Several of the participants in the seminar mentioned the wonderful meeting 
that I organized in Crete in 1978, the best meeting I ever attended as well 
(Appendix 1). Part of the reason it was so good is that EVERY participant was 
there for the whole 12 days. All fares and expenses for the 80 people were paid, 
but the condition was that you stayed for the duration. It also was the first 
meeting to which young scientists from Italy, Greece, Saudi Arabia, Thailand 
and Africa were invited to come and participate as equals with the Americans 
and Brits who were doing most of the talking – many collaborations were started 
there that continued for decades. The WHO, with Bernadette Modell playing 
a major role, was also present at the meeting in Crete, and continued to fund 
workshops to introduce the molecular genetics of thalassaemia in developing 
countries for many years.
We were so much more idealistic…
A lot of us were radical, and politically active (and a lot of science was talked 
on the ‘Ban-the-Bomb’ marches to and from Aldermaston).4 Even those who 
weren’t political still grew up in an environment of great hopes, and fears, for 
the future. Everyone I knew was interested in the social uses and values of 
science, and what we found from our research was immediately interrogated as 
to its usefulness. Socially, it was a time when we shared a lot more than happens 
today: no one patented anything. Indeed, when the CF gene was located to 
chromosome 7 simultaneously by my group at St Mary’s London, and by 
Lap-Chee Tsui in Toronto and Ray White in Salt Lake City, we were horrified 
when a commercial company popped up with its infamous claim: ‘We own 
chromosome 7’. The start of the nightmare! 
4 The Atomic Weapons Establishment in Aldermaston, Berkshire; a target for opponents to nuclear 
weapons since 1958, for instance through the Campaign for Nuclear Disarmament’s ‘Ban-the-Bomb’ Easter 
marches. See, for example, http://www.cnduk.org/about/item/437 (visited 23 October 2013). 
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Technology was hard, ideas easy…
We did have an advantage, though: the technology was really difficult, so it was 
easy to talk about ideas. For instance, when my group in Glasgow was working 
with David Weatherall and Bernadette Modell to determine if alpha-thalassaemia 
is due to a gene deletion, it took my post-doc Sergio Ottolenghi NINE MONTHS 
to make enough alpha-globin gene probe to do the experiment (this was before 
gene cloning, and before PCR). We knew we could talk about it with impunity; 
very few groups could attempt such an experiment (apart from that of YW Kan, 
who came up with a similar result and published side by side with us in Nature). I 
often think it is now the opposite. The technology has become so simple teenagers 
do PCR-based gene analysis experiments in secondary school, but ideas are few 
and far between.
There were unsung heroes…
It is easy to criticize the very English, male-dominated and hyper-intellectual 
world of the 1960s and 1970s, when human molecular genetics was first being 
established in the UK. There were some remarkable unsung heroes as well. 
In Edinburgh, groups around some unlikely and quite eccentric individuals 
flourished: Martin Pollack and Bill Hayes, Peter Walker and Ed Southern, 
Anne McLaren and Ruth Clayton were wonderful. So too were people in MRC 
headquarters like Tony Vickers, who consistently supported human molecular 
genetics, Sir Gordon Wolstenholme at the Ciba Foundation, Bridget Ogilvie at 
the Wellcome Trust, and a few others. When the Wellcome Trust blossomed, it 
created a genetics panel under, I think, David Weatherall that operated in a very 
adventurous, almost futuristic way. Without this support, human molecular 
genetics would have died in the same ditch that clinical biochemistry found itself 
in (but that bit of history, of the demise of much of British pathology, is another 
story, for another time). Some of the clinicians, in particular Peter Harper, were 
extremely generous in making their ‘collections’ of patients available for study, 
and I learned that a good and trusted clinician like Peter is able to count on 
support from his patients and their families. On one occasion, Peter got samples 
from 30 families with DMD in less than a week – a truly outstanding tribute to 
the affection with which his patients embraced him.
And it was all so much fun…
Was it because we were all younger; the field was very non-hierarchical, it was 
new and we were all so excited to be there; we were more radical, or we thought 
we were breaking original ground? Whatever the reason, it was terrific fun. 
xviii
But it also was fun for other reasons – we had tea and coffee in the labs, beers 
in the student bar after 5pm (and then back up to work), and we all worked 
weekends (but also took time off whenever we wanted, during the week). We 
all shared data, our own and other people’s data, and never thought there was 
anything wrong with this. The university helped by making funding available 
(‘to those who hath shall be given’), and the obsessive worry about health and 
safety that has segued into foolish rules had not yet happened – no one ever 
caught anything from drinking tea or coffee in the lab that I can remember. 
Indeed, I feel rather guilty that I helped to establish the environment within 
which these rules were established, through the Gene Manipulation Advisory 
Group, a government committee that met for about 15 years to establish ways 
to deal with a fictional problem. It is astonishing that about 20 of the brightest 
minds in the UK deliberated for so long how to contain recombinant DNA 
species biologically and physically, without noticing there were no problems, no 
‘sentinel cases’, at all! 
And on to today…
The reason why Jim Watson’s book The Double Helix is so good is because 
it portrays with a fair degree of accuracy the three sides of the triangle that 
I remember so well from the start of human molecular genetics. First, the 
long periods of talk, of chat, even of boredom, of trying to master material 
that others thought was important but you suspected was not. Second, the 
incredible excitement at thinking in a new interdisciplinary way and turning 
them into practice: being the first to demonstrate that alpha-thalassaemia is 
due to a gene deletion; showing how the globin genes are organized, proving 
that cystic fibrosis is due to mutations in one gene, that was only located and 
identified using the new techniques that I helped to develop. And third, just 
how much fun it all was. I hope that some of our students and post-docs have 
every bit as much fun with their projects today!
 
Figure a: Professor Bob Williamson
Melbourne, August 2013
CliniCal MoleCular GenetiCs  
in the uk c.1975–c.2000
The transcript of a Witness Seminar held by the History  
of Modern Biomedicine Research Group, Queen Mary,  
University of London, on 5 February 2013
edited by e M Jones and e M tansey
2CliniCal MoleCular GenetiCs  
in the uk c.1975–c.2000 
 
Participants*
apologies include: Professor Dame Kay Davies, Professor Sue Malcolm, 
Professor Christopher Mathew, Professor Marcus Pembrey, Professor David 
Porteus, Mr Paul Rutland, Professor Tom Strachan and Professor Bob 
Williamson. 
* Biographical notes on the participants are located at the end of the volume
Professor Bert Bakker 
Professor Martin Bobrow (Chair)
Dr Rob Elles 
Professor Malcolm Ferguson-Smith 
Professor Peter Harper 
Professor Pat Jacobs 
Mr Laz Lazarou
Dr Ian Lister Cheese 
Dr Fiona Macdonald 
Dr Linda Meredith
Dr Helen Middleton-Price 
Professor Bernadette Modell 
Dr John Old 
Professor Andrew Read
Professor Julian Sampson
Dr Rosalind Skinner
Professor Tilli Tansey
Professor Sir David Weatherall 
Professor John Yates
Clinical Molecular Genetics in the UK c.1975–c.2000
3
Professor tilli tansey:  Can I begin very promptly please and welcome you all 
to this Witness Seminar on Clinical Molecular Genetics. I’m Tilli Tansey and 
I run the History of Modern Biomedicine Research Group, which is now at 
Queen Mary University of London. This began several years ago under the 
auspices of the Wellcome Trust who, thankfully, continue to fund us. We try 
to get together groups of people who have been involved in particular debates 
or discoveries to discuss among themselves what really happened; not just the 
dry record you find in the scientific literature but the stories behind the scenes, 
what happened, what didn’t happen, who made things happen? Not necessarily 
the most famous people and stories that one knows of. So the purpose of this is 
to talk among yourselves, led by our Chairman, and everything is going to be 
recorded, edited and published, and will be freely available to download from 
our website.1 Nothing you say will be published without your permission. 
We’ve held several meetings on various aspects of clinical genetics, and now 
under the auspices of a new Strategic Award from the Wellcome Trust we’re 
going forward for another five years to look at a big project on the Makers of 
Modern Biomedicine. One major theme of that is focused on genetics, for which 
we have a consultant adviser who is Peter Harper, and Peter and Andrew Read 
have advised us a great deal on setting up this meeting, as has our Chairman 
Martin Bobrow. I’m delighted to welcome Martin because he is a glutton for 
1 See http://www.history.qmul.ac.uk/research/modbiomed/wellcome_witnesses/index.html (visited 14 May 
2013). 
Figure 1:  Professor tilli tansey
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punishment; I think this is either the third or the fourth meeting that he’s 
chaired for me, as well as contributing to several others. He is going to keep you 
all in order but also try and prompt reminiscences and we’re so delighted that 
you could come, Martin. Thank you so much. So over to you.
Professor Martin Bobrow:  Thank you, Tilli. I think I know pretty well everyone, 
which is a very rare event for me. For those who haven’t been involved before: 
 these meetings are different. They’re a cross between science, history and a 
revivalist meeting so you must feel free to get up and declaim things you believe 
to be true, and things you remember clearly, and want to be written down, 
even if it’s not easy to document. The essence of this is capturing what is in the 
collective memory of groups of people who have been involved in ventures of 
this sort:  ventures like getting molecular diagnostics going in the UK and in 
continental Europe. I thought it would help to set some background if I asked 
Peter Harper to briefly outline which other meetings of this sort have been held 
or are in planning on related topics, because that will help us collectively to steer 
away from talking about things that are going to be covered elsewhere. 
Professor Peter harper:  Thank you, Martin. Yes, obviously human molecular 
genetics is a huge area and so we had, not problems, but it was quite difficult to 
decide what not to include. Some of this was made a bit easier by the fact that 
we have had other Witness Seminars in this broad field, including the original 
one on genetic testing, then one on clinical genetics and, most recently, one 
Figure 2: Professor Martin Bobrow
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on clinical cancer genetics.2 So that has taken part of the load. We also decided 
from the beginning not to try and cover basic molecular research; that would 
clearly have been impossible – likewise not the Human Genome Project.3 
Also, there’s a plan that we may have a separate seminar on the Human Gene 
Mapping Workshops, which I think really are areas deserving in their own 
right.4 Then we also thought we would make a cut-off around the time when 
whole-genome sequencing started to come in and not to cover that very rapidly 
developing area. So this in part explains why some of the seemingly very obvious 
topics are not on the list today. Hopefully that will give us a bit more time to 
deal with the beginnings of the subjects which are on the outline programme 
(Table 1).
Professor Malcolm Ferguson-smith:  Sorry to make a rude interjection. I’d like 
to make sure that when we consider the whole area of genetics in the United 
Kingdom, we don’t exclude Scotland because I’d like to ensure that this is not 
just about England and Wales; this is about the whole of Great Britain.
2 Christie and Tansey (eds) (2003); Harper et al. (eds) (2010); Jones and Tansey (eds) (2013). 
3 For key historical materials on the development of genetics during the twentieth century, see Codebreakers: 
Makers of Modern Genetics, an online resource of primary archival materials hosted by the Wellcome Library 
from scientists who made landmark breakthroughs: http://wellcomelibrary.org/using-the-library/subject-
guides/genetics/makers-of-modern-genetics (visited 17 June 2013). 
4 A Witness Seminar on Human Gene Mapping Workshops is scheduled for March 2014, in consultation 
with Professor Ian Craig and Professor Sue Povey. 
Figure 3: Professor Malcolm Ferguson-smith (left), Professor Peter harper (right)
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technological advances 
haemoglobin and its disorders
First service applications; haemoglobin disorders 
Positional cloning: From gene mapping to gene isolation; dna polymorphisms
The X chromosome; Duchenne muscular dystrophy 
Cystic fibrosis; trinucleotide repeat disorders; other autosomal conditions
Cancer genetics/molecular testing 
Molecular cytogenetics 
Beginnings of a clinical molecular genetics service: 
Department of Health Three Centres Study 
Scottish Molecular Genetics Consortium 
The Netherlands’ experience
the uk Clinical Molecular Genetics society 
From linkage to mutation: detection and sequencing
table 1: outline programme for Clinical Molecular Genetics in the UK c.1975–c.2000.
5
 
Bobrow:  This is the whole of Great Britain. Scots people unfortunately did not 
find it possible to fit us into their busy diaries. A lot of people were approached, 
some of whom just couldn’t make the day, some of whom don’t travel much any 
more, and some of whom don’t travel at all any more. It’s the nature of history.
Ferguson-smith:  We mustn’t forget about them.
Bobrow:  No, no; you’re here to remind us. Okay. So the next thing I want to 
say before we kick off is that there is a tentative programme in front of you but 
it is very tentative. We’re going to start off on technological enabling advances. 
We’ll handle all of that science development first and then go through disease 
areas very broadly, But this is extremely rough and if people want to stray across 
boundaries, feel free. And if we stray from that order, it doesn’t matter. So let’s 
start off on underpinning technology and the science. 
Professor andrew read:  I was trying to delve back through my deepest, 
foggiest memories and they start, I guess, in about 1961. I did my PhD from 
1961 to 1964 in Cambridge, in Todd’s department where of course nucleic acid 
5 A draft outline programme was circulated to seminar participants to comment on a month in advance of 
this meeting. Table 1 is the final version of that programme, used as a framework for this seminar. 
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chemistry was the big thing.6 And I did my PhD on attempting to get a method 
to sequence RNA by putting it through a series of chemical reactions that 
knocked off the 3-prime nucleotide, which you could identify, and then you 
carried on with the next nucleotide. Of course, everything depended on getting 
a good quantitative yield at each stage, otherwise you rapidly got everything 
out of sync; so I spent most of my time trying to do that. I remember Fred 
Sanger came to my PhD seminar and he had only one question, which was, 
‘Does it work?’ At that time I thought, ‘Oh dear, how unintellectual of him.’ 
[Laughter] I was interested in the beta elimination reaction and the niceties 
of which amine worked best. I now realise that was part of the reason why he 
has Nobel Prizes and I don’t.7 If you think what the state of the art was back in 
6 The department was that of Lord Todd (1907–1997), Chair of Organic Chemistry at Cambridge 
(1944–1971) and Nobel Laureate for Chemistry in 1957. His obituary from the Royal Society and entry 
in the Oxford Dictionary of National Biography are available at: http://www.royalsoced.org.uk/cms/files/
fellows/obits_alpha/todd_lord.pdf and http://www.oxforddnb.com/view/article/64697 (websites visited 
17 June 2013).
7 Double Nobel Laureate, Dr Frederick Sanger (1918–2013) led the group that produced the first whole-
genome sequence. See http://www.sanger.ac.uk/about/people/biographies/fsanger.html (visited 14 May 2013). 
Sanger was awarded the Nobel Prize for chemistry in 1958 (sequencing of insulin) and in 1980, with Paul 
Berg and Walter Gilbert (recombinant-DNA). See Frederick Sanger – Autobiography. http://www.nobelprize.
org/nobel_prizes/chemistry/laureates/1980/sanger-autobio.html (visited 14 May 2013). 
Figure 4: Professor andrew read (left), Professor Peter harper (right)
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those days, well, we’d had Watson and Crick. From about 1960, one had some 
picture of transcription and messenger RNA;8 the genetic code was, I think, 
the big Holy Grail at that time. I remember Paul Zamecnik was working in the 
laboratory then and everybody held him a little bit in awe.9 It was around about 
1963 through to 1966 that the genetic code got worked out so, by the time I 
had finished my PhD, one had quite a decent picture of the DNA-gives-RNA-
gives-protein, almost entirely in bacteria and phage.10 Although, of course, there 
was the work from Pauling and Ingram et al. on sickle cell, which others will be 
more qualified to talk about than I am.11 
Now, at that point I left this area and wandered off in various directions and 
resurfaced in genetics when I joined the Medical Genetics Department in 
Manchester in 1977. If you look at what had happened in the meantime, well 
the basic toolkit that set up clinical molecular genetics had been established 
in the 1970s. Restriction enzymes, I guess, were first properly described in 
1970 and by the mid-1970s there were actually a number of enzymes available 
commercially of good quality and reliable.12 So you had restriction enzymes, you 
had gel electrophoresis, of course. It was a starch gel electrophoresis that [Harry] 
Harris had been using back in the 1960s for protein polymorphisms, but for 
DNA variants I think it was in the early 1970s that people started using agarose 
gel electrophoresis.13 Other people may have better memories of that than me. 
Cloning had come about and probably 1972 to 1974 was the main time when 
people learnt to stitch together recombinant DNA, put it into a vector, clone it 
in bacteria.14 So by the mid-1970s you had clone libraries of DNA from humans 
and other organisms. The Southern blot, Southern’s key paper, was published in 
1975, although, of course, the way he did it then was very different to the way 
8 See, for example, Brenner et al. (1961). 
9 Dr Paul Zamecnik (1912–2009) played a key role in the discovery of both transfer RNA and antisense 
DNA. See his biographical memoir published by the National Academy of Sciences, USA, at http://www.
nasonline.org/publications/biographical-memoirs/memoir-pdfs/Zamecnik_Paul.pdf (visited 4 June 2013). 
10 See, for example, Witkowski (ed.) (2005). 
11 See, for example, Pauling et al. (1949) and Ingram (1957). 
12 See, for example, Smith and Wilcox (1970) and also Smith (1978).
13 Harry Harris (1919–1994) established the Medical Research Council Unit of Human Biochemical 
Genetics at King’s College, London, in 1962. He was Galton Professor of Human Genetics and Director 
of the Galton Laboratory (1965–1975). For agarose gel electrophoresis, see, for example, Laurell (1966).
14 Cohen et al. (1973). 
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it was done later.15 But that gave one a very crucial thing, I think, the ability to 
look at a specific sequence in complex DNA, like human DNA, provided you 
had the probe that could detect that sequence. 
Sanger sequencing emerged in about 1977, but that was very much a research 
tool because you’ve got to have cloned DNA to sequence, so it was never going 
to be part of diagnostic practice until you had some easy way of cloning the 
DNA of your patients without having to make libraries and screen them.16 It 
was a research technique for defining genes. By 1977 you had the toolkit there 
to isolate human DNA, to restrict and digest it, to look for specific sequences 
but absolutely everything hung on having probes for clinically useful genes. 
One only had one set of probes for clinically useful genes, which were the 
globins, so I think the story of clinical molecular genetics really starts with 
that globin work. Certainly I remember the Kan and Dozy paper of 1978.17 
That was the real wake-up call. I had joined the department in 1977 and I had 
a vague feeling that it was surely going to be useful to know something about 
DNA, but actually at that point there was nothing useful I could do with DNA. 
For the first three years I was in the department, I didn’t touch DNA at all. I 
did other things. Meanwhile, the people who worked with globin actually had a 
probe to detect a clinically useful gene and so I suggest we ask them what they 
did with it, if I’m allowed to set the agenda, Martin?
Bobrow:  I’d like to ask other people to comment on that, and on some of the 
developments a little subsequent to that. Two things that I would remind you: 
 first, we’re a group of people who happen to be around and are willing and able 
to come into a room to talk about it today. I think the more we mention the 
names of other people who aren’t here to talk for themselves, the easier it will be 
to tie things together. The mention of Kan and Dozy, and a few related things, 
brings to mind the story of prenatal diagnosis, because that was one of the very 
early points when the science of genetics hit the clinical tracks in a big way.18 
Although they’re not directly germane to today’s topic, I think making those 
links across would be helpful. 
15 Southern (1975). See also Southern’s biography on page 110. 
16 Sanger et al. (1977). See also Sanger and Coulson (1975). 
17 Kan and Dozy (1978a). For Professor Yuet Wai Kan, see also pages 19, 20–2, 24,  and his biography on 
page 105. 
18 See for example, Steele and Breg (1966); Lisgar et al. (1970); Davidson and Rattazzi (1972). See also 
note 78. 
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Professor Bert Bakker:  I remember a lot of things Andrew said. When I joined 
my department in the Netherlands in Leiden in 1977, almost the same time 
as you [Andrew, in Manchester], I was a technician in the lab of Peter Pearson 
and I worked the first years there with immunoprecipitation and other things. 
Around 1979 Peter came with the paper of Kan and Dozy and said, ‘Okay 
we need to find more of these types of polymorphisms – RFLPs (restriction 
fragment length polymorphisms) – and the unique probes to detect them. 
We need many of these RFLPs in the genome to follow genetic diseases in 
pedigrees.’19 But, at that time, there were no probes and we needed probes. For 
preparing those types of probes, we had to go a step back and first get human 
DNA. I got a placenta from the hospital and isolated human DNA from it to 
digest with a restriction enzyme. We needed lots of restriction enzyme, so I first 
had to grow the bacteria and isolate the enzyme, then digest the placental DNA, 
run it on a gel to see a nice smear, and then I ran a sucrose gradient to select 
fragments, of a certain size, and cloned these in a plasmid vector. We had some 
pieces of human DNA prepared in a few experiments. All this work I did in Mill 
Hill, in the MRC lab of Dick Flavell.20 With these probes, we could go back 
19 In 1972 Dr Peter Pearson was Head of the Human Genetics Department at Leiden University. He is now 
Co-Director of the National Institute for Stem Cell Research in Genetic Diseases, Sao Paolo, Brazil. See 
http://genoma.ib.usp.br/?page_id=1232&lang=en (visited 10 May 2013). 
20 Professor Richard Flavell was Head of the Laboratory of Gene Structure and Expression at the National 
Institute for Medical Research at Mill Hill, London; http://immunobiology.yale.edu/people/richard_
flavell-2.profile (visited 10 May 2013). Professor Bert Bakker wrote: ‘At that time it was not allowed in the 
Netherlands to clone pieces of human DNA in bacteria.’ Note on draft transcript, 19 May 2013. 
Figure 5: Professors Julian sampson (left), Bert Bakker (centre), John yates (right)
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to human DNAs on Southern blots. I had to isolate DNA from 30 different 
placentae, digest these DNAs, run them on gels after digestion with different 
enzymes – EcoRI, PstI, HindIII, BglII, and TaqI – all in-house and isolated 
from bacteria because these enzymes were too expensive to buy at that time so 
we needed to prepare them ourselves. With these probes hybridized to the blots, 
we could try to find RFLPs and to localize them on the genome. But first I had 
to select the unique clones, so I pulled the bacteria with human inserts from 
an agar plate onto a nitrocellulose filter and hybridized those with total human 
DNA. The clones that were not repetitive didn’t show up, so these ones were 
the ones that were ‘more unique’ and were used to hybridize against Southern 
blots to see if they showed a single EcoRI band. When a single band was seen, 
we knew, okay, this might be a unique probe and then hybridized them against 
other restriction enzyme digests to see if we could find a RFLP similar to those 
around the globin genes in the paper of Kan and Dozy, which were the kind 
of things we were looking for. I found, for 23-odd probes, all types of RFLPs.21 
In 1981, this was presented at the Human Gene Mapping conference.22 One 
of these probes, L1.28, was later linked to Duchenne muscular dystrophy.23 
But before that, in 1982, we organized a course in Leiden, in the Netherlands, 
where people came from all over Europe to learn about this new technology: 
 Southern blotting, cloning and growing these probes, hybridizing and all the 
things needed to detect RFLPs as tools for genetic studies.24 Some 20 people 
were at the course, amongst whom were Andrew Read and, from Denmark, 
21 Professor Bert Bakker commented further: ‘At that time these probes detected 30 per cent of all known 
polymorphic DNA loci.’ Note on draft transcript, 19 May 2013. For a complete list of the probes involved 
in this discussion, see Bakker (1989), pages 17–30. 
22 Pearson et al. (1982). 
23 Davies et al. (1983). See also Professor Peter Harper’s comments on linkage analysis for DMD on 
pages  38–40. 
24 The postgraduate course was entitled Restriction Fragment Length Polymorphisms and Human Genetics, 
and took place from 19 to 30 July, 1982, at the University of Leiden. Professor Bert Bakker wrote: ‘It was an 
international (European) course with  tutors such as Ray White, Web Cavanee, Mark Skolnick (all from Salt 
Lake City, Utah, USA), and Peter Pearson and me from Leiden. Among the participants were Andrew Read 
(UK); Tobias Gedde Dahl (Norway); Jan Mohr (Sweden); Marianne Schwartz and John Philip (Denmark) 
and many others.’ Email to Ms Emma Jones, 23 July 2013. See Appendix 2 for a sample of the Leiden 
course laboratory manual. The full manual is deposited with the records of this seminar in the Wellcome 
Library at GC/253. 
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John Philip and Marianne Schwartz, so there were quite a few people interested 
in RFLPs at that time.25 We had a lot of probes that could be used for linkage 
and diagnosis.
25 Dr John Philip was a cytogeneticist at the Section of Clinical Genetics, Department of Obstetrics 
and Gynaecology, Rigshospitalet, Copenhagen, Denmark. Dr Marianne Schwartz worked as a scientific 
biochemist at the Metabolic Laboratory, Pediatric Department, University Hospital Copenhagen from 
1979 to 1991, then she became Head of the DNA Diagnostic Laboratory. She retired in 2009 and is now 
Professor Emerita at the same institution. These biographical details were confirmed in an email from 
Professor Marianne Schwartz to Ms Emma Jones, 29 July 2013.   
Figure 6: title page, laboratory manual for postgraduate course Restriction Fragment Length 
Polymorphisms and Human Genetics, university of leiden, 1982
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Bobrow:  Just to fill that in, Peter Pearson was in Leiden having gone from 
Oxford when the MRC Population Genetics Research Unit was closed.26 
Ferguson-smith:  The wonderful thing about these probes was that Peter 
Pearson, Bert and others made them available to everybody. They were sent out 
to all the departments who were working in the field and this was a tremendous 
advance. It cut out competition and made tremendous progress possible for 
Duchenne and many other X-linked conditions. People like Kay Davies,27 our 
group and other people could use these probes in family studies, in mapping 
and in positional cloning.
Bobrow:  Absolutely central point. 
dr John old:  I’d like to follow up on Andrew’s comments and go back to 
when I started. I did a PhD on transfer RNA in Liverpool from 1971 to 1974 
and while I was doing my PhD we had a departmental seminar from someone 
26 This unit was founded in 1958 and closed in 1974. See Landsborough Thomson (1987), page 364. 
27 See her biography on pages 101–2. See also an interview with Professor Dame Kay Davies by Professor 
Peter Harper at http://www.genmedhist.info/interviews/kay-davies-interview (visited 25 June 2013).
Figure 7: Professor Marianne schwartz (left), dr John Philip (right), leiden, 1982
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called Ed Ziff.28 He was from Sanger’s lab and it was all about the wonders of 
RNA sequencing and someone asked this pertinent question:  ‘Would DNA 
ever be sequenced?’ And he stood up and said, ‘No, it’s too complicated; we 
don’t have a handle on how to break it up like we do with RNA’, and everyone 
went away thinking RNA is the future. At that point Professor Weatherall was 
moving to Oxford and he wanted someone to work on RNA and thalassaemia 
patients and he offered me a post-doctoral position. So I moved to Oxford and 
started to prepare RNA from globin and I’d like to give Scotland a reference 
here, Malcolm, because one of the first things I had to do was to travel up to 
the Beatson Institute in Glasgow on a commuter basis, to Bob Williamson’s lab, 
to prepare reverse transcriptase, which was the key in those days for converting 
messenger RNA into cDNA. You couldn’t buy it: you had to spend two weeks 
making it with a long, complicated protein purification process. If you went 
up to Williamson’s lab and participated you could get your hands on a portion 
of reverse transcriptase and make cDNA. Then you could do lots of wonderful 
hybridization studies.29 Back in Oxford the technique was to find a thalassaemic 
patient who made only haemoglobin F and there was one in Stoke Mandeville 
Hospital who was a compound heterozygote, a beta zero/delta beta zero.30 This 
28 Old (1974). Ed Ziff worked in Frederick Sanger’s laboratory from 1973 to 1978; http://www.med.nyu.
edu/zifflab/Zifflab/Welcome.html (visited 14 May 2013). 
29 See, for example, Old et al. (1976). 
30 Ottolenghi et al. (1975). 
Figure 8: dr John old
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patient made only alpha globin messenger RNA (mRNA) and gamma globin 
messenger RNA, so basically if you took normal mRNA and made cDNA out 
of it you could back-hybridize this to mRNA from this patient. You would 
get double-stranded alpha and single-stranded beta and you could separate 
those on an hydroxyapatite column by chromatography and that gave you pure 
alpha, beta and then gamma cDNA probes. That really was the start, I think, 
of molecular genetics with purified probes:  all because the red cell is unique in 
that most of the mRNA is just one of two species. You can’t do that with other 
cells because you get hundreds and thousands of cDNAs. So that gave us a 
handle and then Southern blotting came along and we could start to use these 
probes with Southern blotting. Then, as Andrew said, cloning was developed, so 
instead of purified cDNA probes, people put clones into plasmids and purified 
them to 100 per cent and started to use those. Really, this technique was down 
to Bob Williamson’s lab. He later moved to St Mary’s in London and then to 
Melbourne. Bob was the driving force on that molecular side of things.
Bobrow:  That was a very good background. I think we should go straight to the 
globin story before everyone’s talked globin out before we get to you, David.
Professor sir david Weatherall:  There was quite a lot done before the 1970s. 
As I am sure most of you know, the major haemoglobin disorder, sickle cell 
anaemia, was first recognized just after Garrod’s great lecture.31 Thalassaemia 
was first described in 1925.32 The paper that everybody quotes as the beginning 
of molecular medicine was Pauling’s first description of the structure of sickle 
haemoglobin.33 He was on an overnight train with Bill Castle, the Boston 
haematologist, who told him that there was something unusual about the 
behaviour of sickle cells in bi-refringent light. This suggested to Pauling that 
there might be a structural change in sickle haemoglobin. At that time, moving 
boundary electrophoresis had just been invented so he went back to Caltech, 
built a machine and, with his colleagues, found that sickle haemoglobin moved 
in an electric field at a different rate to normal adult haemoglobin. The famous 
paper appeared in 1949: Sickle Cell Anemia, a Molecular Disease. I think that 
most people do not know that Pauling retracted this paper within three months 
31 Sir Archibald Edward Garrod (1857–1936) delivered a Croonian lecture at the Royal College of 
Physicians, London, in 1908, published as Garrod (1909). See also Weatherall (1992). 
32 Cooley and Lee (1925). See also Weatherall (2010a). 
33 For Pauling, see note 11 and Dunitz (1997).  
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of its publication.34 What he had done was to compare mixtures of the amino 
acid composition of sickle and normal haemoglobin but could not find any 
difference.35 The picture then moves to the UK. In 1951 Max Perutz produced 
his first X-ray pictures of haemoglobin with its pairs of alpha and beta chains.36 
Francis Crick and Max suggested to a young post-doc, Vernon Ingram,  because 
somebody had left some sickle cell blood in their laboratory by mistake, that it 
might be worth trying to determine its structure. Ingram tackled this problem 
using two-dimensional electrophoresis and chromatography, or protein 
fingerprinting as it was called, and found a single amino acid substitution 
difference between the two haemoglobins.37 This was a very under-estimated 
34 See the National Academy of Sciences (1950); Eaton (2003) and Weatherall (2010b). 
35 Sir David Weatherall wrote: ‘In retrospect it seems likely that his technology was just not sensitive enough 
because his first interpretation soon turned out to be correct.’ Note on draft transcript, 26 March 2013. 
36 Perutz (1951). 
37 Ingram (1957). Sir David further commented: ‘In 1981 our group discovered two hypervariable regions 
flanking the alpha globin genes. The 5’ flanking region was later sequenced and it was found to consist 
of a tandemly repeated 36bp sequence. This sequence was also published in the first edition of my book 
The New Genetics and Clinical Practice. Alec Jeffreys told me it was after seeing this sequence and another 
hypervariable sequence published by an American team that he set off to see if there were related sequences 
in other parts of the human genome, work which led to the remarkable era of DNA fingerprinting.  Later 
our team, also using this genetic marker, found that the gene for polycystic disease of the kidney lay close 
to the alpha globin genes on chromosome 16.’ Edited from an email to Ms Emma Jones, 8 April 2013. See 
Higgs et al. (1981); Goodbourn et al. (1983) and Weatherall (1982). 
Figure 9: Professor sir david Weatherall
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paper because it took the concept of one-gene-one-enzyme to one-gene-one-
peptide chain and, incidentally, provided some of the first intimations of the 
nature of the genetic code. A few years earlier, two Italians reported patients 
who had inherited the sickle cell gene from one parent and thalassaemia from 
the other, a condition called sickle cell thalassaemia. It was later found that 
patients of this type had much less haemoglobin A than S.38 In the early 1950s 
some other unusual haemoglobin variants were found in patients with different 
forms of thalassaemia, some of which consisted of four beta chains, others of 
four gamma chains of fetal haemoglobin, suggesting that they might reflect 
defective alpha chain production. These and related observations were put 
together by Vernon Ingram and Anthony Stretton in 1959 in a theoretical paper 
in Nature, which suggested that there were two forms of thalassaemia, alpha and 
beta thalassaemia.39 
When I moved into the field in the early 1960s I realised that it would not 
move much further unless it was possible to actually measure the rates of 
production of the alpha and beta globin chains. I went as a post-doc to Johns 
Hopkins Hospital, Baltimore [from 1960 to 1965], and spent a year or more 
trying to measure haemoglobin synthesis in vitro and obtained linear synthesis 
over short periods because unless you were studying protein synthesis in this 
way, you may be looking at all sorts of artefacts. After a year or so I found a 
way of doing this.40 By chance I ran into John Clegg at this time – who was 
working in the Biophysics Department at Hopkins – and we discussed our 
research problems: I could not separate alpha chains and beta chains and he was 
having an equally difficult time trying to define the synthesis of insulin. During 
our conversations he remembered, from his thesis work in Cambridge, that he 
had been able to separate fibrinogen chains in 8 molar urea; the secret being 
to add mercaptoethanol to prevent their aggregation. This worked a dream 
with my labelled globin samples and we were able to show that the anaemia 
of thalassaemia is not so much due to defective haemoglobin production but 
is the result of unbalanced globin chain synthesis, the damage was done by the 
38 Professor Sir David Weatherall wrote: ‘Since the sickle mutation was in the β globin chain, this suggested 
that this form of thalassaemia might be due to a reduced amount of haemoglobin A, or β chain, production.’ 
Note on draft manuscript, 26 March 2013. 
39 Ingram and Stretton (1959). 
40 Professor Sir David Weatherall added: ‘I obtained unequal labelling of the globin chains from patients 
with thalassaemia but the methods for separating them were not quantitative.’ Note on draft transcript, 26 
March 2013. 
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chains that are produced in excess.41 The nice outcome of all this was that, using 
that method – and Bernadette will talk about this later, because she used it with 
her American colleagues – it became possible to carry out prenatal detection of 
thalassaemia by fetal blood sampling. By 1990 there had been close on 14,000 
prenatal diagnoses carried out globally using the globin synthesis technique.42 
John (Old) has already mentioned some of the molecular research tools that 
were developed in the early 1960s and 1970s, but before direct DNA analysis 
was possible we were able to characterize the molecular basis for at least two 
forms of thalassaemia. One was the tiny amount of variant alpha chain that was 
found in a family from Constant Spring, Jamaica.43 To cut a long story short, 
after we purified this fraction, we found that it was an alpha chain variant due to 
a mutation in the alpha globin gene chain termination codon. Thus this variant 
had an elongated alpha chain due to translation of mRNA which was not 
normally translated.44 This was rather nice because the group in Cambridge was 
sequencing alpha globin mRNA at the time, and we were able to give them the 
sequence they were going to find in advance, from the amino acid composition 
of the extended alpha chain variant. In the early 1970s we had found that babies 
who were stillborn with very severe alpha thalassaemia synthesized no alpha 
chains at all, raising the question of whether the alpha globin genes might be 
deleted. As John Old has told us, it became possible round about that time to 
synthesize complementary DNA, cDNA, on an alpha mRNA template.45 We 
did not know how to carry out this type of hybridization, so we approached 
John Paul’s group in Glasgow and suggested to him that if we could get material 
from one of these babies, and prove that the baby was not making alpha chains, 
and make cDNA, we could test the hypothesis.46 He agreed and put two of his 
41 Weatherall et al. (1965). 
42 Alter (1990). 
43 Professor Sir David Weatherall wrote: ‘A family was referred to us by Paul Milner from Jamaica with a 
relatively severe form of α thalassaemia in which a tiny amount of variant haemoglobin was present which 
was later called haemoglobin Constant Spring after the name of the suburb of Kingston in which the family 
lived.’ Note on draft transcript, 26 March 2013. 
44 Professor Sir David Weatherall elaborated: ‘Hence this variant was produced at a markedly reduced rate 
and caused the phenotype of α thalassaemia.’ Note on draft transcript, 26 March 2013. 
45 Professor Sir David Weatherall wrote: ‘And so we thought it might be possible to use the cDNA probes 
of this type to see if the α globin genes were present or absent in these babies.’ Note on draft transcript, 
26 March 2013. 
46 Dr John Paul (1922–1994) was Founding Director of the Beatson Institute for Cancer Research, 
Glasgow. For an obituary, see Freshney (1994). 
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post-docs, Bob Williamson and Sergio Ottolenghi, on the project.47 Using this 
approach, in 1974, we found that these babies had complete deletion of both 
their alpha globin genes.48 In the Nature paper that followed this work we saw, 
much to our surprise, and annoyance, a similar paper with an identical finding 
from Y W Kan’s group.49 Like us, Kan did not know how to carry out this type 
of hybridization but he had gone for advice to Harold Varmus, in California, 
who was using this technique.50 They had carried out an identical experiment 
to us and got exactly the same result! So by the mid-1970s at least two forms of 
alpha thalassaemias had been defined at the molecular level. In the late 1970s 
the application of Southern blotting together with gene cloning allowed the 
further definition of the molecular basis of the alpha and beta thalassaemias.51 
There was the big problem of ‘everybody’s going to be working on the same 
damn mutations, with a lot of wasted work’. One of the major problems that 
arose was the considerable amount of work that was required for cloning the 
globin genes and many groups were finding the same molecular defect after 
all this work. This problem was solved by several groups, who found that the 
globin genes were highly variable in their structure and that different haplotypes 
were linked to different mutations. So already by the early 1980s, a large 
number of molecular forms of thalassaemia had been identified and I think 
John (Old) of our group, together with Bernadette’s group were probably the 
first to describe prenatal diagnosis of beta thalassaemia using chorionic villus 
sampling (CVS) for prenatal diagnosis.52 So that provides the background to the 
story of the period that we are discussing. Just one addition: in the early days 
of the haemoglobin field, we were able to start to understand the remarkable 
phenotypic heterogeneity of sickle cell anaemia and the different forms of 
47 Sergio Ottolenghi was based at the Beatson Institute for Cancer Research, Glasgow, Scotland 
(1973–1974) and is now Professor of Molecular Genetics at the University of Milano-Bicocca, Milan, Italy. 
48 Ottolenghi et al. (1974). 
49 Taylor et al. (1974). 
50 Dr Harold Varmus was Lecturer in the Department of Microbiology and Immunology (1970–1979), 
University of California, San Francisco, a Nobel Laureate in 1989 and Director of the National Institutes of 
Health, USA, from 1993 to 1996; http://profiles.nlm.nih.gov/ps/retrieve/Narrative/MV/p-nid/184 (visited 
30 May 2013). 
51 See note 15. 
52 See note 61 and pages 21–7. In addition to the account of how CVS developed in the following pages, a 
previous Witness Seminar on genetic testing held in 2001 also addressed this topic; see Christie and Tansey 
(eds) (2003), pages 43–9. 
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thalassaemia. In other words, we were able to ask the question: ‘You have the 
same mutation; why is the phenotype so different?’ I will not bore you with the 
findings of these studies now but I think it is still likely that these diseases are 
much better understood than any other monogenic diseases in terms of their 
phenotypic heterogeneity.53
Bobrow:  Fascinating. 
old:  Shall I just talk about the service development? I think the thing to remember 
is, it was very exciting times in those days. From the moment you could Southern 
blot and you had these pure probes, you could start to make restriction enzyme 
maps of the globin gene clusters, mainly the beta globin gene cluster. There were 
half a dozen groups worldwide all competing with each other to produce maps and 
each had a supply of patient material as well, sort of mutant maps, especially the 
deletional types of thalassaemia, which were the most revealing types of mutations.54 
You kept these maps to yourself a bit. Then in 1978, Bob Williamson – I think 
he was the prime mover in this – organized a two-week conference in Crete at a 
monastery in Kolimbari, and managed to get virtually everyone from these labs 
worldwide to attend this conference (Appendix 1). Being a monastery, the nearest 
place was Chania about 15 miles away, and it was on the coast. There were one or 
two little tavernas nearby so we were very isolated and it was perfect for discussing 
research and it was probably the best conference I’ve ever been to because we all 
had our own maps, we all swapped data and it was so inspiring to see all this data 
put together. It made me want to go home and really work on this. Y W Kan was 
at this meeting and for 13 days he sat on that Hpa-1 data; he didn’t reveal it. We all 
revealed our maps:  there were polymorphisms that we’d discovered but they didn’t 
exist in linkage disequilibrium so they were just different maps. On the very last 
day Kan produced this data about the Hpa-1 polymorphism being linked to the 
sickle gene in West Africans and it just blew everyone away. He was a showman. 
I’m sure he wouldn’t mind me calling him that because he loved to present data 
that way but it was a most impressive piece of data.55 As well as that paper in 1978, 
53 See Weatherall (1965). 
54 Dr John Old wrote: ‘The main groups were: Orkin in Boston (Orkin (1978)), Kan in San Francisco (Kan 
and Dozy (1978a)), Bank in New York (Mears et al. (1978)), Maniatis in Pasadena (Lawn et al. (1978)), 
Williamson in London (Flavell et al. 1978)), B Forget in New Haven (Tuan et al. (1979)) and D Weatherall 
in Oxford (Higgs et al. (1979)).’ Edited from a note on draft transcript, 2 August 2013. 
55 In the Witness Seminar on genetic testing, Professor Sir David Weatherall recalled: ‘It was something of 
a difficult talk because the speaker, Yuet Wei Kan, had left all his slides on the aeroplane and had to ad lib 
as he went along.’ Quotation from Christie and Tansey (eds) (2003), page 32. 
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he also published a paper using the Hpa-1 polymorphism for the very first prenatal 
diagnosis of sickle cell using amniotic fluid DNA, so that really kick-started 
the idea that you could do prenatal diagnosis with amniotic fluid DNA.56 In the 
same year Stuart Orkin’s group published a paper showing you could do alpha 
thalassaemia, alpha-0 as we know now, where you have all the genes deleted, and 
also delta beta thalassaemia, which is again a gene deletion.57 So by 1978 three 
different types of haemoglobinopathy had been diagnosed prenatally. The next 
step was in 1980. Again it was Y W Kan’s group and they published the first 
prenatal diagnosis of beta thalassaemia and this was a link between the BamH1 
polymorphism and the beta thalassaemia mutation that is common in Sardinia, 
the codon 39 mutation.58 By 1980, all the different haemoglobinopathies could 
be prenatally diagnosed. Then Kan’s group again, in 1981, showed a different 
method and this was the direct detection of mutation by a restriction enzyme.59 
Up to now it had been polymorphisms but Kan showed that the enzyme Dde1 
could recognize the sickle cell site by either cutting or not cutting the DNA. The 
problem with Dde1, was that it produced very small fragments, which were very 
hard to see on a Southern blot because they were maybe 30 to 40 bases long. 
But in 1982 Stuart Orkin’s group found and published the enzyme MstII which 
was much better; it gave much larger fragments – it was really easy to Southern 
blot.60 Our group published the first chorionic villus DNA diagnosis in 1982 and 
this was with Bernadette and the group at University College Hospital.61 In just 
six years, or less, we’d moved from no prenatal diagnosis with DNA, through 
amniotic fluid DNA diagnosis by linkage of RFLPs, and then direct mutation 
detection through to first trimester CVS diagnosis. 
Bobrow:  Great paradigm. 
Professor Bernadette Modell:  I’m glad you mentioned the meeting in Crete 
because what we’re moving on to now is the clinical application of the molecular 
methods that we’ve been talking about. From the clinician’s angle, the clinical 
application of any method is a multidisciplinary activity. I’d also like to 
56 Kan and Dozy (1978b). 
57 Orkin et al. (1978). 
58 Kan et al. (1980). 
59 Chang and Kan (1981). 
60 Orkin et al. (1982). 
61 Old et al. (1982). 
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emphasize the importance of meetings because when you’re a clinician, you’re 
not following all the basic science, but if you go to the right meeting and you 
meet the right person – who is longing to apply that science to help people 
– and you start talking to them, then you pick up on what the possibilities 
might be. So if you don’t mind me winding back to go through a process of 
development, we have to go back to 1974/5 when there was a meeting of the 
Cooley’s Anemia Foundation in the United States – a patients’ group that 
supported scientific meetings with an emphasis on the clinical applications of 
science.62 I attended this meeting, and David (Weatherall) was there, and Y W 
Kan produced a very important paper.63 Now, we’re talking about the early 
1970s when prenatal diagnosis was beginning to come in for neural tube defects, 
for Down’s syndrome and the paediatricians and the obstetricians were beginning 
to see that this really had a future.64 But I felt frustrated because, though I was 
62 Founded in the 1950s, in the USA, by Frank Ficarra – a parent of two children diagnosed with 
thalassaemia major – Cooley’s Anemia Foundation funds research into treatments and potential cures for 
the disorder; http://www.thalassemia.org/ (visited 20 June 2013). 
63 Mr Craig Butler, of Cooley’s Anemia Foundation, wrote: ‘Yuet Wai Kan presented on “Intrauterine 
Diagnosis of Thalassemia” at the Third Conference on Cooley’s Anemia, presented by the New York 
Academy of Sciences and the Cooley’s Anemia Foundation on April 9 to 10, 1973.’ Email to Ms Emma 
Jones, 17 May 2013. 
64 See note 18.
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always interested in the application of genetics in medicine, and as a young 
paediatrician I had picked up on the haemoglobin disorders as the most 
common, really common, disorders. I was also interested in culture, and we had 
a growing multi-ethnic society. As I had a family and couldn’t travel very much 
I thought, ‘How nice. If I specialize in this I’ll see people from lots of different 
cultures and I can learn about culture as well as haemoglobin.’ I ended up 
running a thalassaemia clinic at University College Hospital where we had 
people of diverse backgrounds. So I was specializing in the clinical management 
of thalassaemia and what happened within a month, a few months of my having 
set up this clinic, was that a rather rapidly growing number of patients attended 
our own hospital or were referred to us from adjacent hospitals. The struggle for 
independence in Cyprus from 1957 to 196065 caused a large number – 10 per 
cent – of the entire Cypriot population to migrate to the UK because of civil 
strife and economic depression.66 Most came to North London in the intake 
area of my hospital (University College), and adjacent hospitals, and so we 
started seeing thalassaemia major.67 First of all, using the Hardy–Weinberg 
statistical technique, I counted up how many births there were and how many 
new cases there were, and worked out that at least 14 per cent of these people 
carried beta thalassaemia, which was a lot.68 It turned out to be 17 per cent in 
the end.69 So we had a population at very high risk, and patients started cropping 
up in all the hospitals round about, so I became a sort of referral centre. I very 
quickly found out that if a woman who had had a child with thalassaemia major 
became pregnant, they rang me up in a panic and asked me to arrange a 
termination because they were so afraid of having another child with this 
hopeless prognosis and a very punishing treatment of monthly blood 
65 See, for example, Anon. (1957) and Anon. (1960). In 1974 the island was de facto partitioned between 
Greece and Turkey. See also Greater London Authority (2009), in particular pages 7, 9 and 11. 
66 For more context from Modell on Cypriot migrants to the UK and thalassaemia statistics in their 
population, its presence in other ethnic groups in the UK and the effects of genetic counselling on birthrates 
of babies with thalassaemia major, see Modell and Berdoukas (1984); chapter 4, Thalassaemia in Britain; 
pages 78–9, 81–2. 
67 Professor Bernadette Modell elaborated: ‘Cypriots first came to Camden by chain migration, then to 
Islington, and moved further north as they got more established and had families. Green Lanes in Haringey 
was favourite, near North Middlesex Hospital.’ Note on draft transcript, 9 August 2013. 
68 Modell et al. (1972). 
69 Gill and Modell (1998), page 761. 
Clinical Molecular Genetics in the UK c.1975–c.2000
24
transfusions. It was about this time that I went to the Cooley’s Anemia meeting, 
and heard Y W Kan’s paper.70 Why was I frustrated? I was frustrated because 
these people wanted prenatal diagnosis and could we give it to them? No, 
because thalassaemia and sickle cell are both disorders of the beta globin gene, 
which only affects adult haemoglobin, whereas fetuses have fetal haemoglobin, 
so even if you could develop a technique for getting fetal blood, which wasn’t 
available at the time, you wouldn’t be able to make the diagnosis using 
conventional methods. At the Cooley’s Anemia meeting Y W Kan presented a 
paper showing that in fact the early fetus did have a certain proportion, less than 
10 per cent of haemoglobin A, and if you used radioactive labelling, you picked 
up synthesis rather than quantity, and you could detect haemoglobin A from 
about 11 to 12 weeks onwards. This meant that it would be possible to do 
prenatal diagnosis if you could get sensitive enough laboratory techniques, and 
if you could develop an obstetric technique for getting fetal blood on which to 
make the diagnosis. We felt this was so important and I ended up coming away 
from that meeting having established a link with David Nathan and Blanche 
Alter, in Boston.71 They had the same vision as us, but they could not proceed 
because legislation in Massachusetts meant that you could not do experimental 
work on the products of an abortion. So they couldn’t develop it, whereas here 
we were in London, regularly arranging for highly at-risk women to have 
terminations of their pregnancies without any restriction on access to, or use of, 
the fetal material. So I started collecting material from terminations and sending 
it to my colleagues in the United States for analysis. Now, we had to be able to 
distinguish normal and heterozygotes – that was the crucial thing – and 
homozygotes who, in principle, shouldn’t be making any or very little adult 
haemoglobin. It took quite a lot of work; you’ve all done this kind of work and 
know that the most demanding part of it can be collecting the material. At this 
time, I had patients coming to me, young women with one child with 
thalassaemia, saying they wanted to be sterilized, and I said, ‘No, under no 
circumstances because it looks as if we might be able to do prenatal diagnosis. 
70 See note 63. 
71 Dr David Nathan was Chief of Hematology at the Children’s Hospital Boston (1967–1984) and is 
now President Emeritus of the Dana-Farber Cancer Institute, Boston. See http://doctors.dana-farber.org/
directory/profile.asp?pict_id=0000299 and http://www.childrenshospital.org/cfapps/research/data_admin/
Site309/mainpageS309P0.html. Dr Blanche Alter undertook a fellowship at Boston Children’s Hospital in 
pediatric hematology/oncology and worked in David Nathan’s laboratory. She is now a Senior Clinician 
at the National Cancer Institute, USA; http://dceg.cancer.gov/about/staff-directory/biographies/A-J/alter-
blanche (all websites visited 24 June 2013). 
Clinical Molecular Genetics in the UK c.1975–c.2000
25
Get your contraception organized.’ So all my patients’ mothers knew that this 
was in the wind:  one of them was a Pakistani paediatric haematologist with a 
child who had thalassaemia major. She came in one day and asked, ‘How are 
you getting on?’ And I said, ‘It’s getting very exciting. Would you like to come 
into the lab and see?’ So I showed her results for five cases:  we’d got one normal, 
three that looked like heterozygotes, one that looked like a homozygote, so it 
looked as if we could do it. She said, ‘Oh, that’s very interesting’, and she went 
away. We carried on. Three months later she rang up and said, ‘I’m pregnant. I 
want you to try and do a prenatal diagnosis because the worst you can do is 
cause a miscarriage, and if you won’t do it I’m going to have to terminate this 
pregnancy.’ I said, ‘But we haven’t got a technique for getting fetal blood.’ So I 
rang Blanche Alter in the United States and said, ‘A terrible thing has happened’, 
and I told her what had happened, and she started laughing. I said, ‘It’s not 
funny.’ She said, ‘I know, the same thing happened to us yesterday.’ The point 
I’m making here is that the patients really pushed the pace. I said to Blanche, 
‘What are you going to do?’ and she responded, ‘Well, we’re going to try.’ In fact 
they had a couple of obstetricians who had been trying to develop techniques 
for fetal blood sampling with rather promising results. So I went to our Professor 
of Obstetrics, who had a background in prenatal diagnosis for Rhesus haemolytic 
disease – I called him Feather Fingers Fairweather – Professor Denys Fairweather, 
who is a Scot and it was a typical Scottish interview.72 I didn’t know him very 
well at the time but I stood in front of his desk and explained what had happened. 
There was a three-minute silence which he broke:  ‘Alright, why don’t we try?’ So 
we tried and the end result was that we were hustle-bustled into actually having 
to provide a prenatal diagnosis service for thalassaemia. When the news got 
about, people started getting on planes in Cyprus, Italy and Greece to come for 
the service. We were under no illusion whatsoever that this was a service that 
was needed. But the experience was awful because we were only seeing patients 
at 25 per cent risk, which meant that we had 25 per cent affected fetuses, and 
25 per cent of those women terminated that pregnancy, and they came at 
18 weeks and they terminated at 20 weeks. As part of our clinical responsibility, 
we accompanied them; sat with them through the termination; showed them 
72 Professor Bernadette Modell elaborated: ‘I became extremely fond of Denys, who was a wonderful 
operator and is a kind man. I was asked to give a talk at his Festschrift. In it, I described the development 
of our collaboration approximately as follows: I had said to Humphrey Ward – the obstetrician with whom 
we later developed CVS – that I found Professor Fairweather somewhat scary. He replied, “Oh don’t worry. 
He’s a Scot. The first three years are the worst.” The audience collapsed as they all knew exactly what was 
meant.’ Note on draft transcript, 9 August 2013. 
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the baby and discussed the baby with them at the end.73 It was the same for all 
prenatal diagnosis at this time. I think it’s important to emphasize and record 
that the experience of genetics for these women at that time was with techniques 
for prenatal diagnosis, which were at the absolute borderline of acceptability. 
Another important meeting was the one you have spoken about in Crete.74 But 
before that, David (Weatherall) organized another meeting in Oxford where he 
brought Bob Williamson. When you met Bob you began to understand what it 
was all about. By the time we had the meeting in Crete, I was really getting a 
grip on what molecular biology could do and was thinking, ‘Well, what can this 
add?’ We’ve got a technique for prenatal diagnosis that actually is protein-based. 
It looks at the end product and on the whole it gives you a good diagnosis, 
though the cut-off is a bit shaky. It was clear to us that if the new molecular 
techniques could offer us the possibility of first trimester prenatal diagnosis that 
would be a major advance. So, having had the experience of developing one 
obstetric technique – fetal blood sampling – we were able to move on to develop 
CVS.75 We approached women who were having social abortions, and they 
agreed for us to take samples during the procedure. Those samples were sent to 
John Old in David’s laboratory to make sure that you could get DNA out, and 
we started collaborating with Bob Williamson’s group, sending them material to 
do the diagnosis in parallel with us, so that they could compare their DNA 
73 Professor Bernadette Modell wrote: ‘This was in the early 1980s, when it was becoming recognized 
that stillbirth was a bereavement and should be handled as such. Previously it had been customary in 
cases of stillbirth to try to protect the mother by hiding the baby and essentially trying to pretend it had 
never happened. Therefore, obstetricians and midwives began to show the dead baby to the mother and 
accompany her through the bereavement, including offering funeral and burial services. We agreed with 
Professor Fairweather that late termination of a wanted pregnancy fell into the same category, discussed it 
with the midwives, and used the same approach from the beginning of our prenatal diagnosis service. I was 
the person principally involved. It was, of course, very emotional, but from the beginning we understood 
it was the right thing to do. The mothers really appreciated the opportunity to greet and say goodbye to 
the baby. We were privileged to share these deep moments of truth with our patients – and it also helped 
to give us confidence in the service we were providing. This was a new concept at the end of the 1970s: 
it is standard practice now. Some mothers want photos. Some Church of England chaplains (and perhaps 
others) also offer a small service for the baby. I remember particularly one Cypriot uncle, resident in the UK, 
who accompanied his young niece who had come alone from Cyprus for PND (prenatal diagnosis) – when 
we discussed this he was shocked at first, but then said “Oh, I see, at least she will know she was a mother.”’ 
Note on draft transcript, 9 August 2013. 
74 See page 20. 
75 For another account of how chorionic villus sampling developed, from Professor Bernadette Modell and 
other Witness Seminar contributors, see Christie and Tansey (eds) (2003); pages 46, 47–9 and 50–1. 
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results with our protein-based prenatal diagnosis. In fact, they found that they 
could make the diagnosis using DNA.76 Can I say one final thing, one very final 
thing, about the patients? 
Bobrow:  We have to move on. Sorry to hassle you but you understand why.
Modell:  Yes, I understand. When we started using first trimester CVS for 
prenatal diagnosis, we had patients who had been through the old procedure. 
When they went through the new procedure we felt so gratified because they 
said, ‘It’s a miracle! The baby’s only “so big” and we already know the answer’, 
‘so big’ being an inch. We felt wonderful; then, as time passed, we started getting 
patients who hadn’t been through the old procedure and they sat there and they 
looked at us just like the other ones used to do and said, ‘This is awful. Can’t 
you do anything better than this?’
Bobrow:  That is a very important message. The links with the developing 
capabilities in prenatal diagnosis have also come out very clearly, as has the 
fact that the globin story is an absolute paradigm of how the science of disease 
genetics developed.77 There is one question that I would like to put, which 
is whether the model for clinical delivery, as opposed to scientific discovery, 
presented in a way that turned out not to be the way in which clinical genetics 
services as a whole developed? I wondered whether you thought that, was there 
any special reason for that or do you have any reflections? Would you have 
preferred, from the position as a physician doing genetics, all of genetics to have 
stayed within mainstream departments of medicine and never to have run out 
into a separate medical and laboratory specialty?
Weatherall:  Well it’s very interesting you say that. I’ve been cogitating on this 
question recently. The question you’re asking really is:  Why did the haemoglobin 
field drift away from the mainstream of medical genetics?
Bobrow:  Well, the other way around, I would put it. Let’s not quibble.
Weatherall:  No, let’s not quibble about that. I just did not want to start with 
the inferior part of the field first. [Laughter] I think the only way I can put this 
together is to consider the way clinical genetics as a specialty developed after 
76 Little et al. (1980). 
77 Professor Martin Bobrow wrote: ‘As Weatherall says in the next paragraph, the intensive investigation of 
the globin genes meant that many broad principles were learned there long before the rest of the genetics 
field had caught up.’ Note on draft transcript, 31 July 2013. 
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World War II.78 There really was nothing before that. It started in places like 
Baltimore and the west coast of the USA and one or two centres here in the 
UK. It was natural for those departments to focus on local diseases, as it were, 
chromosomal abnormalities in particular, and standard monogenic diseases. I 
suspect that what happened was that the haemoglobin disorders tended to drift 
into haematology departments and there was a beginning of the separation. 
This is the case if you look at the literature over the period, for example in 
Paul Polani’s Royal College of Physicians lecture on genetics in 1988, there 
is a whole list of recessive diseases yet the haemoglobin disorders are not even 
mentioned.79 In fact, they are not mentioned at all in this extensive lecture. Even 
as early as that the two fields had begun to drift apart. I think it is a great pity 
because, examining the current situation, I think there are so many lessons that 
both parties could learn from each other. We’re not talking about genome-wide 
association studies here but these issues are particularly important in the field 
of phenotypic diversity. I well remember that when those wretched mice were 
developed with the cystic fibrosis mutation and a modifier gene was discovered, 
the message that ‘monogenic disease is not as simple as all that’ was paraded all 
over the literature, including Nature.80 Yet we had known in the haemoglobin 
field for the previous 20 years that this was the case. I think you will find, in the 
haemoglobin field we still know a lot more about the genetic, environmental and 
adaptive factors that modify phenotypes of monogenic disease than any other 
conditions of this type. That is how it all happened. It is a shame it happened 
and I hope that there will be some kind of coming together again. 
Bobrow:  I have to say it’s exactly my view but we aren’t really dealing today 
with the whole history of cytogenetics, which also drove the clinical genetics 
agenda very strongly at around that time (late 1960s to early 1970s), but just 
differently – they were just ships that passed in the night.81 That was a really 
helpful discussion of a group of diseases but they are a pretty unusual group of 
diseases. 
78 Professor Malcolm Ferguson-Smith wrote: ‘Arguably, clinical genetics did not take off as an effective 
practical service for patients before 1967 when prenatal diagnosis became an option. Prior to that, genetic 
counselling had little to offer and was mostly unavailable.’ Note on draft transcript, 1 June 2013. See also 
Professor Peter Harper’s comments in Harper et al. (eds) (2010), pages 5–7, and Professor Rodney Harris’ 
comments in Christie and Tansey (2003), pages 64–5. 
79 Polani (1990). 
80 Ratcliff et al. (1993). 
81 For histories of cytogenetics see Ferguson-Smith (1993) and Harper (2006). 
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Weatherall:  What do you mean by unusual?
Bobrow:  Unusual in the depth of understanding and the fantastic talent of the 
people who work on them. [Laughter]
Ferguson-smith:  There were links here with cytogenetics and mapping the 
globin genes. Although we knew which chromosomes they were on, from work 
on somatic cells, the actual position on the chromosome was determined by in 
situ hybridization using cDNA probes. This was done by Sue Malcolm, who 
worked in my lab on an MRC grant that Bob Williamson and I had together.82 
So globins came into the in situ work as well and spurred on the development 
of FISH (fluorescent in situ hybridization).
Bobrow:  Excellent, that ties that story together as well. Very satisfying; thank 
you for reminding me Malcolm. 
Professor John yates:  Well, I struggle a bit to know where one starts with such 
a large topic but I’ll start with how I got into this whole game. I was training 
as a paediatrician when I got interested in genetics and so I spent a year with 
Alan Emery in Edinburgh learning some medical genetics.83 Then, in 1982, I 
went to work with Malcolm Ferguson-Smith in Glasgow where there was a very 
strong interest in gene mapping. Two years previously Botstein and colleagues 
had published their famous paper describing how restriction fragment length 
polymorphisms could be used to map genes.84 I think it’s easy to forget how 
feeble the resources were to map human disease genes at that time; there were 
just a handful of blood groups and a few protein polymorphisms with very low 
heterozygosity. The effect of that paper, certainly in Glasgow, was quite dramatic 
because Malcolm had a very well set up laboratory with experienced technical 
staff who could type all the blood groups, and protein polymorphisms, and that 
was rapidly being shut down when I arrived in 1982, and these people had to 
retrain to type RFLPs. Although that was a major advance in terms of giving 
us a handle for gene mapping, again it’s easy to forget just how rudimentary 
even the RFLPs were at that time and indeed the difficulty of typing RFLPs, 
certainly in my hands, in the lab. Southern blot analysis was problematic; you 
82 See Professor Sue Malcolm’s biography on page 106 and Malcolm et al. (1977). 
83 In 1964 Professor Alan Emery founded the first medical genetics clinic in the UK outside London, in 
Manchester. He became Professor of Human Genetics at the University of Edinburgh in 1968. See Professor 
Peter Harper’s interview with him at http://www.genmedhist.info/interviews/Emery%20Alan (visited 31 
May 2013). 
84 Botstein et al. (1980). 
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had to get the chemical buffer exactly right or the background was terrible. It 
could take you up to two weeks to get a result and if the wretched nitrocellulose 
filter fell to bits, as they often did, you’d find yourself trying to reconstruct 
it like a jigsaw to stand a reasonable chance of getting an autoradiograph at 
the end. If you were lucky, you’d genotype perhaps a dozen subjects – it was 
hard work. I rapidly got recruited to this activity, partly because before doing 
medicine I had done some maths at university and so I was asked to try and 
sort out the linkage data, which I found quite a struggle. My recollection of 
that time was first of all trying to understand what linkage analysis was all about 
and then getting my head around the complicated computer programmes, 
and then trying to get enough computing power to actually do the analysis, 
which, in Glasgow at that time, required the use of the university mainframe 
computer. If I wanted to run a multi-factor analysis, I had to negotiate the use 
of this machine for the weekend, because its power was so feeble. Malcolm’s 
interest, of course, was in the X and Y chromosomes and sex determination 
and, in particular, the tip of the short arm of the X chromosome and trying 
to understand the phenomenon of X chromosome inactivation.85 The first 
disease I worked on was X-linked ichthyosis because the steroid sulphatase 
gene associated with that condition escapes X inactivation and was known to 
be on the short arm of the X chromosome. Much of my time for the first 
year or so in Glasgow was spent chasing around all over the country trying 
85 For his early work see, for example, Ferguson-Smith (1965). 
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to find families with this skin condition and doing linkage studies.86 The X 
chromosome is certainly my favourite chromosome because linkage analysis 
on it is so much easier than on the autosomes and not only that, but of course 
X-linked inheritance is usually obvious from a family tree and so diseases and 
traits are much more easily assigned to the X chromosome than the autosomes. 
When I started working on the X chromosome, following the Human Gene 
Mapping Workshop in Oslo in 1981, there were over 100 genes assigned to the 
X chromosome, which was well in excess of any of the autosomes.87 Although 
we knew a lot of diseases that were on the X chromosome, the map of the X 
chromosome was rudimentary.88 Effectively there was a linkage group on the 
tip of the short arm dependent on the Xg blood group, and a linkage group 
on the tip of the long arm dependent on colour blindness and G6PD. But 
rapid progress was made with the use of RFLPs and at the same time as the 
genetic map was being developed, there was also steady progress being made 
with physical mapping using, first of all, yeast artificial chromosome clones and 
pulsed field gel electrophoresis and then other techniques. Spectacular progress 
was achieved by extensive international collaboration – that was the key – with 
the sharing of resources and information. That collaboration was driven by the 
international Human Gene Mapping Workshops that were held through the 
1970s and the 1980s – also in 1990/1.89 And for those of us who were interested 
in the X chromosome, of course, there were chromosome-specific workshops. 
For me the key workshops on the X were held in St Louis in 1993, Heidelberg 
in 1994, Banff in 1995 and, finally, Cambridge in 1996.90 There was extensive 
86 Yates et al. (1987). 
87 The Sixth International Workshop on Human Gene Mapping took place at the University of Oslo, 29 
June to 3 July 1981. See Berg (1982).
88 See, for examplee, Miller and Siniscalco (1982). 
89 The First International Workshop on Human Gene Mapping was held at Yale University, New Haven 
(1973). See Ruddle et al. (eds) (1974) for the published report and papers from the workshop. Subsequent 
Human Gene Mapping Workshops (HGMW) took place in Rotterdam (1974); Baltimore (1975); 
Winnipeg (1977); Edinburgh (1979); Oslo (1981); Los Angeles (1983); Helsinki (1985); Paris (1987); 
interim meeting New Haven (1988); New Haven (1989); Oxford (1990); London (1991). Full reports 
and papers from each HGMW are published in the journal Cytogenetics and Cell Genetics. See also note 4. 
90 International Workshops on the Human X Chromosome are all documented in Cytogenetics and Cell 
Genetics. For St Louis see Schlessinger et al. (eds) (1993); for Heidelberg see Willard et al. (eds) (1994); for 
Banff see Nelson et al. (eds) (1995). For Cambridge, 1996, Professor John Yates confirmed that a report 
was not published. See correspondence deposited with the archives of this meeting in the Wellcome Library 
at GC/253. 
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collaboration, albeit with some healthy competition as well, and there was some 
great teamwork between clinicians and scientists, which was also key to the 
progress that was made. Clinicians were recruiting and evaluating families for 
genetic studies but were also spotting unusual patients, who sometimes were 
the key to isolating particular disease genes. Of course, the families also played 
an important role in taking part in the studies by raising significant amounts 
of funding through their patient organizations – much of my research over 
those years [in the 1990s] was funded by patient organizations.91 What about 
Duchenne? I think no disease better exemplifies the success of this sort of 
collaboration than Duchenne muscular dystrophy (DMD). The cloning of the 
Duchenne gene is well documented; I’m not going to try and go through that 
in any detail at all, and in any event there are other people here who are much 
better qualified to talk about that than I am.92 But the positional cloning of 
the Duchenne gene depended on all the factors that I’ve already mentioned. 
There were invaluable contributions from clinicians identifying, for example, 
girls affected by Duchenne due to X autosome translocations who were crucial 
to the cloning of the gene, and the identification of the key patient, BB, who 
had a huge deletion that not only caused DMD but also chronic granulomatous 
disease, retinitis pigmentosa and the McLeod phenotype. These meetings also 
enabled the recruitment of large numbers of Duchenne patients and families in 
many centres right across the world. There was outstanding work done by all 
the scientists who were involved in this activity. With regard to international 
collaboration, just to take one example, when Lou Kunkel’s lab identified the 
pERT-87 probes that could detect deletions in some Duchenne boys,93 these 
were made widely available for researchers right around the world and led to 
data being collected on well over a thousand cases in quite a short period of 
time, which was a tremendous achievement. These discoveries were very rapidly 
implemented clinically. If we think of the beginning of the 1980s, determining 
91 For research funded by the Muscular Dystrophy Group of Great Britain, see Yates et al. (1993) and by 
the Tuberous Sclerosis Association (UK) and National Tuberous Sclerosis Association (USA), see Green 
et al. (1994). 
92 Professor Bert Bakker wrote: ‘The most important events in this were the BB deletion detected by Uta 
Francke et al., the probe 754 cloned by Hofker et al. (our Leiden group), p754 was located within the 
BB-deletion, and the work by Kunkel et al. to isolate more clones from the BB-deletion which enabled 
Monaco et al. to clone the DMD gene.’ Note on draft transcript, 18 July 2013. See Francke et al. (1985); 
Hofker et al. (1985); Kunkel et al. (1986) and Monaco et al. (1986). See also Davies et al. (1983) and Bakker 
(1989), in particular pages 17–30. 
93 Kunkel et al. (1986).
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carrier status for Duchenne relied on pedigree analysis and a measurement of 
serum creatine kinase levels, but once the gene had been mapped, linkage data 
was also taken into account.94 Still, the results often left families with great 
uncertainty. Advising a woman who was contemplating starting a family that 
she had a 20 per cent risk of being a carrier and therefore a five per cent chance 
of having an affected child was not really terribly helpful. All that changed 
dramatically for two thirds of families when it became possible to identify a 
deletion in the Duchenne gene.95 Carrier detection immediately became more 
straightforward and reliable; prenatal diagnosis was an option. I think it’s fair to 
say that many diagnostic laboratories cut their teeth on the molecular genetics 
of DMD.
dr rob elles:  I worked in Bob Williamson’s lab in St Mary’s Hospital, in 
Paddington, as a technician from 1977 to 1983 and for most of that time I 
was associated with Kay Davies’ group. Her group started to work on the X 
chromosome I guess about 1978 or 1979. At that time, as Bert has already 
described, we needed to pick out clones that were extracted from whole human 
DNA cut with a restriction enzyme. Of course, if you took the whole genome, 
then finding a probe that was relevant, for example for the X chromosome, was a 
pretty inefficient process – although Bert did it magnificently.96 So there was a lot 
94 Harper et al. (1983). 
95 See, for example, Monaco et al. (1985). 
96 Hofker et al. (1985). 
Figure 12: dr rob elles
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of effort to try and purify fractions of the genome in order to make that process 
more efficient and there were some weird and wonderful machines that were 
used.97 I remember a huge slab of agarose in a cylinder and there was an attempt to 
electrophorese the material out and collect fractions and then clone that – I don’t 
think that was ever very successful.98 But one approach which was successful in 
Kay Davies’ group was a collaboration with Bryan Young from Glasgow, which 
involved Fluorescence Activated Cell Sorting (FACS) of chromosomes.99 They 
took a cell line that had four copies of the X chromosome, again to enrich for 
the X chromosome, successfully FACSed that material, collected fractions and 
then cloned the material into a bacteriophage vector, lambda G2WES.100 There 
was a bit of a production line going on in the laboratory:  there was a doctoral 
worker who was responsible for the ligations and then the ligations went into 
the transfections, and my job was to plate out clones and to be the curator of 
the cloned library. Once we had clones, we picked them out into grids and our 
first method of identifying whether we might have a single copy probe was 
to hybridize blots on nitrocellulose filters taken from those plates, with whole 
human DNA. Those clones that did not light up on the autoradiograph were 
candidates as being single copy clones, and in fact I’ve got an artefact here that 
is one of the plates which is gridded out.101 At that time [in 1982 to 1983], we 
worked with Marcus Pembrey’s group in Great Ormond Street and there was 
97 See, for example, Carreira et al. (1980). 
98 Dr Rob Elles elaborated: ‘We also trialled but did not persist with a centrifugal method that involved 
pumping a mixture of DNA restriction fragments through a coil containing a two-phase organic system.’ 
Note on draft transcript, 14 August 2013. See Elles and Sutherland (1980). 
99 Professor Bryan Young was a Research Fellow at the Beatson Institute, Glasgow, from 1972 to 1984. See 
http://www.bci.qmul.ac.uk/index.php/staff/item/bryan-young.html (visited 1 July 2013) 
100 Davies et al. (1981). 
101 Dr Rob Elles brought a sample of one plate on a transparency to the meeting, but we were unable to 
reproduce this successfully as a printed image. He further explained: ‘The clones were grown on a Petri 
dish in a grid pattern and screened with a probe labelled with a radioisotope that was specific for the highly 
repeated sequences that are widely scattered in the genome. A dark signal represented a clone that contained 
repetitive DNA and was not useful as a bio-marker. Some clones did not darken the film and these were 
candidate markers to help map inherited diseases such as Duchenne muscular dystrophy carried on the X 
chromosome. The clone in the C8 position was shown to be close to the DMD gene and was one of the 
first biomarkers to be applied in tracking the DMD gene through families.’ Email to Mr Adam Wilkinson, 
26 February 2013. A digital copy of this sample can be viewed on the History of Modern Biomedicine 
Research Group’s website, and one will also be deposited with the records of this meeting in the Wellcome 
Library at GC/253.
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a kind of ‘proof of concept’ paper that we published with his group about how 
this particular RFLP might be used as a linked marker for carrier detection and 
prenatal diagnosis.102 We showed that, in a woman heterozygous for RC8, male 
fetal material would only inherit one allele clean from the second allele that the 
woman carried, and so it demonstrated that chorionic villus biopsy diagnosis 
was possible and could be free from maternal contamination. So that work 
went on at St Mary’s and my own personal story is that I was quite interested in 
the clinical application of these technologies and actively looked to move from 
the research environment into the clinical environment. Bob Williamson was 
always very helpful about moving his people on in their careers and said, ‘Well, 
either go to Cardiff or Manchester’ and I would have been very happy to go to 
Cardiff but in fact I went to Manchester, where I had family links, in 1983. One 
of the things that astonished me in moving from a research environment into 
that clinical environment was the efficiency with which the clinical department 
could gather samples from families with experience of DMD. It was very 
far-sighted of that clinical community to start to develop voluntary family 
registers in advance of these technologies being available because that really 
drove the clinical application of these technologies. We worked with Andrew 
(Read), and we were quite quickly able to establish a series of families from 
the North West and started to demonstrate in a real clinical environment the 
application of these technologies.103
102 See Pembrey et al. (1984). Professor Marcus Pembrey was Consultant Clinical Geneticist at the 
Hospital for Sick Children, Great Ormond Street from 1979 to 1998. See also his biography on page 109. 
Professor Marcus Pembrey commented: ‘I would like to emphasise the key role of Bob Williamson’s lab 
and Kay Davies’ X chromosome library. Kathy Harper was a laboratory technician I met during my 
haemoglobinopathy work in Saudi Arabia and Bob agreed to let her train in his lab as part of a grant I 
had to investigate Fragile X. When the DX13 probe proved not to be linked to Fragile X, Robin Winter 
suggested we look at the haemophilia A families he had collected with Ted Tuddenham. DX13 was closely 
linked and we immediately applied it clinically for carrier testing and prenatal diagnosis (or exclusion) with 
Kathy Harper doing much of the service work until Sue Malcolm and Helen Middleton-Price arrived. It 
was very stimulating in the early 80s – we learnt as we went along. I remember how the ability to “exclude” 
a male fetus being affected, even though we could not determine the mother’s carrier status, dawned on 
us (actually I think it dawned on John Burn, who was training with us) during a clinical meeting. I also 
remember introducing the term “gene tracking” (wrote it in my diary) to avoid the clumsy “by linkage 
analysis”, to see if it would fly – it lasted a few years and even got into Strachan and Read (1996).’ Note on 
proof transcript, 1 November 2011. See Harper et al. (1984) and Winter et al. (1985). 
103 Read et al. (1986). For the records of the North West of England’s Regional Genetic Register, based at 
St Mary’s Hospital, Manchester, see the papers of Rodney Harris, archival reference GB 133 ROH, located 
at The John Rylands University Library, University of Manchester. 
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Bakker:  I will go back a little bit to how I came to switch from pure research into 
the clinical setting. Around 1981 we had these RFLP-detecting clones, a whole set 
of 20 to 30 clones we had made that were unique and displayed polymorphisms all 
over different places in the human genome and we had to localize them to different 
chromosomes with somatic cell hybrids. One was on the X chromosome. Peter 
[Pearson] went to the HGM (Human Gene Mapping) Workshop in Oslo and 
showed all these polymorphisms. Then he went to the human genetics conference 
in Israel and there he met, on the airplane, a guy from a patient organization in 
the Netherlands and he was Ysbrand Poortman, who was interested on behalf of 
the families with DMD.104 He told Peter, ‘If you have a DNA probe on the X 
chromosome, you could work on DMD.’ So Peter came back in 1981 to Leiden 
and he said, ‘We are going to work on Duchenne muscular dystrophy.’ I was doing 
research, finding polymorphic clones and putting them on the human genome 
map. He hired a clinician, a clinical geneticist in training – clinical genetics was 
not yet a specialty at that time. This guy, Henk Venema, went out to the families to 
get DNA samples in for linkage analysis of the Duchenne gene. In the meanwhile 
we had had contact with Bob Williamson’s group (St Mary’s Hospital) to exchange 
their probe RC8 with our L1.28 and together we could do carrier detection by 
linkage.105 In a small number of the families we showed carrier detection was 
possible. At that time, there was a PhD student in our lab, Marten Hofker, who 
made more of these polymorphic probes, one being probe 754, which later turned 
out to be located within the deletion of the BB patient, described by Uta Francke.106 
By using more of these probes we could improve the linkage analysis and get very 
high informativity over the whole region and perform carrier detection in most 
of the families. Also, in 1984, the first prenatal diagnosis worldwide for DMD 
took place.107 Prenatal diagnostics was going into the clinic and we had to choose 
either research or diagnostics. Gert-Jan van Ommen, who had started in Leiden 
in 1983 said, ‘I will go with research and try to find the gene defect in DMD.’108 
I said, ‘Okay, I will do the DNA diagnostics side, setting up the DNA diagnostics 
104 See note 87 for Oslo meeting. The Sixth International Congress of Human Genetics took place in 
Jerusalem from 13 to 18 September 1981. See Bonné-Tamir (ed.) (1982). 
105 Davies et al. (1983). 
106 See note 92. 
107 Bakker et al. (1985). 
108 Subsequently, Professor Gert-Jan van Ommen was Head of the Department of Human Genetics, Leiden 
University Medical Center; http://rd-neuromics.eu/contact/gert-jan-van-ommen/ (visited 11 September 
2013). 
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lab.’ At the same time, requests came through for Huntington’s, for haemophilia, 
so around 1984/85 we started up the whole DNA diagnostic clinical setting. 
But at that time it was not yet financed. The finance for the clinical work came 
only later. The first money we got from the Dutch Medical Research Council 
and Dutch Prevention Funds was to stimulate the development of techniques 
for diagnosis and therapy. With this research funding, we showed that prenatal 
diagnosis was possible, and then we asked the health insurance companies to give 
money for genetic tests. Now, I have to go a little back in time to explain how the 
clinical setting arose because genetic counselling started in the Netherlands in the 
1980s.109 So the rise of clinical genetics was actually from different disciplines, from 
haematology, from ophthalmology and all different areas where genetic diseases 
were apparent. At a certain point the acting clinical geneticists or the paediatricians 
came together and said, ‘Okay, we should form clinical genetics centres funded by 
the government.’ It was in 1977, I think, this plan was already discussed by Hans 
Galjaard in the Health Council Committee.110 In 1980 clinical genetics centres 
started; eight all aligned to university medical centres with funding for genetic 
counselling, cytogenetics and prenatal diagnosis, or prenatal diagnosis for what was 
possible at that time:  haemophilia and the three haemoglobinopathies. There was 
lots of cytogenetics in clinical genetics at that time. The people involved were, of 
course, Hans Galjaard from Rotterdam, who really drove things to get the funding 
and Professors Anders and Geerts and other people in the Netherlands helped; 
also Peter Pearson for the cytogenetics.111 And then the eight centres were set up, 
but the committee was demanding that it would be a foundation outside of, but 
aligned to, the university medical centres and specialized because they were afraid 
that the money that they put into clinical genetics would diffuse into the academic 
centres. This was the foundation of clinical genetics services and these services had 
109 Professor Bert Bakker wrote: ‘Genetic counselling in the Netherlands was set up between 1979 and 1983 
as individual foundations aligned to each of the eight university hospitals. The driving force behind the 
start and later the recognition of clinical genetics as a medical profession was Professor Hans Galjaard from 
Rotterdam.’ Note on draft transcript, 18 July 2013. 
110 The Health Council of the Netherlands, in the organization’s own definition, ‘is an independent scientific 
advisory body. It is our task to provide the government and parliament with advice in the field of public 
health and health/healthcare research’. Quoted from the Council’s website; http://www.gezondheidsraad.
nl/en (visited 25 June 2013). 
111 In the Netherlands, Professor Hans Galjaard initiated medical genetics research at Erasmus University 
Rotterdam; see http://www.genmedhist.info/interviews/hans-galjaard-interview (visited 30 May 2013); 
G J Anders was Professor of Antropogenetica at the Department of Human Genetics, State University of 
Groningen from 1965 to the early 1970s. S J Geerts was Professor of Antropogenetica at the Department 
of Human Genetics from 1965 until the early 1970s at the Radboud University, Nijmegen Medical Centre.
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cytogenetics and counselling and, of course, biochemical genetics which was, at that 
time in Rotterdam, very strong. Later, in 1985, when we had these DNA probes 
ready, DNA diagnosis could come in. In 1988 we asked the government to fund 
the DNA-diagnostics as well. Each of the eight centres was asked:  ‘Who is doing 
diagnosis for what?’ In Leiden we did Duchenne, haemophilia and Huntington’s; 
in Groningen it was retinoblastoma and SMA (spinal muscular atrophy); in 
Nijmegen it was myotonic dystrophy (MD); and in Rotterdam, Fragile X and CF 
(cystic fibrosis). We got a lump sum for each of the four laboratories, so these four 
centres started. The other four centres didn’t yet have DNA techniques running. 
With this lump sum of money we could show that it worked and, after a couple of 
years, and a health technology assessment in 1988, it was officially funded. 
Bobrow:  Actually, that was not a dissimilar model for service provision in the 
UK but different in a few important respects that we might come back to later. 
harper:  Just before we leave the X chromosome, I’d like to reinforce some of 
the things that people have already said about Bob Williamson and also Kay 
Davies, who together really were such a powerful combination at that time. Bob’s 
enthusiasm and the collaborations he created were quite outstanding and, even 
more so, the number of people that he trained in some way or another who 
went on to form very distinguished careers themselves elsewhere, including Gill 
Bates, Keith Johnson and Brandon Wainwright, among many others. It’s an 
extraordinary list.112 We were very fortunate in Cardiff to start collaborating more 
or less as soon as Bob had come down from Glasgow to London [in 1976]. Bob 
was just starting to think about Duchenne, perhaps largely as a proof of principle, 
as Rob said, and realized that we had very large numbers of well-worked-on 
families, which we’d done quite a bit with in terms of linkage analysis and broad 
family analysis and which were, so to speak, there to be studied. So that was the 
beginning of our collaboration – firstly Kay coming back from France where she’d 
been and I remember the great changes in the lab that she brought to London.113 
She very rapidly moved from cystic fibrosis to the X chromosome. I remember her 
going to Bryan Young for chromosome sorting and the excitement that came out 
from those first probes. I remember in particular when the RC8 probe came out 
and we were looking at a sample in a Duchenne presumed heterozygote and there 
112 For further details on Professor Bob Williamson’s influence on the careers of others, see Professor 
Peter Harper’s interview with him at http://www.genmedhist.info/interviews/Interviews%20web (visited 
25 June 2013). 
113 See note 27 for details of an interview with Professor Dame Kay Davies by Professor Peter Harper in 
which she discusses her time in Paris. 
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were two bands.114 I said to Kay and Bob, ‘Look! You can absolutely, definitely see 
two bands; this person’s a definite heterozygote.’ They looked a bit blankly at me 
and said, ‘Well, yes, of course, you see two bands:  it’s DNA.’ What they hadn’t 
realized from the point of view of clinicians working with X-linked diseases, is 
how frustrating and difficult it had been until then, that every phenotypic or 
biochemical test you did on heterozygous females had a quite sizeable margin of 
error due to X-inactivation; there were people who you just couldn’t pick up.115 
Having DNA probes just removed that uncertainty at a stroke. I remember also 
that Bob had a fairly naive idea about how rapidly you could progress and after 
we’d looked at the first family he turned to me and said:  ‘Do you mean to say we 
need more than one family to prove linkage in Duchenne?’ I had to let him down 
gently and said, ‘Well, 25 families might do it.’ At the same time, we got a bit of 
discouragement because we went to a meeting of the Muscular Dystrophy Group 
of Great Britain [and Northern Ireland] and were presenting some of our data 
– not the linkage then – when John Edwards got up and proved mathematically 
that it was quite definitely impossible to find the Duchenne gene by linkage and 
we looked rather sheepish, because we already had some suggestion of linkage by 
then, and said nothing.116 But John convinced the whole panel there that it was 
definitely impossible and probably not worth funding, although I don’t think he 
actually said that. Then at the same time, in the early 1980s in Cardiff, we were 
also working on the Becker late onset, X-linked dystrophy. Received wisdom had 
said that the gene was located at the other end of the X chromosome. My colleague 
Helen Kingston showed very rapidly that it wasn’t and it was indeed likely to 
be allelic to Duchenne.117 At that time we had a site visit from the Muscular 
114 Davies (1985). For details of the X chromosome library see, in particular, pages 243–4, and for the RC8 
and other Duchenne muscular dystrophy-related probes, see page 245. 
115 Professor Peter Harper elaborated: ‘Because one of the two X chromosomes in the cells of a female 
is randomly inactivated, there will be some Duchenne carriers that have most cells with the abnormal X 
chromosome inactivated, making conventional tests give a normal result. Conversely, a few heterozygotes 
will have most of their normal X chromosomes inactivated and may have symptoms. This had been a 
long-standing, general problem for carrier detection of X-linked disorders – hence my excitement at seeing 
an unambiguous result for the DNA of Duchenne heterozygotes.’ Note on draft transcript, 23 August 2013. 
116 John Edwards (1928–2007) was Professor of Human Genetics at the University of Birmingham 
(1971–1979) and Chair of Genetics at University of Oxford, Keble College (1979–1995). His archival 
papers, which have been catalogued by the Genetics and Medicine Historical Network project at Cardiff 
University, are available for public consultation at the Cadbury Research Library: Special Collections, 
University of Birmingham, at reference US99. 
117 Kingston et al. (1983). During this period Dr Helen Kingston was a Clinical Research Fellow and 
trainee in medical genetics at Cardiff University. 
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Dystrophy Group [of Great Britain and Northern Ireland]118 and I showed them 
rather proudly our Becker family records and they were very indignant and said, 
‘What do you mean? We funded you to work on Duchenne. Why are you using 
our money to work on a completely different disease?’ Well, it turned out okay in 
the end.119 But those early days were, well, they were very exciting, but it was just 
a unique time and Bob’s contribution – I’m sorry he has to be in Australia rather 
than here so he can’t tell it himself – was huge. 
dr helen Middleton-Price:  I’d like to talk a little bit on behalf of Marcus 
Pembrey and Sue Malcolm who can’t be here today.120 I joined Sue Malcolm’s lab 
in the department of Marcus Pembrey at the Institute of Child Health, Great 
Ormond Street in 1985. I was a research assistant doing my PhD at the time but, 
of course, we all sat in the same lab cheek-by-jowl with the new Special Medical 
Development lab, which started in May 1985.121 One of the great things about 
working with Marcus and with Sue was their capacity for collaboration and the 
way that enabled us to develop the techniques that we started to use in the lab. In 
118 This organization is now called the Muscular Dystrophy Campaign; see http://www.muscular-dystrophy.
org/about/history (visited 29 May 2013).
119 Professor Peter Harper clarified that the Becker and Duchenne genes ‘proved to be alleles, both at Xp21’. 
Note on draft transcript, 23 August 2013. See Murray et al. (1982) and also Davies et al. (1983). 
120 For Professor Marcus Pembrey see note 102 and for Professor Sue Malcolm see note 82. 
121 Middleton-Price (1989). 
Figure 13: dr helen Middleton-Price
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particular, I remember the work of Judith Goodship with the immunologists and 
the late Roland Levinsky, and his department’s work on the development of carrier 
detection and prenatal diagnosis for the very rare paediatric immunodeficiencies, 
in particular X-linked agammaglobulinaemia (XLA) and severe-combined 
immunodeficiency (SCID).122 We had to work very closely with the clinical 
and research departments to develop linked probes for these conditions and 
also to develop carrier detection methods using X chromosome inactivation 
studies in B cells for XLA, and in T cells for X-linked SCID.123 I think that the 
outward-facing, collaborative capacity also created an enormous number of 
opportunities in ICH and Great Ormond Street too.
read:  Just in passing, I was interested in Peter’s anecdote about John Edwards 
‘proving’ that linkage in Duchenne was impossible because I had an extremely 
similar experience about CF where he proved to me that that was ‘impossible’. I 
pointed out to him that you could actually establish phase from the grandparents 
and this was clearly something he had somehow overlooked. At that moment 
I had this embarrassing situation where he believed that I was one of the very 
few people apart from himself and Newton Morton who understood linkage 
and, of course, this led to me going about the whole time believing that I was a 
fraud about to be unmasked.124 [Laughter] Also, with regard to what you (David) 
were asking before about the difference between the haemaglobinopathies and 
the other diseases,125 maybe part of it is that they were recessive conditions and 
you didn’t get the big, extended families. Certainly in Manchester, the model 
on which we were working all the time was one in which the risk extended 
122 Professor Judith Goodship was based at the Mothercare Department of Paediatric Genetics, Institute of 
Child Health, Great Ormond Street Hospital for Children, University of London, as a Lecturer in Clinical 
Genetics/Honorary Registrar in Clinical Genetics (1985–1988) and is now Professor of Medical Genetics 
at Newcastle University. Details confirmed in an email from Dr Helen Middleton-Price to Ms Emma Jones, 
20 August 2013. Professor Roland Levinsky (1943–2007) was Hugh Greenwood Professor of Immunology 
at the Institute of Child Health, University College London (1985–2002). 
123 See Lau et al. (1988); Goodship et al. (1988) and Goodship et al. (1989). Prior to these research 
developments, Professor Marcus Pembrey noted that the Department of Paediatric Genetics was ‘the first to 
publish a useful probe for haemophilia A, with a series on clinical use including prenatal diagnosis’. Email 
to Ms Emma Jones, 28 October 2013. See Harper et al. (1984) and Winter et al. (1985). 
124 Newton Morton is Senior Professorial Fellow in Human Genetics at the University of Southampton, 
formerly Director of the Cancer Research Campaign Research Group in Genetic Epidemiology at 
Southampton, from 1987, and Director of the Population Genetics Laboratory at the University of Hawaii 
(until 1985). See http://www.genmedhist.info/interviews/Morton (visited 1 October 2013). 
125 See page 28. 
Clinical Molecular Genetics in the UK c.1975–c.2000
42
beyond the nuclear family. We had a genetic register that we’d set up in 1980, 
inspired by a register that Alan Emery had in Edinburgh called RAPID (Register 
for Ascertainment and Prevention of Inherited Disease).126 I think RAPID was 
more of an epidemiological tool, whereas ours was very much a management 
tool.127 We established this register for Duchenne, for Huntington’s and for adult 
polycystic kidney disease.128 We saw that as a very central tool for our ability 
to deliver a service to these families. When we started on the early Duchenne 
stuff, after I had been to Bert Bakker and Peter Pearson’s course in Leiden, we 
set up ‘DNA corner’ and then we were able to bring Rob (Elles) in, who could 
actually make these things work.129 He brought the RC8 probe and Peter and 
Bert generously gave us L1.28, with which we worked through our families. That 
126 Emery et al. (1974). 
127 Dr Rosalind Skinner commented: ‘…RAPID was really more than an epidemiological tool. It was used 
to facilitate patient and family management.’ Note on draft transcript, 24 April 2013. RAPID was the first 
computerized genetic register to be created with the intention of preventing ‘a greater proportion of cases 
of serious unifactorial disorders’, through ascertaining individuals who could benefit from genetics advice. 
Quote from Emery et al. (1974), page 145. 
128 For adult polycystic kidney disease, see Elles et al. (1994). 
129 For the University of Leiden course, see note 24. Professor Andrew Read elaborated: ‘Initially we had about 
two metres of bench in a corner of the cytogenetics lab. Personnel were myself and Jonathan Waters, who was a 
member of the cytogenetics lab staff – I suppose he must have been allowed to spend time on the DNA work. 
There were no salaries specifically for DNA work until Rob Elles arrived on our first grant, a Locally Organised 
Research grant by the local NHS to Rodney Harris – I can’t remember whether or not I was a co-applicant. 
As for what we were doing, it was mainly learning how to extract DNA from blood (our own, or volunteers 
among lab staff ), digest with restriction enzymes and run gels. Also developing some infrastructure – I wrote 
programmes to set up and maintain databases of samples, tests and results, and we started the DNA archive 
(sample 82/0001 was my DNA). We didn’t attempt Southern blotting until Rob came, although I had had 
a go at it in Leiden – it would have meant tooling up for P-32 radioactive work, which would have been a 
big development. A couple of years previously, I had introduced the acetylcholinesterase test into the lab – a 
method of testing amniotic fluid for fetal neural tube defects, as a supplement to measuring alphafetoprotein. 
My main work pre-DNA was on neural tube defects; but also I knew I had to up the biochemical expertise 
in the lab in anticipation of the work becoming more molecular, and this test, using polyacrylamide gel 
electrophoresis, was a step in that direction. So we had electrophoresis rigs and I can’t remember whether we 
borrowed or bought one for the DNA. I suspect initially we were using polyacrylamide gels – I remember 
eventually the hospital workshop made some tanks for us for running horizontal submerged agarose gels. They 
didn’t work very well, so we bought commercial ones. We could check the quality of the whole procedure 
because DNA digested with HindIII (I think) enzyme gave some discrete male-specific bands derived from 
the Y chromosome, which you could see directly on the gel by UV fluorescence. As for equipment, we must 
have had a gel rig, some general biochemical stuff like pipettes, a water bath, probably a pH meter. We must 
also have had a UV light in the cytogenetics darkroom for looking at our gels, but nothing very much at first.’ 
Note on draft transcript, 4 July 2013. 
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first cycle using RC8 and L1.28, I think we worked up something like 50 families 
and there was only one single individual where we were able to make a clinically 
significant change to their risk because it was a combination of the relatively low 
informativeness of both of those probes and the relatively high recombination 
rate of about 20 per cent for each probe.130 So, although in principle they looked 
wonderful, actually they didn’t deliver much. But by the time we had found 
that out we had the probes 99-6 and 754 which were closer with, perhaps, 10 
to 15 per cent recombination.131 Again, they were good to score because you 
could score both of them on a single Pst1 digest and that was considerably 
more helpful. We were just beginning to get quite useful information about our 
families from those probes, when along came Kunkel’s pERT87 probes and, like 
everybody else, we greatly appreciated the generosity with which he immediately 
made those available to the whole community.132 That was really the point at 
which our ability to deliver a useful clinical service took off, both the deletions 
and the polymorphisms you could detect with various probes – 87-1, 87-8 and 
87-15 – completely revolutionized our ability to deliver clinically useful results 
to our patients.133
130 Read et al. (1986). 
131 Professor Andrew Read wrote: ‘... we had two probes, 99-6 (DXS41) and 754 (DXS84) that were 
closer ... Note that the DXS names, but not the probe names, should strictly speaking be italicised. If, for 
consistency, you want to do the same for the RC8 and L1.28 probes mentioned above, they are DXS9 (RC8) 
and DXS7 (L1.28).’ Email To Ms Emma Jones, 4 October 2013. DXS refers to markers for the locus to 
which a probe relates on a chromosome. 
132 See note 95. 
133 Professor Andrew Read further commented: ‘I had been opportunistically collecting and storing DNA 
from Register families ever since we had the ability to do so. Then once Rob had RC8 and L1.28 working 
we started working through the families and would have reported any useful results we got, but there were 
precious few. It all speeded up a little with 99.6, then again much more so with the pERT probes. But there 
never was a formal start date for the molecular service. As for the name – well, it was very much an arm 
of the Genetic Register operation. All my reports were to the Register clinicians and counsellors, so I don’t 
think it had a specific name. It was part of the North West Regional Genetics Service. At that time the 
department (University and NHS) was called the Department of Medical Genetics. I was always paid by the 
University and I don’t think I ever had an NHS contract – things were more flexible and informal in those 
days. Eventually I realized that managing the increasing DNA service work was a job I couldn’t justify doing 
on my university pay, and anyhow I wanted to concentrate on research, where I was having fun mapping 
genes, so Rob took over formal responsibility. That would have been sometime around 1988.’ Note on draft 
transcript, 4 July 2013. Central Manchester University Hospitals NHS Foundation Trust’s clinical genetics 
services are now based at the Manchester Centre for Genomic Medicine; http://mangen.cubecore.co.uk/
about-us.php (visited 26 June 2013). 
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Bobrow:  It would probably be fair to say the period of history over which 
people tried to get real clinical utility out of moderately linked probes was 
mercifully short, because these probes were a pain. Should we tidy up the rest 
of the genome quickly? That’s not meant to be disrespectful of autosomes 
– it’s just because the first action came where nature did her best experiments. 
Peter, I would like you to kick off on triplet repeats. I thought we should do 
Huntington’s and CF. 
harper:  I’m only going to say a few words about these because actually my 
lab colleagues in Cardiff, Laz Lazarou and Linda Meredith, can cover this a 
lot better. I suppose there are two trinucleotide repeat disorders which we 
were especially involved with in Cardiff:  Huntington’s disease and myotonic 
dystrophy. Of course, the strange thing was that for the first 20 years of the 
work, before the molecular side had begun, one had no concept that the basic 
mechanism would be the same for both and so there were parallel lines of work 
going on, at first mainly clinical, then gene mapping. The mapping was on two 
different chromosomes and it was only at the end that the work suddenly came 
together, when both were found to be trinucleotide disorders. Actually, I think 
this brings up a general theme of this phase of the work – so long as one was 
working at the DNA level, one could run several diseases in parallel and the 
technology was very much the same. Whichever chromosome you were using, 
you just had a different lot of markers. The moment the mutation came out, 
though, and you had some clue as to the function of the gene, then everything 
went to the winds in different directions and it became impossible to run a 
whole pack of genes through to their function. You had to concentrate just on 
one or two unless your lab was unbelievably well resourced, which was certainly 
not the case with us in Cardiff. I also think people have very little concept of the 
length of time this process took for both myotonic dystrophy and Huntington’s 
and I think it was probably much the same for PKD.134 It took about ten years. 
Now people wouldn’t believe you if you said it took ten years to map and isolate 
a gene; people would not be prepared to invest that amount of time now. It 
was a huge effort. I don’t want to go into the details of the isolation of these 
genes except to say that one end result, which was hugely important, was that it 
turned out that one had a single, unique mutation for each of these trinucleotide 
repeat disorders that could mean a single diagnostic test, not like cystic fibrosis 
or Duchenne where you have lots and lots of different mutations requiring 
134 Huntington’s Disease Collaborative Research Group (1993). 
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different ways of looking for them. These disorders had just one, which meant 
the test could be used not only in prediction in a known family but in primary 
diagnosis as well. That was something of general importance. 
Professor Pat Jacobs:  Just before we leave trinucleotide repeats, which I’m 
astonished to see we almost have without mentioning the Fragile X, I think 
that’s absolutely unique and we really have to mention it in this context. 
Fragile X syndrome is the only disease I know that’s had both a cytogenetic 
marker and a molecular mutation. It’s enormously added to our knowledge 
about trinucleotide repeat diseases and, as far as I’m concerned, it’s the most 
fun disease I ever had anything to do with, so I really think we must just at least 
mention it.
Bobrow:  Who were the big players?
Jacobs:  Jean-Louis Mandel was the big player.135 The group in Hawaii, where 
I was at the time, did both cytogenetics and a very considerable amount of 
work trying to understand the way this syndrome was inherited. This curious 
phenomenon came to be known as Sherman’s paradox after Stephanie Sherman 
135 Jean-Louis Mandel is currently Professor of Human Genetics at the Collège de France (since 2003). 
From 1982 he led research into genetic diseases including Fragile X syndrome; http://www.usias.fr/en/jean-
louis-mandel/ (visited 27 June 2013). 
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who did the analysis of what appeared to be an extremely common disease.136 It’s 
somehow become less common and I can’t quite understand that either. Maybe 
there were huge numbers of families out there waiting to be diagnosed and then 
they were all diagnosed because now, as anybody here would know, it’s actually 
quite exciting when you find a new family with Fragile X and it doesn’t happen 
very often. Maybe in our lab, and we do a lot of Fragile X testing, not only for 
ourselves but for people who send them to us, we get quite excited if we find a 
new family but very few turn up now.137
Mr laz lazarou:  I think originally what happened was that the family registers 
were very good in actually pulling together a lot of the Fragile X families, so that 
we were all prepared at that point when the gene was found to actually do the 
testing. A lot of them were found via the genetics clinics. I remember the first 
time I started testing, I was getting a 10 per cent pick-up rate of the individuals 
I was testing for Fragile X. Now it’s dropped to 0.5 per cent. It’s because 
the referrals we’re now getting are from paediatricians and they are referring 
everybody who has developmental delay, no matter what other characteristics 
136 Sherman et al. (1985). 
137 At the Wessex Regional Genetics Laboratory, of which Professor Jacobs was Director until her retirement 
in 2001, four tests for Fragile X disorders are conducted to detect mutations of FMR1 in carriers as well 
as those who may have the syndrome. Mutations in this gene cause a spectrum of intellectual disabilities. 
See http://ukgtn.nhs.uk/find-a-test/search-by-laboratory/laboratory/salisbury-rgc-41/f/ (visited 1 October 
2013). 
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they have, dysmorphology of any kind, etc. Consequently your pick-up rate 
is going to be a lot less, but, because the registers were so well-established and 
the referrals were primarily from clinical geneticists, who were more clinically 
selective, we picked up a lot of cases. 
Bakker:  The Fragile X gene was actually cloned by the groups in the Netherlands 
and the States, Annemieke Verkerk in Rotterdam.138 
dr linda Meredith:  I want to mention a little bit about the work that we did in 
Cardiff both on Huntington’s disease and myotonic dystrophy. From a practical 
point of view, I remember that to actually perform RFLP analysis was really 
quite challenging because each stage of analysis that you did could be, shall we 
say, less than robust, quite time-consuming, and did not always give you the 
result that you wanted, or that was clinically useful in the end. As Professor 
Read just mentioned, the RFLPs weren’t always that informative in the person 
who wanted a test done and the family structure sometimes might not allow 
you to make an accurate prediction.139 So the usefulness of the RFLPs was quite 
138 Professor Pat Jacobs wrote: ‘The first paper was by Jean Louis Mandel’s group, Heitz et al. (1991); 
followed by a second paper from the same group, Oberlé et al. (1991); then, from Australia, Yu et al. (1991). 
Later that year Verkerk et al. (1991) was published, which identified a gene that looked to be involved in 
the Fragile X syndrome. Because of the complexity of the Fragile X gene and the fact that its mutations 
represented an entirely new type of event in biology, it is impossible to claim priority for any of these four 
papers.’ Email to Ms Emma Jones, 8 August 2013. 
139 See Professor Andrew Read’s comments on page 43. 
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limited in some ways. Obviously, as more RFLPs were developed we could use 
those families with recombinants identified to them, replace and relocate the 
new markers and so the whole thing became a lot easier with the momentum 
of the extra work that we did. I do recall that we were fortunate enough to get 
a grant from an American group – I don’t know whether you recall this, Peter? 
When they’d come over, first of all we told them we believed, based on initial 
linkage studies, that the myotonic gene was on chromosome 4. Then when 
they came back, it had been located to chromosome 19 and the guy who was in 
charge of giving the money remembered our first location of the myotonic gene 
and he gave us a few sticky minutes trying to explain why things had changed. 
We did explain ourselves quite successfully and we were given the money for 
locating the gene for myotonic dystrophy.140 
harper:  I can’t resist embroidering that anecdote, Linda, because you’re 
absolutely right in what you say, and the evidence that it was on chromosome 
4 was incredibly flimsy. This was an application we made with Bob Williamson 
and I remember it was at the international meeting in Jerusalem where the 
chromosome 19 location of myotonic dystrophy was proved indirectly because 
they’d assigned complement C3 to that, and it was already known to be linked 
to myotonic dystrophy.141 I remember thinking, ‘Oh my God, we’ve just sent 
off this application to say we’re going to map it on chromosome 4 and it’s on 
another chromosome. Now that’s the end of our grant.’ I rushed into the office 
when we came back from the meeting and said, ‘Has that grant application 
gone off?’, and the girls in the office said, ‘Oh, we’re terribly sorry, it’s been 
awfully busy here this last week; we haven’t quite got round to putting it in the 
post.’ [Laughter] So we fished it out; I remember using Tipp-Ex, which I don’t 
think is in use now, ‘tippexing’ out ‘4’ and then waiting till it dried and blowing 
on it and writing in ‘19’, by hand, on the top. As Linda said, we got the grant.
Bobrow:  Julian, other autosomal diseases and bringing research up to date a bit? 
Professor Julian sampson:  Well, we’ve already heard quite a bit about the 
identification, or positional cloning, of genes, particularly in the settings of 
Huntington’s and Fragile X, where large families are the norm. I think you 
wanted me to mention tuberous sclerosis because here large families actually are 
unusual; most cases are isolated; two-thirds of cases are isolated, with no family 
140 Shaw et al. (1985). The funding body referred to by Dr Meredith was the Denver Fund for Health and 
Medical Research.
141 See note 104 and also Eiberg et al. (1983). 
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history. This imposes limitations on the positional mapping, the refinement that 
you can get in positional mapping. It was further compounded by the fact that, 
unlike most of the other diseases we’ve heard about, our work showed fairly 
quickly that although a gene for tuberous sclerosis was certainly linked to the 
ABO blood group in some of these families, in others it was not. So it appeared 
there were at least two different genes that could cause tuberous sclerosis. We’ve 
heard about John Edwards’ proclamations of the impossibility of mapping some 
disease genes.142 Tuberous sclerosis was actually a third one that he declared to 
be formally impossible to map, certainly in the northern hemisphere I seem to 
remember, because of the limited family size and the prevalence of the condition. 
Again, fortunately, that didn’t come to pass.143 Certainly the cloning of TSC2 
and PKD1 was very dependent upon chromosomal rearrangements.144 In relation 
to TSC2 they were particularly important because of the relative lack of good 
linkage information. We were very fortunate in Cardiff to have a visit from Isabel 
Cordeiro from Portugal, Lisbon, in 1992. She had been sent to work with us 
on neurofibromatosis type 1, and her boss, Heloisa Santos, asked her to tell me 
that she had already identified, several years before, a family with a translocation 
142 See page 39. 
143 See, for example, Connor et al. (1987); Haines et al. (1991); Nellist et al. (1993) and Cheadle et al. 
(2000). 
144 For the cloning of TSC2 see the European Chromosome 16 Tuberous Sclerosis Consortium (1993) and 
for PKD1 see European Polycystic Kidney Disease Consortium (1994). 
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in a boy with tuberous sclerosis.145 Further investigation of that family showed 
that they also had polycystic kidney disease and this was of great interest because 
of the co-occurrence sometimes of the polycystic kidney phenotype as part of 
tuberous sclerosis. That translocation really facilitated identification of both of 
those genes, largely through the application of another technique that we’ve heard 
a little bit about today:  pulsed field gel electrophoresis. This enabled the more 
precise physical mapping of stretches of DNA as opposed to linkage analysis that 
we’ve heard a lot about.146 Our progress in tuberous sclerosis depended on critical 
clinical observations made by Heloisa in Lisbon. 
You wanted me to mention a little bit about the move from linkage analysis 
into mutation analysis and this was something that I think the diagnostic labs 
were doing in parallel with the same moves happening in research labs following 
positional cloning of disease genes. At the start of our discussions this afternoon 
we heard an awful lot about haemoglobinopathies where, of course, the proteins 
and the genes were already known although the molecular pathology was not. 
For most of the Mendelian disorders that were filling the genetics clinics, we 
recognized the disorders clinically but didn’t have the genes and in most cases we 
had absolutely no idea about the pathophysiology of the disorders. So linkage 
analysis was a way for researchers to try and get at these disease genes.147 We heard 
about RFLPs but progressively more informative groups of markers were identified, 
the VNTRs (variable number of tandem repeats) and then the microsatellite 
repeats, which enabled increasing amounts of information to be derived from 
families.148 The markers were increasingly densely placed onto genetic maps and 
transposed onto physical maps. So we began to build up sort of ‘mini-genome 
projects’.149 Each disease that was being worked on created its own mini-genome 
project, a little area of the human genome. The genetic markers were taken up 
rapidly by the diagnostic laboratories for clinical application, but the approach in 
linkage was usually very dependent on close interaction with the clinical services 
145 See European Polycystic Kidney Disease Consortium (1994), pages 882–6.
146 Professor Julian Sampson elaborated: ‘Where genetic distances are determined but vary in relation to 
physical distance in different parts of the genome.’ Note on draft transcript, 25 October 2013. 
147 For elucidation on linkage analysis in the sphere of cancer genetics, and specifically hereditary 
non-polyposis colorectal cancer, see, for example, Jones and Tansey (eds) (2013), pages 37–45. 
148 For an explanation of the use of these markers in forensic DNA profiling and genetic linkage analysis, 
see, for example, Bennett (2000). 
149 van Slegtenhorst et al. (1995). 
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because we needed samples from additional family members. So sometimes you’d 
need samples from spouses or grandparents to establish phase, for example, and 
so the clinical and lab services got very used to working with extended families.150 
We’ve already heard from Andrew that until these markers were really close to the 
disease gene concerned, they were of limited clinical utility. That changed over 
a period of a few years. This was really all going on, I guess, during the 1980s 
and into the early 1990s and during that period many genes were positionally 
cloned and so things moved to a point of direct mutation analysis.151 We have 
heard that in Huntington’s disease this was very straightforward because the 
same mutation was present in every, or virtually every, patient. That, of course, 
wasn’t the case with many other disease genes, where hundreds of individual 
different mutations could underlie the disease. So we really needed ways, once 
the disease genes had been identified, of scanning across large genes looking 
for various types of mutation and so we saw the emergence of a lot of different 
mutation-detecting technologies like single strand conformation polymorphism 
analysis and denaturing gradient gel electrophoresis, and chemical cleavage of 
mismatches and so on. These were all very labour-intensive processes. They were 
manual and very time-consuming and often actually not that sensitive because 
they frequently couldn’t be applied comprehensively, just for logistical reasons 
to the whole coding sequence of large genes. There was a gradual transition in 
diagnostics from linkage to the application of these screening modalities, and 
it wasn’t really until sequencing became more practical, and quicker, that this 
transition was complete. Initially, sequencing was also based on very manual 
procedures. I can remember using panes of glass that had to be meticulously 
cleaned and then gels would be poured between two panes of glass held together 
by bulldog clips, usually leaking out all over the place, and you’d run the gel and 
develop autoradiographs. The whole thing was really quite bizarre and when 
these plates broke someone had to go down to the local glazier shop and get 
another one. It was really a cottage industry. People are giggling because they can 
remember, you see; it’s all true! [Laughter]
Bobrow:  Ah, nostalgia! [Laughter] 
150 Professor Julian Sampson wrote: ‘In order to determine which genetic marker(s) were associated with 
a disease gene, linkage analysis usually required the genetic analysis of multiple family members including 
spouses and members of preceding generations. The laboratories working on these projects would therefore 
have to work very closely with clinical geneticists and other members of the clinical team to recruit and 
obtain samples from extended families.’ Note on draft transcript, 25 October 2013.
151 See, for example, MacMillan et al. (1993). 
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sampson:  It was the emergence of automated sequencing that enabled the 
completion of that transition from linkage analysis to mutation detection as the 
technique we use to diagnose these diseases now. 
Bakker:  What helped tremendously for the linkage analysis was the CEPH (Centre 
d’Etude Polymorphisme Humain) pedigrees because we needed to have all these 
markers sorted out; we needed to have linkage groups.152 We needed markers, 
which you could use in searches for disease loci. So having these huge, normal 
CEPH families and putting probes to these families and finding the segregation 
in these large pedigrees produced enormous amounts of data. That was all done 
in a European project run by Nigel Spurr called EUROGEM.153 I worked mainly 
on the map of chromosome 4, and other groups worked on other chromosomes. 
Sue Povey and John Edwards were involved, and we made a lot of mileage into 
getting all these maps, and later the meiotic break point maps, to really pinpoint 
loci and set the basis for the sequencing of the whole human genome.154 So the 
CEPH pedigrees and this project, EUROGEM, were tremendously useful. You 
had genetic markers as well, all the Généthon STR (short tandem repeat) markers, 
CA repeats, which were very informative.155 Although they were labour-intensive, 
because you had to do radioactive PCR, running gels using the same glass plates 
that Julian Sampson described.156 This was a lot of work to do all the linkage, but 
it helped enormously to make the maps.
152 ‘The Centre d’Etude du Polymorphisme Humain (CEPH) is a research laboratory created in 1984 
by Professor Jean Dausset.’ In 1993 CEPH was renamed the Fondation Jean Dausset. Quotation from 
organization’s website; http://www.cephb.fr/en/index.php (visited 27 June 2013). 
153 Professor Malcolm Ferguson-Smith wrote: ‘EUROGEM was part of the EC Human Genome Analysis 
Programme established and funded in 1990 through a committee in Brussels which Peter Pearson and I 
chaired over several years. It consisted of two resource centres: CEPH that made and distributed Southern 
blot membranes and DNA samples for PCR made from 750 members of 60 families; and ICRF, responsible 
for distributing the DNA probes that recognized polymorphisms. This material was sent for linkage studies 
to a network of 20 research labs throughout EU member states. Results were presented at HGM Workshops 
and chromosome-specific workshops before joint publication. The programme encouraged effective 
collaboration in Europe and made major contributions to the human gene map.’ Note on draft transcript, 
1 June 2013. See also Ferguson-Smith (1991). 
154 Professor Sue Povey was Deputy Director of the MRC Human Biochemical Genetics Unit (1989–2000) 
and Haldane Professor of Human Genetics (2000–2007) at University College London; now Professor 
Emerita of Human Genetics. She was Chair of the HUGO Genome Nomenclature Committee from 1997 
to 2007. See also note 4. For John Edwards, see note 116. 
155 See, for example, Gyapay et al. (1994). 
156 See previous page.
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Middleton-Price:  Going back very briefly to Fragile X and I’m looking to 
Pat because she’ll tell me if I’m wrong about this, but I believe it was Marcus 
Pembrey and Kay Davies who together coined the term ‘premutation’ in a 
hypothesis to explain the Sherman paradox,157 in which a premutation in normal 
transmitting males and non-manifesting females required transmission through 
a female meiosis in order to develop into what was called a full mutation, the 
nomenclature we still use today.158 
Jacobs:  You may very well be right. I can’t remember exactly who said what 
because there were a lot of people involved and that’s what made it so interesting. 
When I think of the days, weeks and years I spent thinking and discussing this 
problem of the Fragile X, it was just the most intriguing thing.159 
dr Fiona Macdonald:  I want to carry on from what Julian was saying. When I 
started in the lab in 1988, my first disease to work on was familial adenomatous 
polyposis (FAP) and we did that originally by linkage using Southern blotting 
which was, as you know, a pain. We then developed some PCR markers. We 
were greatly supported by having a European FAP network. There were a lot of 
UK and Dutch labs involved, particularly with the EuroFAP project that then 
extended into HNPCC (hereditary non-polyposis colorectal cancer) and we were 
able to share linked markers around.160 At the time my boss in the department 
was Maj Hultén and she was a good friend of Professor Meera Khan who was 
157 For Professor Dame Kay Davies see note 27 and for Professor Marcus Pembrey see note 102. Professor 
Pat Jacobs discusses the Sherman paradox on pages 45–6. 
158 Professor Marcus Pembrey wrote: ‘I believe we were the first to use premutation in relation to Fragile X. 
If I remember correctly, I was unaware of the term’s earlier use at the time, but was put right by John Opitz 
in an editorial accompanying our paper in the American Journal of Medical Genetics. This editorial seemed 
to be largely devoted to explaining why the review process had taken nearly a year, but added that the term 
delayed mutation or “premutation” had been used earlier in relation to achondroplasia pedigrees. In fact, 
when our paper came out I was surprised, but happy, to see that John Opitz had added a sentence and his 
reference at the beginning.’ Email to Ms Emma Jones, 4 October 2013. See Opitz (1981); Opitz (1985) 
and Pembrey et al. (1985). 
159 Professor Pat Jacobs wrote: ‘But in the end it was Jean-Louis Mandel who found the answer.’ Note on 
draft transcript, 8 March 2013.
160 For collaborative research on HNPCC in Europe, see Dr Pål Møller’s comments in Jones and Tansey 
(eds) (2013), page 18. 
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in Leiden.161 We set up a collaboration with Meera and with Riccardo Fodde 
and that was primarily to develop mutation detection once the gene had been 
found.162 Riccardo was setting up denaturing gradient gel electrophoresis, which 
he thought was probably the best mutation detection method around at the 
time if you didn’t want to go down the sequencing route. So we did that and we 
had to set up a register with Carol McKeown as the clinical geneticist.163 We had 
probably 200 to 300 families at the time, so we could do the mutation analysis 
relatively straightforwardly though, again, we had horrible gels to pour that 
leaked all the time and which were stuck together with bits of Sellotape. I also 
went out to the glaziers to buy some glass plates.164 Things have clearly moved 
161 Dr Fiona Macdonald wrote: ‘Professor Maj Hultén was Clinical Director of the West Midlands Regional 
Genetics Laboratory at Birmingham Heartlands Hospital from 1975 to 1997. She became Honorary 
Professor in Medical Genetics/Reproductive Genetics at the University of Birmingham (1989–1999). Her 
main research interest was devoted to studying patterns of meiotic recombination in males and females.’ 
Note on draft transcript, 6 September 2013. Professor Meera Khan (d. 1998) worked at the Department of 
Human Genetics, University of Leiden from 1966; see Pearson (1999). 
162 Riccardo Fodde is now Professor of Experimental Pathology at Erasmus Medical Centre, Rotterdam. 
163 Dr Carole McKeown was a Consultant Clinical Geneticist for the West Midlands Regional Genetics 
Service from 1987 to 2012. 
164 See comments by Professor Julian Sampson on page 51 and also Professor Bert Bakker’s comments on 
page 52. 
Figure 18: dr Fiona Macdonald
Clinical Molecular Genetics in the UK c.1975–c.2000
55
on because now, in our lab, we have the next generation sequencing panel for 
colorectal cancer with 10 to 15 genes on it, so we can look for all of these genes 
at the same time in about probably a tenth of the time that it took then.
Middleton-Price:  I want to mention one of the experiences I had working in 
the lab just after the 1989 paper that cloned CFTR.165 We had a family with a 
child who died of cystic fibrosis and we’d used the KM19 probes for a linked 
marker to do several subsequent prenatal diagnoses, each of which showed the 
fetus to be affected with cystic fibrosis and each was followed by termination. 
This family got more and more distressed as time went on. It went on over a 
period of two or three years. Marcus, I remember, was counselling the family 
and having difficulty explaining that this was a real result and not some sort 
of artefact. When the gene was cloned, we were able to use allele-specific 
nucleotides to detect the delta-F508 mutation and we could show within a few 
weeks of that paper that each of these fetuses, which had been terminated, really 
was homozygous for the delta-F508 mutation and, therefore, affected.166 The 
family was relieved and finally convinced that their potential babies did have 
cystic fibrosis.
Bobrow:  I would hate to leave this section without a brief word on population 
screening. I wonder if Bernadette can manage to do just a little bit on that just 
so that we don’t pass off without it ever being mentioned? First, though, we’re 
going to have a few words on cancer genetics. 
Macdonald:  I’ve talked already about FAP, so all I wanted to add is to explain 
how it took quite a long time before any of the other cancer genes started to be 
used routinely.167 There was a little bit of linkage going on for MEN and VHL at 
Cambridge [in the 1990s] and we started to do some for HNPCC.168 Once the 
breast cancer gene became identified, we all started to do mutation analysis.169 
Quite a lot was going on with Myriad Genetics, which was starting to talk about 
165 CFTR (cystic fibrosis transmembrane conductance regulator) is the gene in which mutations cause cystic 
fibrosis. See Kerem et al. (1989) and also Christie and Tansey (eds) (2004), pages 59–62. 
166 McMahon et al. (1990). 
167 For cancer gene testing, see also, for example, Jones and Tansey (eds) (2013), pages 69, 72–3, 75–6. 
168 For MEN, see Ponder (1990) and, for VHL, see Maher et al. (1992). The HNPCC research did not 
conclude with a publication; note on draft transcript from Dr Fiona Macdonald, 6 September 2013. 
169 Miki et al. (1994).
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the patent they owned for that gene.170 Maybe Rob can mention something 
about that because he was secretary of the CMGS (Clinical Molecular Genetics 
Society) at the time and he did quite a lot of talking to the European labs about 
the patent and discussed it with Myriad. 
elles:  Other people might have to fill in the gaps but I remember that there was 
a cancer genetics group meeting in London in 1998 at which the chief executive 
or some executive from Myriad stood up and said, ‘What’s gone before has gone 
before but we’re drawing a line in the sand now, and if it’s not for research use, 
you owe us money or you have to stop.’171 I’m paraphrasing what he said but it 
was pretty clear and blunt, as I recall, and everybody kind of rocked back on 
their heels. I was secretary of the CMGS at the time.172 We thought it was a 
serious issue and we also thought that it was a policy issue and so we referred 
to the Department of Health (DoH). There was a precedent for it because 
there had also been the story of the Taq polymerase patent and the attempt 
to restrict the use of polymerase chain reaction (PCR) that had also gone for 
central negotiation by the DoH.173 The CMGS dealt with a unit at the DoH for 
a couple of years, feeding it information about the scope and level of activity on 
breast cancer genetics research in the UK and the potential damage, as we saw 
it, to the development of the field in the UK. I think it’s fair to say that BRCA 
was really quite a driver in terms of the public’s connection to clinical molecular 
genetics at that time.174 There was a build-up of pressure from the patients, with 
Breakthrough Breast Cancer and other cancer patient organizations driving a 
greater awareness of the potential for this type of testing and its benefits among 
170 See Jones and Tansey (eds) (2013), page 74. 
171 Dr Rob Elles wrote: ‘This was the Cancer Family Study Group, forerunner of the Cancer Genetics 
Group. The meeting was on Tuesday 8 December 1998 at St Thomas’ Hospital, London. Greg Critchfield 
was the Myriad Executive who spoke.’ Note on draft transcript, 14 August 2013. 
172 Dr Rob Elles was Secretary of the CMGS for two three-year terms between 1988 and 1994. 
173 The Probe newsletter (of the CMGS), autumn 1995 issue, included an article on the royalty fees charged 
by Hoffman-LaRoche for PCR tests, noting that the corporation waived fees pre-April 1995; pages 3–4. A 
copy of this newsletter will be deposited with the records of this Witness Seminar at the Wellcome Library 
under reference GC/253. 
174 See Professor Gareth Evans’ comments on the impact of the identification of cancer genes and referrals 
to clinical genetics services in the UK in Jones and Tansey (eds) (2013), pages 53–4. 
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the public.175 All of that fed into a policy within the DoH. Anyway, to cut a long 
story short, the upshot was that we got the message – maybe not quite overtly 
– that it was okay to carry on, and we did. However, I think the patent issue 
did put a ‘planning blight’ on the field for a couple of years. I think it’s true to 
say that BRCA service efforts, others may also comment, were very fragmented 
for a while:  the field was poorly funded and we didn’t do very well. In part, that 
led to the development of pressure because there were huge backlogs of patients 
waiting to be tested.176 It was only really, we’re rolling forward a little bit, with 
the genetics White Paper that there was an overt decision to invest in this field 
and even to set us quite stringent targets to clear our BRCA backlogs.177 So the 
UK came out with a position on the patenting issue, I think. 
Bakker:  On the European level, a lot has happened because the BRCA1 patent 
was also enforced by Myriad Genetics in all other countries, in the Netherlands, 
in Belgium, etc.178 The guys from Myriad came and visited the lab and said, 
‘Okay, you should go for licensing’. We didn’t want to do that because we were 
already performing pre-symptomatic tests based on an earlier paper that had 
been published, and the patent was on a later gene sequence, before their patent 
came into force and that point was also argued. Together with the clinical 
genetics centres in Netherlands and in Belgium, we put money aside and hired 
an attorney on patent rights and he successfully revoked the patent:  Myriad 
now only has the patent on the Ashkenazi Jewish mutation.179 To come back to 
175 The charity Breakthrough Breast Cancer was founded in 1989 to create the UK’s first dedicated 
breast cancer research centre. It presently funds approximately 25 per cent of breast cancer research in 
the UK; http://www.breakthrough.org.uk/about-us/our-work/our-story (visited 28 June 2013). For recent 
international media coverage of genetic testing issues for BRCA1 and BRCA2, see also Hurley (2013). 
176 Dr Rob Elles wrote: ‘By 2001 there were substantial backlogs of BRCA patient samples awaiting testing 
in all areas of England. All services bid against £18m lab modernisation funding from the 2003 White Paper 
in 2004 and rationalised their capability in BRCA testing. From 2005 to 2006 all services were required to 
report their progress on clearing BRCA backlogs to the Genetic Commissioning Advisory Group. This was 
the only service area for which we were asked to provide this data. In 2006 and 2007 we and other services 
were asked to provide an audit of performance against BRCA reporting time targets for Breakthrough Breast 
Cancer, so the pressure came from patients and the DoH in my opinion.’ Note on draft transcript, 14 
August 2013. 
177 Department of Health (2003). 
178 See, for example, Matthijs and Halley (2002). 
179 The Myriad patent for BRCA2 that specifically related to people who are Ashkenazi Jewish, or their 
descendants, is for the mutation 6174delT associated with breast-ovarian cancer. See, for example, Gold 
and Carbone (2010).
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the PCR patent, at a certain moment the company PerkinElmer had bought 
the patent from [Kary] Mullis and they wanted to enforce this patent on the 
laboratories that were using PCR for diagnostic services.180 
At that time my position was that we had paid royalties when we bought the 
enzyme. Buying the enzyme pays for everything in there and with the diagnostic 
service we don’t earn money because it’s closed patient care, so we are not going 
to pay for that and if you want you can come and sue us, but then you would 
have to sue all the laboratories which were performing these tests. So they never 
did that. Then they sold the patent to Roche and again the circus started and 
Roche came to ask for royalties.181 We said the same, just moved it up to the 
Ministry of Health and said, ‘Okay, we are not going to pay to do it. Come and 
sue us.’ And they never did. 
Bobrow:  And there was, I can’t remember his name, Jacques –
Bakker:  In Belgium it was Gert Matthijs.
Bobrow:  That’s right; it was Gert Matthijs who devoted years of his life to 
leading this effort.
Bakker:  He led this consortium that we had with all the clinical genetics centres 
in Belgium and Netherlands to get the patent revoked. Gert Matthijs was the 
spokesman and he had an article in the European Journal of Human Genetics on 
that.182
Bobrow:  He deserves much thanks. Let me just note in passing that one of the 
things that is now self-evident, but to me was quite surprising at the time, is that 
out of this very large morass of what could have been coincidental accumulations 
of breast cancer, a very common disease in families, people actually in the end 
managed to drag out a monogenic set of conditions. To my recollection it was 
not self-evident at the time that these aggregations represented anything other 
180 Dr Kary Banks Mullis (b. 1944) developed the process of polymerase chain reaction in 1983, for which 
he was awarded the Nobel Prize for chemistry in 1993. For a full biography, see http://www.karymullis.
com/biography.shtml (visited 7 October 2013). 
181 ‘[In 1991] Hoffman-LaRoche Inc. acquires worldwide rights and patents to PCR.’ Quoted from 
Timeline of PCR and Roche at http://molecular.roche.com/About/pcr/Pages/PCRTimeline.aspx (visited 28 
June 2013). 
182 Professor Gert Matthijs is Head of the Laboratory for Molecular Diagnosis, Center for Human Genetics, 
University Hospital Leuven, Belgium. For the work of the consortium see, for example, Aymé et al. (2008). 
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than chance aggregations. It was quite a lot of hard work to make that step. 
Let’s go to molecular cytogenetics and I was hoping that Malcolm might have 
something to lead off on.
Ferguson-smith:  First, an observation that, of course, molecular cytogenetics 
emerged 43 years ago, so there’s quite a long period to cover.183 It started in 
1970 with Mary Lou Pardue and Joe Gall and their work with major mouse 
satellite DNA, which they obtained by ultra-centrifugation; they labelled this 
DNA with tritiated thymidine and showed by autoradiography that all the 
hybridization signals on metaphases occurred at the centromeric regions of 
the mouse chromosomes.184 At the same time, they observed that these mouse 
chromosomes, after this denaturation treatment and stained with Giemsa, showed 
a dark band over the region of satellite DNA. This was the start of C-banding 
and all the rest of the C-banding methods, including trypsin banding, emerged 
from that experiment with the exception of Q-banding, which Caspersson, with 
Lore Zech, independently discovered in the same year.185 The next step was made 
by Angie Henderson who mapped the human ribosomal genes to the satellite 
regions of the acrocentric chromosomes, again using the same technique of 
183 For further accounts of the history of human cytogenetics, see Ferguson-Smith (1993) and 
Ferguson-Smith (2008). 
184 Pardue and Gall (1970). 
185 Caspersson et al. (1970). 
Figure 19: Professor Malcolm Ferguson-smith
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labelled, moderately repetitive ribosomal DNA material made from Xenopus.186 
This was the first example of human gene mapping by in situ hybridization. 
Then along came Kurt Hirschhorn and Price whom you will remember in 
1972, claimed to map globin.187 They used rabbit messenger RNA and claimed 
that the beta globin gene was mapped to chromosome 4. Everybody laughed 
heartily because, of course, the amount of radioactive DNA they used couldn’t 
possibly have given the results they claimed in their experiment. It took a long 
time after that before we got the first single copy genes correctly assigned by in 
situ hybridization.188 During the interval, between 1972 and 1981, when the 
recombinant DNA we just heard about was developed, the ability to obtain large 
amounts of the same DNA fragment became possible by cloning it in bacteria 
and various vectors, including YACs (yeast artificial chromosomes), plasmids, 
cosmids, and later on BACs (bacterial artificial chromosomes). So in 1980, as 
I mentioned earlier, Sue Malcolm joined our group to map the globin genes 
using the highly labelled, cloned DNA.189 At the time, the only person I could 
find who would support an application to the MRC for this project was Bob 
Williamson. Bob joined in and agreed that it might now be possible to map 
single copy genes. We’d been working on the ribosomal genes before that and 
knew how to do the in situ technique. So when Bob provided the cDNA probes, 
Sue managed to map both the alpha and the beta globin genes to the short arm 
of both chromosomes 16 and 11 using in situ hybridization with probes labelled 
with tritiated thymidine. Afterwards, in 1982, we went on to map the kappa 
light chain genes to chromosome 2.190 In the same year Harper and Saunders 
mapped insulin to the short arm of chromosome 11.191 These were the first 
papers on single copy gene assignments. Now the problem with this work, and I 
was involved in doing it too, was the terrible business of autoradiography, which 
involved dipping slides into photographic emulsion, counting grains after three 
weeks’ exposure and trying to do a statistical analysis to see if you got a significant 
result on any particular chromosome. It was clear that these radio-isotopes had 
to be replaced by something better. This is where the fluorescent labels came in. 
186 Henderson et al. (1972). 
187 Price et al. (1972). 
188 Malcolm et al. (1981). 
189 See page 29. 
190 Malcolm et al. (1982). 
191 Harper et al. (1981). 
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The key people who were working on this, around about 1982/83, were David 
Ward and Sam Latt in Boston, Ton Raap and Hans Tanke and others.192 Ton 
Raap, as far as I recall, had some of the best technology.193 First, we used confocal 
laser microscopy and then moved to digital fluorescent microscopy with image 
processing. That was made possible using a cooled charge device, the CCD 
camera that was able to identify the signals of very low luminescence which 
is critical for fluorescent in situ hybridization (FISH). FISH soon had many 
applications in gene mapping, positional cloning of disease genes, aneuploidy 
detection in interphase and fibre-FISH. I mention fibre-FISH particularly 
because it had such high resolution for mapping closely linked sequences on 
chromosomes. Then, in the late 1980s, chromosome painting came onto the 
scene; first of all using cloned chromosome libraries.194 The key people in those 
days were Joe Gray and Dan Pinkel in Livermore lab in San Francisco, who 
made cloned chromosome libraries from sorted chromosomes, starting about 
1972.195 I was introduced to chromosome sorting in 1980 by Bryan Young, 
who has been mentioned already in connection with the construction of the 
X chromosome library for the work on X-linked markers.196 Bryan came to me 
one day and asked if I could help in the interpretation of the flow histogram of 
the MRC cell line with multiple X chromosomes. There were lots of peaks that 
seemed to correspond to chromosome size, so I suggested that we should sort 
chromosomes from peripheral blood samples. We did this and were soon able 
to identify chromosomes and chromosome aberrations from the sorting preps. 
This took me into a technology that I’ve stuck with for over 30 years thanks 
to Bryan Young. In 1992 there was an important development, from a PhD 
student, Haakon Telenius in my Department of Pathology at Cambridge. He 
developed a novel method for the amplification of DNA from any source, using 
random primed oligonucleotides as primers. So, from our sorted chromosomes 
it was possible to make quantities of fluorescent chromosome-specific DNA 
probes using DOP-PCR as it was called.197 Soon we were able to share these paint 
probes made from sorted chromosomes, labelled in either red or green, with 
192 For Ward, see Lichter et al. (1991). See also Latt (1973).
193 See, for example, Raap (1986) and van der Ploeg et al. (1985). 
194 See, for example, Cremer et al. (1988). 
195 Pinkel et al. (1988). 
196 See pages 34 and 38. 
197 Carter et al. (1992). 
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our colleagues. Eventually they were distributed around the world by Cambio 
in Cambridge.198 These whole-chromosome paints have been used mostly to 
improve the diagnosis of chromosome rearrangements and, more recently, in 
phylogenomic studies.199 A few years later, Thomas Reid at NIH developed 
M-FISH using our assorted chromosomes, labelling them in different colours 
from combinations of five different fluorescent colours. This gave a different 
colour to each individual chromosome in one FISH hybridization, allowing the 
easier identification of aberrant chromosomes. Identification was also possible by 
using colour-banding techniques to look for intra-chromosomal rearrangements. 
We were particularly excited about using gibbon chromosome-specific DNA to 
generate colour bands in human chromosomes, a method we named Harlequin 
M-FISH.200 In 1992, I should mention Kallioniemi, who introduced chromosomal 
comparative genome hybridization (CGH).201 In 2001 we had the draft sequence 
of the human genome that gave us reference BAC clones. So around 2004, roughly, 
array CGH replaced chromosomal CGH as a way of diagnosing chromosomal 
aberrations. It’s now fair to say that array CGH has almost replaced conventional 
cytogenetics in the detection of chromosome aberrations. So this has been a most 
important development. Some people argue about this but I maintain that is what 
is happening now. In the end, of course, the sequencing of individual genomes 
will replace both array CGH and FISH. History shows that the emergence of 
FISH, in the 1980s, rendered obsolete mapping by genetic linkage, somatic 
cell hybrids, RFLPs and Southern blotting. All these techniques, previously so 
important in medical genetics, are now replaced because FISH has a far higher 
resolution. Gert-Jan van Ommen, in particular, claimed that a resolution of one 
to two kilobases was possible using FISH. So there’s still a very strong place for 
FISH in gene mapping and for some diagnostic work, but I think it will be taken 
over eventually by individual genome sequencing. 
Bobrow:  So although cytogenetics and molecular genetics started in different 
places, actually the subject matter that they deal with is pretty similar and the 
two have approximated to the point where they are now together at a scientific 
198 Cambio is a company that supplies molecular biology reagents and consumables to scientific research 
laboratories; http://www.cambio.co.uk/about/ (visited 1 July 2013). 
199 See, for example, Stanyon and Stone (2008). 
200 See, for example, Ferguson-Smith et al. (2005). 
201 Kallioniemi et al. (1992). 
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level. I think there’s some interesting discussion as to whether they have come 
together at a clinical level and how that’s going to happen. But we’ll come 
to that. 
Weatherall:  There is a very nice example of that in the alpha thalassaemia mental 
retardation syndromes.202 The types that affect chromosome 16, of course, 
turned out to be due to submicroscopic telomeric rearrangements or deletions. 
These findings led to the widespread use of screening for other submicroscopic 
deletions.203 I think this is a very nice example of interplay between the 
two worlds.
Ferguson-smith:  Yes, I’m sorry that I skipped over diagnostic FISH rather 
rapidly and didn’t cover all the important techniques. The subtelomeric sequence 
probes were used for identifying the most frequent parts of the chromosome 
involved in rearrangements, because it is usually the ends of chromosomes that 
take part in interchromosomal rearrangements. FISH using the subtelomeric 
repeat probes played a really important part in identifying cryptic chromosome 
aberrations in mental handicapping conditions. So this was another important 
advance in clinical cytogenetics.
Bobrow:  Would you just like to give us a name or two associated with that stuff, 
please, for the record? 
Ferguson-smith:  Yes, Jonathan Flint in particular.204
sampson:  It was just to add that FISH was extremely useful for defining 
mosaicism for deletions, and actually though next generation sequencing 
will surpass it, it’s still much more sensitive for identifying mosaicism than, 
say, MLPA (multiplex ligation-dependent probe amplification) or the other 
techniques that are in current use.
Bobrow:  I want to ask Pat Jacobs a question because she has been the eminent 
director of a very large integrated laboratory. Are cytogenetics and molecular 
genetics still separate disciplines?
202 Weatherall et al. (1981).
203 Professor Sir David Weatherall added: ‘[This screening] has now become a routine part of cytogenetic 
analysis for unexplained cases of mental retardation.’ Email to Ms Emma Jones, 8 October 2013. See Flint 
et al. (1995). 
204 Knight et al. (1999). 
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Jacobs:  Unfortunately they are, although we try very hard, but people hold on 
to what they are familiar with. It is not a popular choice to integrate molecular 
and cytogenetics people, to realise they’re all part of one big team. However, it 
is happening slowly. I’m not head of the laboratory anymore and haven’t been 
for years. It is very difficult to lose a discipline that has given so much to clinical 
genetics and to some extent I’m sympathetic because I’ve been very sad at seeing 
cytogenetics go because it was, for me, so aesthetically pleasing. I realise that’s 
not why we do science but it should be one of the reasons why we sometimes 
do science. But for all practical purposes, nobody in our lab now looks down 
a microscope.
Ferguson-smith:  It’s evolution, for goodness sake! Evolution occurs in our 
science and every other aspect of life in this world. We’re all slaves of our 
technology, as somebody said. So we must make way for new technologies and 
I think we have to embrace the fact that we simply can’t spend the time looking 
down the microscope counting chromosomes in the way we used to do it, and 
take so long to give reports to our patients. We have to give them the benefit of 
the new technology. Okay, array CGH is expensive to begin with but only by 
applying it to a larger number of people will the costs go down, and that’s what 
always happens with technology.
Bobrow:  Well, unlike Pat, I thought that what had actually happened is that 
cytogenetics, which is aesthetically very pleasing, has really advanced enormously 
in the sort of resolution that you can now achieve by using slightly different 
techniques. So I think it’s cytogenetics that’s won.
Jacobs:  Oh good. But it hasn’t really because there is little that is aesthetically 
pleasing about arrays. 
Bobrow:  No, you’re probably right. 
Jacobs:  Array CGH doesn’t look biological but it gives a lot of information. 
Anyway, it’s happening and I don’t want you to think our lab’s not doing it, 
because we are. 
Bakker:  Although, of course, it’s outside this window that we’re looking at 
now; since 2006 the two laboratories, molecular genetics and cytogenetics, 
have become one group. It’s called genome diagnostics. Of course, there is 
a discipline that looks at chromosomes and a discipline that looks at DNA 
and at arrays, and we’re going towards whole genome sequencing but the two 
will merge, and we still occasionally will need the chromosomes. If you find a 
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trisomy 21 you need to know if it’s a translocation or not. You need to look at 
these chromosomes to see if it’s inherited Down’s syndrome or not. So we will 
keep the chromosomes but at a much smaller level.
Bobrow:  Right, we are all in agreement:  historic inevitability. I was now going 
to draw a line under science and look much more directly at clinical application 
and organizational and patient-facing things for the rest of our time, by asking 
two people who were involved in managing this at a higher level in England and 
Scotland to talk to us about the way in which the clinical lab services developed 
over this period of time. 
dr rosalind skinner:  Can I, before I go into molecular genetics, just round off 
something about the picture on the cytogenetic front? I totally sympathized with 
what Pat was saying and the emotions felt by people who worked for many years 
in cytogenetics. For 24 years in Edinburgh, I lived next door to Ann Chandley 
and I had daily sentiments of the same ilk from her.205 But we have moved on, 
and the two professional associations, the Clinical Molecular Genetics Society 
(CMGS) and the Association for Clinical Cytogenetics, have just merged and 
they will have their inaugural joint meeting at the BSHG (British Society for 
Human Genetics) meeting in September. There is a significant proportion of 
labs which are now integrated and those that aren’t are certainly moving in that 
direction.206 Cytogenetics was incorporated into the Scottish Molecular Genetics 
Consortium from about 2007 after our last review.207 So things are moving that 
way but absolutely no disrespect to the huge input from cytogenetics in the 
past. Cytogenetics started it all off; I think we have to remember that. 
You’ve asked me to talk about the consortium in Scotland: this developed in the 
window of time between me leaving front-line genetics in 1983 in Scotland, and 
re-emerging to organize, as it were, and be involved with, the arrangement of 
genetic services from the health department in Scotland at the end of 1988. If I 
could just paint the picture very quickly for folk: by the mid-1980s in Scotland the 
four university medical centres all had academic interests in medical genetics; they 
205 Dr Ann Chandley worked as a cytogeneticist at the MRC Human Genetics Unit in Edinburgh and 
was heralded by Professor Malcolm Ferguson-Smith as ‘an international authority on cytogenetics’. See 
Ferguson-Smith (1997), quotation from page 3. 
206 Dr Fiona Macdonald provided a copy of the Resolution for CMGS members on the formation of a 
British Society for Human Genetics, c.1994, which will be deposited in the Wellcome Library, London, 
with the records of this meeting at reference GC/253. 
207 Scottish Executive (2006). 
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all had people working in medical genetics and there were consultant-led clinical 
genetics services in three of them, in Aberdeen, in Edinburgh and in Glasgow. In 
Dundee, although there was academic interest in genetics, there was no clinical 
geneticist in post in the mid-1980s. That said, Mike Faed, who was a cytogeneticist 
based in the pathology department there, did his level best to make sure patients 
there weren’t too disadvantaged. They did, in the early 1980s, travel mostly for 
complicated cases either up to Aberdeen or they came down to us in Edinburgh 
for counselling. But in 1985, as molecular genetic testing really began to take off, 
the great foresight of the leaders of the academic centres was to come together and 
discuss how they could organize genetic testing for Scotland from then on. Malcolm 
was involved, so I hesitate, but we did discuss it and he said I should lead off, but 
he will feel free, I know, to chime in if I get any of it wrong. They showed great 
foresight to come together and see how they could coordinate the development 
of this new, rapidly developing, field for Scotland. And the people involved were 
Malcolm, David Brock in Edinburgh, and Alan Johnston in Aberdeen, who was 
not a trained geneticist but was a physician with a very keen interest in genetics.208 
208 David Brock (1936–2004) was Emeritus Professor of Human Genetics at the University of Edinburgh; 
http://www.scotsman.com/lifestyle/obituaries/david-brock-1-564914 (visited 23 July 2013). Dr Alan 
Johnston (1928–2012) was Consultant Physician, Aberdeen Hospitals and Senior Lecturer in Genetics, 
Aberdeen University. Professor Peter Harper commented on Dr Johnston’s career: ‘… he was actually a 
trained geneticist: he trained with McKusick but there was no clinical genetics job at the time in Aberdeen.’ 
See also Johnston (2012) and Professor Peter Harper’s interview with him, available at http://www.
genmedhist.info/interviews/Johnston (visited 8 October 2013). 
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Most of his genetic work was in cytogenetics but he was an assertive man and he was 
very anxious to build up a proper service in Aberdeen and he did that remarkably 
well. In Glasgow there was Malcolm and in Dundee was Mike Faed. So, as I said, 
they came together, there were a few hiccups, but then after some discussion they 
decided to put a joint bid into the then Scottish Home and Health Department 
(SHHD) for some development funding to try a new service approach for providing 
molecular genetic testing for the population across Scotland.209 They were successful 
and were awarded what was called ‘New Developments in Healthcare’ money by 
the SHHD but this was relatively short-term funding. None of my ex-colleagues 
can find the original archive files for me, so I don’t know if it was three-year or 
five-year funding. What they aimed to do was to fund four labs from this money, 
one in each of the centres, to provide molecular genetic testing but very wisely 
decided that, with the population around five million in Scotland, and it is relatively 
rare disorders we’re dealing with, it would be silly for each of the four centres to try 
and provide the full repertoire of tests that was becoming available. It would be very 
wasteful in terms of effort and resources. So they agreed that they should work in a 
consortium mode and they would agree a list of disorders for which it was possible 
to provide tests, divide up this list of diseases between the laboratories and each 
tackle an allocated number of diseases and provide testing on behalf of the whole 
population in Scotland. The way it was to work was that patients would be seen 
by their local clinical service; they would receive their counselling from their local 
clinical service, the blood would be taken and the local laboratory would extract 
the DNA and then send it to the Scottish laboratory that had been allocated that 
disease to test. The test was done, the results went back to base and the family was 
counselled by their own local service. So it was absolutely marvellous for the patient 
population of Scotland and it provided total equity of access to the whole repertoire 
of genetic tests that were available at that time and the new developments as they 
came along. I really have to salute my forebears in this because really and truly 
I think you (Malcolm) put in place the basis of a model service. I hope we have 
done you justice in the way we have built it up since then. I came into the Scottish 
Home and Health Department at the end of 1988. I think I was, it is fair to say, 
the only person within the walls of St Andrew’s House who’d ever had any contact 
with genetic services at all.210 So, though my remit was really public health, I was 
209 Professor Malcolm Ferguson-Smith wrote: ‘All four of us had made separate applications to the SHHD 
without success. Our joint bid simply amalgamated these bids with additional proposals to share the load. 
There were no hiccups! The grant awarded amounted to the total sum requested initially.’ Note on draft 
transcript, 2 June 2013. 
210 St Andrew’s House is headquarters of the SHHD. 
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immediately asked, because the consortium funding was coming up for review after 
five years, would I be prepared to lead a review of the service so they could decide 
on future funding? I happily agreed to do that. I had able help from some civil 
service colleagues; we went around, assessed the situation in each of the centres, 
put a report together. Then, with two very helpful colleagues from south of the 
border, Peter [Harper] and Rodney [Harris], who agreed to act as external referees, 
I’m happy to say that all our recommendations were accepted. So, as a result, it was 
decided the consortium would stay and it was put on a firm funding basis from 
then on. It would be centrally funded as a national service in Scotland, which meant 
money would be top-sliced from the 15 health boards – there were 15 in those days 
– and this put it absolutely on a stable basis. Also, it would continue working in the 
same mode but we would formalize the arrangements a little bit; we suggested there 
should be a formal steering group set up. For the first time the users of the service 
were brought in to have their say on future developments as new funding became 
available and things gradually began to develop. Laboratory standards were put in 
place, result turnaround times were agreed, and they were put into contracts for the 
labs long ahead of any similar contractual turnaround times anywhere else in the 
UK. The service developed activity units, Welcan, for assessing laboratory activity; 
workload units, that’s the best way to describe them.211 By the time all that was 
done, at the end of the 1990s, there was a very stable and successful service in place 
in Scotland. As I said, it did provide equity of access for the whole range of genetic 
tests that was available; the funding was available not just to provide testing within 
Scottish laboratories. If any Scottish families needed tests that couldn’t be provided 
locally, the test could be done in any UK or even European laboratory where it was 
available and would be funded from this same pot of money. So it did away with all 
the postcode lottery disputes that have upset people with other services. I really do 
admire what you started, Malcolm, and give full acknowledgement. I think we must 
also acknowledge the huge input from David Brock into molecular genetics. Sadly, 
David died some years ago, long before he should have. He was very young, only 
68 when he died, and recently Alan Johnston in Aberdeen has died too.212 Lastly, in 
2005, after the White Paper in England, each of the countries in the UK took the 
opportunity again to review where they were with genetics. We had a major review 
in Scotland and as a result of that we got a large amount of additional funding. I’m 
delighted to say we got £10 million of additional funding for genetics in Scotland as 
211 ‘The Welcan workload measurement system, developed from the Canadian schedule of unit values for 
clinical laboratory procedures, attempts to provide a series of relative weighted procedure values reflecting 
labour input.’ Quoted from Tarbit (1990), page 92. 
212 For Brock and Johnston, see note 208. 
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well as some rolling money. So the Scottish Molecular Genetics Consortium was put 
on an even stronger basis then. Apart from just getting money for consumables and 
staffing, they now have a rolling capital budget so they don’t have to compete with 
other services within a trust for new equipment in the laboratories, which has been 
a huge step forward. It was decided, as cytogenetics was increasingly using molecular 
techniques, it made sense to try and integrate the service and so cytogenetics is now 
integrated into the genetic laboratory consortium service. 
dr ian lister Cheese:  My recollections come from about the same time as 
those from Ros Skinner, 1984 to 1985. But I have rather a different view from 
the one Ros has just described, a much less tidy one. Donald Acheson had, I 
think, received a copy of Sir David’s (Weatherall) book, the second edition, 
and he passed it to me.213 That was really the beginning of my responsibility 
for that area of policy in the Department of Health.214 At the same time I got 
to know a number of people, I might say the leaders in the field, Sir David, 
Rodney Harris, Marcus Pembrey, Peter Harper, yourself Martin, and many 
others. What soon became clear was that in the DoH there was no substantive 
policy for genetics or for matching laboratory services. I think one can say there 
was no policy for genetics services or laboratory services for almost another 
213 Sir Donald Acheson (1926–2010) was Chief Medical Officer, Department of Health (1983–1991). See 
Weatherall (1985). 
214 Dr Ian Lister Cheese was a senior civil servant in the Department of Health (1984–1996) and had 
responsibility for genetics services. 
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20 years.215 In one particular way this didn’t greatly matter. It became quite 
obvious from the existing services that the pattern of genetics services, the 
organization of services, the conduct of services, the specialties, the components 
that were needed to give a coherent and cogent genetics service were already 
in place, but they lacked capacity and the conditions necessary for growth. 
Our colleagues in the genetics profession who came to the department, before 
this area was my responsibility, to propose that there should be a development 
of their existing services, must certainly have known about this problem. But 
they presented a case, saying:  ‘Let us evaluate services in three major centres 
– four originally but Sir David Weatherall’s centre didn’t participate in the 
end – in Cardiff, in Manchester and in London, and determine their clinical 
and cost-effectiveness.’ In 1985 the DoH agreed to fund a Special Medical 
Development (SMD).216 The condition of evaluation was to determine the 
cost-effectiveness and the value to the community and to patients of the 
introduction of these services into the NHS. A great advantage of this was, I 
think, that monies were provided to the existing services to expand them. Money 
was also provided to another unit to evaluate them. It became clear within a very 
short time that these services were needed and were valued by patients and the 
outcomes were the outcomes that patients desired. In a way the policy was already 
there but unwritten. There was a sense in which the SMD was unnecessary, 
unnecessary for the reason I’ve given but also unnecessary in the sense that what 
was going to happen could have been foretold. No one was going to wait or be 
influenced by the cost-effectiveness evaluation, which didn’t appear until two 
215 Developments for a national policy on genetics during that period included the Government’s 
appointment of a Science and Technology Select Committee (1994–1995) under the banner of Human 
Genetics: The Science and its Consequences, which culminated in the creation of the Human Genetics Advisory 
Commission (1996–1999), of which Professor Martin Bobrow was a member. This body was absorbed into 
the new Human Genetics Commission in 1999; http://webarchive.nationalarchives.gov.uk/+/www.dh.gov.
uk/ab/Archive/HGAC/index.htm (visited 2 July 2013). Another policy development was the publication 
of Genetics and Cancer Services in 1996, known as the ‘Harper report’, after its Chairman Professor Peter 
Harper, which recommended ‘a core service in cancer genetics’. See Department of Health (1996), quoted 
from page 1. For the later policy that Dr Lister Cheese refers to, see Department of Health (2003). 
216 Dr Ian Lister Cheese wrote: ‘The Special Medical Development (SMD) was led by Professors Peter 
Harper, Rodney Harris and Marcus Pembrey, and included Drs (now Professors) Angus Clarke and Dian 
Donnai and Drs Helen Hughes, Helen Kingston and Maurice Super. The interim report was not published 
formally but was made available to participants.’ Note on draft transcript, 1 May 2013. Dr Lister Cheese 
explains that the SMD was ‘to explore the application of new genetic probes in the service context’; quoted 
from Harper et al. (2010), page 57. In the same volume, see also pages 50, 60–1, 79. See also Meredith et al. 
(1988) and Harris et al. (1989).
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or three years later anyway. That’s my view of the SMD. Knowing that the final 
evaluation wouldn’t appear for several years, with the help of Rodney Harris 
and Marcus Pembrey and Martin Bobrow, we wrote an interim report in which 
we talked not about cost-effectiveness of the service but simply about the value 
to patients.217 That, I think, was probably the most valuable outcome of the 
SMD. The department seemed rather refractory to change, and subsequently 
resisted central direction in favour of a competitive internal market. Malcolm 
talked about us being driven by technological advance; the department was not 
driven at all by such advances – it had to be prodded into action. And it is one 
of the most disappointing features that, given the expert advice it received from 
outside, none of these things happened as they should have done, as indeed 
happened in Scotland.218 Other colleagues have talked today about the value 
of their professional meetings. I was a non-geneticist, of course, and I cannot 
say too much how I valued and learnt from the meetings with colleagues in 
the profession, in their societies, the Royal College of Physicians’ Genetics 
Committee, the Society – I think it was still called the Eugenics Society at the 
time but soon became the Clinical Genetics Society.219
Bobrow:  No, they were different, just for the record, different. 
lister Cheese:  But all the elements of a policy had been well-established by 
authoritative bodies and had been tested, one might say, through collaboration 
and peer review long before the department set its eyes on them. It’s one of 
the disappointing things, as I said, that the department seemed not to take the 
authority of external bodies in the development of its own policies. 
217 See Department of Health and Social Security (1987). 
218 Dr Ian Lister Cheese wrote: ‘At that time, the Department refrained from giving any kind of specific 
instructions to the NHS. However, the Chief Medical Officer (CMO, Sir Kenneth Calman) and the 
Chief Nursing Officer (CNO, Yvonne Moores (later Dame)) were able to write a joint Professional Letter 
on clinical genetics services, and to draw the attention of people to their importance in the developing 
NHS.’ Note on draft transcript, 1 May 2013. See Department of Health (1993). Sir Kenneth Calman was 
CMO, Department of Health (1991–1998). Dame Yvonne Moores was CNO, Department of Health 
(1992–1999). 
219 The Eugenics Education Society was founded in 1907, becoming the Eugenics Society in 1926 and then 
the Galton Institute in 1989. See Hall (2002). Founded in 1970, the Clinical Genetics Society (CGS) was 
created ‘to bring together doctors and other professionals involved in the care of individuals and families 
with genetic disorders…’; quoted from http://www.clingensoc.org/about-us.aspx (visited 2 July 2013). See 
also Harper et al. (2010), pages 52–3.
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skinner:  Could I just say something, a key thing that I forgot to mention on 
the Scottish scene? When we did the 1989 review and were successful in getting 
the central funding and the national service set up – what would not happen 
now at all – we managed to succeed in getting the centre to pay the funding 
to set up a consultant clinical genetic post in Dundee so that there would be a 
proper service established in Dundee and equity of access for all the population 
of Tayside. Following on from what Ian said, he’s absolutely right. We found it 
difficult, to say the least, to communicate between departments because there 
really wasn’t an identified policy group dealing with genetics and it was equally 
true in Scotland; I was a lone person there doing it as a ‘hobby’ because I was 
interested in genetics. Ian was in London. It wasn’t until around about 2000 that 
the Department of Health, I think, put together a genetics team and we began 
cross-border discussions and greater UK-wide collaboration. It was then, when 
Mr Milburn was going to make his speech, that I got a call from colleagues to 
say, ‘Do you know this is going to happen? You’d better come and listen; there’s 
going to be a White Paper and you need to know about it.’220 From then on, we 
have worked extremely closely together, the departments around the UK, but 
until then it was difficult because neither side of the border had policy teams 
that could really talk to one another. 
Bakker:  In the Netherlands we had a similar situation as in Scotland. When the 
first probes came out, we sat together with the different centres and divided the 
diseases.221 That system has continued over the years and all eight centres have, at 
certain times, done different portfolios of diseases. For the frequent diseases, every 
lab was setting up diagnostic tests such as for Fragile X and breast cancer. But 
for the rare disorders, tests were designed in expert centres for the whole of the 
Netherlands, so each centre had its specific portfolio of genetic tests. The samples 
had to travel, not the patients. We sent the samples to the different laboratories 
and results came back and the patients got counselling at the local place. So that 
has been the system since that time and the major advantage of that is, with the 
eight centres, we now offer tests for over 1,300 genes at the DNA level, and if each 
different laboratory should have done that it would have been impossible.
Ferguson-smith:  Can I just say that the organization of services in the 
Netherlands was really excellent. I was fortunate to be invited to go and talk 
to people in the Netherlands about genome services some years ago and it was 
220 See note 177. 
221 See Professor Bert Bakker’s comments on pages 37–8. 
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really very encouraging to learn about their experience. What I wanted to ask, is 
why it was that genetics departments in England didn’t share conditions in the 
way that was done in both the Netherlands and Scotland? Well, perhaps they 
did later on, but it took a number of years for this to happen. It seemed that 
each lab wanted to do everything.
Bobrow:  We have a volunteer in the form of Rob Elles who is going to answer 
your question. 
elles:  I’ll comment on that but first I think Ian underestimates the impact of the 
Special Medical Development on molecular genetics in England and Wales.222 
Locally, I can speak for Manchester. I don’t think that molecular genetics would 
have embedded itself with the speed and scope that it did, in fact, without that 
core funding over two cycles and I think it was tremendously important. During 
that period, there was also a tremendous ethos of sharing and collaboration 
among the laboratories in England and UK more generally; the development 
quite early on of the CMGS and John (Old) was our first secretary and Andrew 
(Read) was the first Chair, which brought molecular genetics people together. 
We were aware of the Scottish model, we were aware of the model in the 
Netherlands, there were discussions from a fairly early period, certainly the 
mid-1990s, along the lines of  ‘not everybody can do everything; we need to share.’ 
It’s never been as fundamental as the systems in the Netherlands or in Scotland 
but nonetheless those discussions were successful and were professionally led in 
creating the UK Genetic Testing Network and also in influencing policy and 
the Milburn announcement that has been mentioned. I think this was a brief 
moment in government, where government listened to the professions. The 
people who were around at the time, John Burn, Peter Farndon, Di Donnai, 
and others, acted at a key moment and had the ear of Alan Milburn and that 
led to what has been the foundation, certainly in England of, at that period, a 
relatively well-funded genetics laboratory service. So I would say that in some 
ways that does trace itself back to the Special Medical Development.
harper:  My colleagues will be able to add to this, I think, or correct me, but 
I absolutely agree that the SMD was key to getting a core of the staffing and 
expertise off the ground. It was hugely valuable and the fact that it was this 
grouping of centres, it encouraged interactions. So far as the Netherlands’ 
system of sharing and not duplicating disease diagnostics went, that actually was 
considered in some detail pretty early but there were two, essentially political, 
222 See note 216.
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problems that held it back for a long time. The first was the introduction of 
the ‘internal market’ in the NHS, across the UK actually, by the government of 
the time, so that at the precise time when we were trying to collaborate and do 
things in a complementary fashion, we were being told: ‘No, you must compete 
with each other.’223 So we were having to work against opposition. Then locally 
in Wales, there was an additional factor:  having to some extent survived the 
difficulties of the internal market, just when England was coming out of this 
tricky phase, we had a particularly reactionary Secretary of State, banished from 
Westminster to Wales, who saw it as his aim to disband all centrally funded 
services.224 So we had to fight against that. Essentially, there were a number of 
years when the energies we should have spent improving our patient services 
were quite largely spent fighting to hold on to what we had, against very unwise 
political attitudes. I could be wrong on this and my colleagues may correct me. 
sampson:  Just to add to what Peter’s already said:  certainly the political 
emphasis was on competition and there was a lack of support for centrally 
commissioned services. But in Wales there was only one service and that was 
commissioned through one trust, so we were very dependent on the support of 
the chief executive of that trust and his team.225 At the time of those political 
difficulties, there were also great difficulties at that more local level as funding 
for genetic services was processed through a trust that may have, and did have, 
other priorities. It’s true to say that the funding that should have been coming 
to genetics didn’t; it helped solve financial problems elsewhere. We were fighting 
against problems at a lot of levels at that time.
Middleton-Price:  I want to correct any impression that we might have given that 
we didn’t share samples and patients from the very beginning. For those very 
rare conditions, for which specialist services were offered in different centres, we 
started to send samples around the country in the mid-to-late 1980s. For ICH 
and Great Ormond Street this included the rare immunodeficiencies and other 
rare metabolic conditions. Further to this, I have a question for Rob and others: 
 wasn’t one of the reasons why we were, in England, slower in moving towards 
223 For the ‘internal market’ policy of the NHS reform, see, for example, Best et al. (1994).
224 Rt Hon Mr John Redwood, Secretary of State for Wales from 1993 to 1995; http://www.parliament.uk/
biographies/commons/mr-john-redwood/14 (visited 9 September 2013). 
225 University Hospital of Wales and Llandough Hospital NHS Trust. 
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sharing more common diseases because each centre had a larger population? 
In other words, every centre had sufficient patients and samples to develop 
expertise and provide a full workload.
lazarou:  I was just going to say that the SMD did have an influence because 
it brought the centres together and it created a community of diagnostic labs, 
of scientists working at different stages for different disorders.226 So much so, I 
actually memorized telephone numbers of the different laboratories and if I was 
struggling with a particular thing, I would just pick up the phone and talk to a 
colleague in another centre. John (Old) and Rob (Elles) were very helpful with 
their molecular experience in helping us set up things within our laboratories, 
so it was important.
Bobrow:  I would like to make a comment myself at this stage. I think that 
the people involved in that development did their very best with what was 
happening at the time. The molecular genetics and clinical genetics communities 
in England did their level best to continue delivering a sensible and reasonable 
service. But that SMD, although it was undoubtedly very useful for the centres 
that got the money, actually did very little for moving the thing on over England 
as a whole. There are 30-odd clinical genetics centres delivering patient services: 
 three of them had money and the rest of them actually just got on and did it. 
So absolutely no aspersions on the people in the centres or the people outside 
the centres, but as a policy I think it was a waste of time, just a way of putting 
off an inevitable planning decision. That’s not, of course, what Ian said; that’s 
what I’m saying. 
lister Cheese:  That was precisely the point that I was making:  the SMD monies 
were extremely valuable to the centres that received them because they were able 
to develop but didn’t really establish substantive policy one iota. We had to wait 
nearly 20 years for the White Paper.227
yates:  Two things:  first, I want to address this point of trying to achieve better 
coordination and say that Peter Harper tried very hard in the late 1980s and 
early 1990s to improve coordination of services in England by setting up what 
was called the Joint Medical Genetics Coordinating Committee that brought all 
226 See, for example, ‘Minutes of the meeting of SMD Groups’, 20 September 1989, deposited with the 
records of this meeting at the Wellcome Library, reference GC/253. 
227 Department of Health (2003). 
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the relevant people together with Ian (Lister Cheese) coming along representing 
the Department of Health.228 I was secretary of that committee and I think we 
met in 1988 for the first time and for some years after. It was very frustrating 
because the message that we were getting from the Department of Health was 
that they didn’t want to facilitate any sort of coordination. They wanted to 
see cut-throat competition and, of course, that was exactly what you didn’t 
need because laboratories weren’t going to set up rival services for less common 
diseases with only small numbers of patients. Second, just to look at the effect 
this had on particular diseases, tuberous sclerosis being a particular interest of 
mine; after the two genes had been identified and mutation testing became an 
option, both Cambridge and Cardiff set up services and so there were two labs 
happily sharing the diagnostic workload and that was exactly the model that 
you might want, but the funding for testing then had to come from individual 
budgets and individual genetics services.229 That was not forthcoming in some 
parts of the country and so even though the service existed, it wasn’t being used 
and we recently published a study looking at a large cohort of children with 
tuberous sclerosis diagnosed between 2001 and 2005, and access to genetic 
testing for those families was patchy and the reason was simply that in some 
centres they didn’t have the funds to pay for it.230
Bobrow:  One of the things we haven’t mentioned at all is that there were 
– there still are – some situations in which population screening for monogenic 
disorders using molecular techniques have been either tried or established in 
practice. 
Modell:  Yes. For population screening using molecular techniques in this 
country, the top candidate would be cystic fibrosis and I hope that we might 
have some comments about that. But you’re asking me about the concept of 
population screening for genetic disease, or for genetic risk. It’s very important 
to distinguish in the haemoglobin field, because both types of screening occur. 
228 Professor John Yates wrote: ‘The Committee had representatives from the Association of Clinical 
Cytogeneticists, the Clinical Genetics Society, the Clinical Molecular Genetics Society and the Genetic 
Nurses & Social Workers Association and contributed to the subsequent formation of the British Society 
for Human Genetics.’ Note on draft transcript, 28 March 2013. 
229 For Cardiff ’s service, see, for example, Professor Julian Sampson’s comments in Jones and Tansey (eds) 
(2013), pages 42 and 66–7. Cambridge’s service was, and still is, based at Addenbrooke’s Hospital as part of 
the East Anglian Medical Genetics Service. 
230 Yates et al. (2011). 
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Bobrow:  We’re talking about identifying, not diagnostic screening, but risk 
carrier type screening.
Modell:  Screening for a genetic disease is often seen as genetic screening in 
the world out there. It’s not, it’s case identification. Neonatal screening is 
case identification for management, like screening for non-genetic diseases. 
What we’re talking about here is screening for identifying carriers in order to 
inform them of risk, to allow them to manage their risk. So the paradigm is 
really premarital or antenatal screening for haemoglobin disorders. We now 
have extensive experience and I’m hoping to push the envelope out a little bit 
here because we now have global experience. In this country, when it became 
possible to do prenatal diagnosis for thalassaemia, the local hospitals had some 
very interested haematologists. The person whose name I want to mention is 
George Marsh, consultant haematologist at the North Middlesex Hospital, 
who unfortunately died far too early.231 As soon as prenatal diagnosis became 
possible, he called meetings at his hospital and said: ‘Look, we have the largest 
Cypriot population in London. For years we have been screening all the 
pregnant women to see if they carry thalassaemia in order to distinguish iron 
deficiency from thalassaemia so that we can treat iron deficiency correctly, and 
what have we done when we’ve found thalassaemia? Nothing. We have given 
them no information and I think this is quite wrong.’ So he immediately started 
screening all the pregnant women for fetal thalassaemia and haemoglobin 
disorders and set up a system for informing the carriers, and advising them to 
get their husbands tested. Being Cypriots, the husbands came along at once so 
he picked up the at-risk couples in early pregnancy and referred them to us.232 
That really stretched our prenatal diagnosis service, but it also allowed us to 
collect statistics on uptake. George collected statistics on how many women 
got their partner tested and how many couples came to us, and we counted 
how many asked for prenatal diagnosis and how many terminated when the 
fetus was affected. Together we found that 96 per cent of Cypriot at-risk 
couples asked for prenatal diagnosis and 96 per cent terminated, which was 
really quite convincing information. George was the person who had the vision 
to initiate the population screening in a way that he could manage because it 
was under his control. We could come back at this point to clinical geneticists 
231 See, for example, Wainscoat et al. (1983). 
232 Professor Bernadette Modell wrote: ‘Cypriot and Asian husbands almost all come immediately for 
testing, feel very concerned about the baby, and tend to give the wife priority in decision-making re prenatal 
diagnosis. “It’s her decision. She will be looking after the baby”.’ Note on draft transcript, 9 August 2013. 
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and their family pedigrees, because if you’re a clinician you start off with an 
affected person who is surrounded by a cluster of people at risk. You have some 
control over the situation because you’ve got the patient and can then proceed 
at the specialist level to study the family and identify carriers. But if you want 
to identify carriers of a recessive disorder, you’ve got to get out there to the 
population. You’ve somehow got to find an appropriate point in your service 
for reaching every member of the population, getting them all to go through a 
turnstile where you can test them. That differs in different countries. In Cyprus 
this happened very quickly, because thalassaemia was a priority health problem: 
 one in 144 children born had thalassaemia major and the cost of treatment 
was completely beyond available resources. Today it might be manageable but 
once the patients start surviving, in ten years’ time it would be hopeless. So the 
Ministry of Health introduced premarital screening.233 The way that worked 
was the ministry went to the government and said: ‘Everybody gets married 
here. We could mandate a blood test at that time and we could detect all the 
carriers at a stage when they’ve actually got a choice.’ The archbishop had said 
he thought it was wrong just to do antenatal screening because people then only 
have one choice:  whether or not to terminate. He thought that they should 
be tested earlier so that all the choices were available. So what did the Cypriot 
government say? It said:  ‘No, that to mandate testing would be an invasion of 
people’s human rights.’ So the archbishop said words to the effect of: ‘Right. 
Well if you won’t do it, well we will, because everybody gets married in church, 
practically. We’re going to issue a religious ruling that nobody can get married 
unless they’ve been tested.’ The results of the test are not divulged, all they 
need is a certificate that the couple have been tested and advised accordingly. 
So the Cypriots were first off the mark, and that had an extremely rapid effect 
on the birth rate of thalassaemia major in Cyprus.234 In this country, there 
wasn’t that option because there was no such thing as premarital testing and 
anyway people are getting married less and less, so a premarital test isn’t really 
an option. You have to find some other turnstile. The ideal, of course, is for 
people to be informed early. There’s the possibility of testing in high school and 
233 Professor Bernadette Modell wrote: ‘It was the Ministry of Health that took the initiative with suggesting 
mandatory premarital screening to the parliament. The parliament declined because they considered it 
would infringe human rights. This left the situation that women would have to be offered testing during 
pregnancy.’ Note on draft transcript, 9 August 2013. 
234 Angastiniotis and Hadjiminas (1981). 
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this has been beautifully developed in Canada by Scriver and his co-workers.235 
I think this has been extended in Montreal to carrier testing for cystic fibrosis, 
Tay-Sachs disease and thalassaemia.236 But it’s not a model that has been followed; 
it hasn’t been picked up here because there are just too many problems getting 
everybody to agree, or getting ministers to talk to each other. An alternative is to 
get general practitioners to provide carrier testing in primary care. The problem 
really is that there’s no infrastructure in this country for offering this kind of 
service. It took 20 years from the time that we were able to show, with ample 
scientific evidence, that people wanted and would use the service to the decision 
in 2001 that a national sickle cell and thalassaemia screening programme should 
be set up.237 In frustration, I feel like tearing out my hair and covering myself 
with sack-cloth and ashes. I say to my husband, ‘This is terrible’. My husband 
is a GP, and he says, ‘Well, we know that in general practice, it always takes 20 
years for an approved, tested advance in medicine to get into really universal 
practice.’ So perhaps you shouldn’t be so appalled as you are. But anyway, 
that is this country. Now we have come to the possibility of leapfrogging, not 
technology, but leapfrogging organizations. We are held back organizationally 
by the fact that all these advances have been developed slowly piece by piece by 
our brilliantly talented scientists. When another country decides that it wants 
to implement these services, they can consider the whole pattern and work 
out a way of doing it from scratch. The best example I know is Iran, which 
actually has a genetics office in the Ministry of Health and Medical Education, 
and a very well-organized primary healthcare system. The Iranians recognized 
thalassaemia as a ‘point of entry’ for this kind of technology but as only one 
235 This research concluded that screening interventions for thalassaemia major were more effective in the 
context of high schools versus community clinics, with an average of 116 attendees at schools’ clinics (over 
80 per cent of the school population) versus 28 attendees at the average community clinic. See, for example, 
Scriver et al. (1984). 
236 For Tay-Sachs and thalassaemia screening at high schools in Montreal, see, for example, Mitchell et al. 
(1996). See also Kaplan et al. (1991). 
237 A national antenatal and neonatal screening programme for England and Wales was introduced in 2001 
following the publication of The NHS Plan in July 2000; see Department of Health (2000); page 109. 
See also, the NHS Sickle Cell and Thalassaemia Screening Programme (2011), which notes: ‘During the 
mid-to-late 1980s, national recommendations for sickle cell and thalassaemia began to emerge. … The 
1990s saw a period of heightened lobbying, but despite this and the various recommendations regarding 
screening for sickle cell and thalassaemia, screening was patchy with some areas carrying out universal 
screening and some selective screening.’ Quotations from pages 4 and 6. See also, for example, Anionwu 
and Atkin (2001). 
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part of a comprehensive genetics service, so the country’s infrastructure for 
thalassaemia screening was created as an infrastructure for the entire genetic 
service.238 They realised at an early stage they needed to create a cohort of 
community genetic counsellors, which they’ve done. In fact, they are organizing 
a modern genetics service from scratch, having learnt all the lessons about how 
not to do it that we’re still struggling with here. They’re just one example but 
let’s hope that it will be followed by others. 
Bobrow:  That’s exactly what I wanted you to bring out and I think we should 
add that you, firstly, stuck at that with a few other people for decades and it’s not 
at all clear that it would have happened without a few people who really drove 
it through. Second, without going into details, there are a number of other 
interesting, similar stories. There is an arcane story about Tay-Sachs screening 
and religious Jewish sects in New York, which we don’t have time to go into 
now.239 There is an equally interesting story that Bernadette knows a lot about, 
which was in relation to an early enthusiasm for population carrier screening for 
cystic fibrosis, which was widely touted, hugely advocated and failed basically in 
the face of massive public disinterest. 
Modell:  I’ve been very puzzled by that, because the evidence is that when people 
know they are at risk they use prenatal diagnosis, as far as I remember from 
Rodney Harris’ study on cystic fibrosis.240
Bobrow:  There’s no country in the world that I know of which ever implemented 
CF population screening for carriers.
Modell:  No. My guess is because it was too expensive. If it was as cheap as 
haemoglobinopathy screening, why not? 
skinner:  The MRC held a workshop more years ago than I care to remember 
and myself and several others attended. And, I think, the MRC actually funded a 
suite of studies to look at trying carrier screening in the UK in different settings. 
238 See, for example, Samavat and Modell (2004). 
239 See, for example, for a range of references to this topic, the section on ‘Tay-Sachs Disease and Ashkenazi 
Jewish Uniqueness’ in Brandt-Rauf et al. (2006); in particular page 1980. 
240 In Harris’ study, it was reported: ‘All but one patient (75/76) booking before 14 weeks of pregnancy 
accepted the offer of cystic fibrosis carrier testing. … Overall, 72/75 (99.6%) of patients felt that they had 
made the right decision to have a cystic fibrosis carrier test in early pregnancy. One patient regretted having 
the test.’ See Harris et al. (1996); quotation from page 226. See also Murray et al. (1999). 
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Hilary Harris ran the GP-led service from Rodney’s department in Manchester.241 
Nick Wald did couple screening and David Brock did another form of couples’ 
screening in Edinburgh.242 But at the end of the day we have a thing called the 
UK National Screening Committee (NSC) that was set up in 1996 and carrier 
screening has never flown with the NSC.243 They did agree eventually – I have 
to measure my words here, as a founder member of that committee; they did 
once the Wisconsin study on children with CF showed some improvement, 
clinical improvement shall we say, from early detection and then additional 
dietary measures.244 The NSC did then agree to the implementation of neonatal 
screening for cystic fibrosis in 2001.245 As a result of that, of course, there were 
some carriers detected and that led to a huge discussion then about whether the 
carrier status that was disclosed through neonatal screening should be disclosed 
to the parents. The NSC isn’t really yet, I think it’s fair to say, geared up to look 
at genetic screening issues. It does work looking at prospective new screening 
programmes against a set of criteria that are based on the original Wilson and 
Jungner criteria.246 These criteria have been adapted over time to try to address 
genetic aspects and Neva Haites ran workshops for the NSC to help with this. 
They look at some elements and consider possible genetic screening programmes 
but at the moment it’s not a feature that is at the forefront in the UK. They are 
currently looking at the provision of preconception testing or screening. The 
241 This study was funded by the Wolfson Foundation, rather than the MRC. See, for example, Harris et al. 
(1993).
242 Research on carrier screening was also conducted at the Wolfson Institute of Preventive Medicine, 
St Bartholomew’s Hospital Medical College, London. See, for example, Wald (1991). For research funded 
jointly by the MRC and Cystic Fibrosis Trust, see Brock (1996). 
243 ‘The UK National Screening Committee was founded in 1996 with Sir Kenneth Calman (Chief 
Medical Officer for England 1991–1998) as its first Chairman. … From the outset, the concept of screening 
doing more good than harm and the importance of quality at every step of the screening journey were at the 
heart of the work the UK NSC did.’ The organization developed a framework for screening and subsequent 
screening policies that informed this framework for specific diseases. Quoted from History of the UK NSC; 
http://www.screening.nhs.uk/history (visited 22 July 2013). 
244 See, for example, Farrell et al. (2001). 
245 For a discussion about the introduction of this cystic fibrosis neonatal screening policy and associated 
research see, for example, Parsons et al. (2003). See also Mrs Rosie Barnes’ comments in Christie and Tansey 
(eds) (2004), page 69. 
246 Wilson and Jungner (1968). See also, for example, Petros (2012). 
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NSC did raise this topic with the Human Genetics Commission (HGC)247 just 
before it was wound up and there was a joint working party between the NSC and 
HGC to look at this and see whether there were any legal, social or ethical issues 
involved that would preclude the NSC doing any further work in this area. The 
conclusion was there were not, so they are now looking again at preconception 
testing and making it more available, if it’s acceptable. They are about to fund 
a pilot study. This has all come from the sickle cell and haemoglobinopathy 
screening programme because there’s been huge demand from the populations 
at risk actually to move in this direction.
Bobrow:  I don’t disagree at all with what you have said about the NSC but I 
do, personally, disagree with your assessment of the scientific basis of the public 
enthusiasm for all of those screening programmes. I think they’ve been driven 
very largely by the people who want to screen, rather than the people who would 
need to be screened. There’s a lot of research evidence from years before then 
suggesting that unless you push people into screening, they are fundamentally 
not very interested in it.248 But it isn’t a very good topic to hammer out in this 
forum – on some other occasion perhaps. 
harper:  Very briefly, largely to confirm what you were saying:  Cardiff and the 
region around was one of the centres where there was a pilot project, which my 
colleague Angus Clarke led, of carrier screening. Basically, the broad conclusion 
was that, while it was perfectly acceptable if people were approached in a GP 
surgery by a helpful nurse while giving information, when it was left with them 
to take further action it really wasn’t pursued very far. So it was very much an 
initiative coming from the professionals rather than from the families themselves 
in this case.
Modell:  Where haemoglobinopathy screening is concerned, the initiative has 
come entirely from the professionals. We did not wait for the population as a 
whole to come and say, ‘We want to be screened’. It was our responsibility to 
tell them.
247 The Human Genetics Commission was created in 1999 and abolished in 2012. It was ‘the UK 
Government’s advisory body on new developments in human genetics and how they impact on individual 
lives … with a particular focus on the social, ethical and legal issues.’ Quoted from the organization’s former 
website ‘About HGC’ page; http://webarchive.nationalarchives.gov.uk/20121102204634/http://hgc.gov.
uk/client/content.asp?contentid=5 (visited 24 July 2013). 
248 See, for example, Bekker et al. (1993). 
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Bobrow:  There are two things that I would like to deal with:  first, a brief history 
of the UK Clinical Molecular Genetics Society, which I think is important 
because it sets the professional background to some of this; and second, I’d like 
another few words from somewhere about what in the end ought to be and has 
often been the biggest driver in all of this. We have had very active collaboration 
and pressure from patients and patient organizations, and I’m not sure we’ve 
quite said enough about that yet. First; the CMGS. 
read:  Very briefly, there was a time when the molecular geneticists were a 
relatively small and close-knit band and they had really a fairly different ethos 
from the cytogeneticists, who were the other laboratory band in genetics, and 
clearly we needed to organize and be represented in some way, and one option 
would have been to go in with the cytogeneticists. There were a number of 
reasons why we didn’t do that, some of which were purely personalities, but I 
think there were some real reasons. One:  we were in a very different situation 
from the cytogeneticists. We were a very rapidly developing, very research-based 
service. With honourable exceptions, looking to my left and right [at Professors 
Pat Jacobs and Malcolm Ferguson-Smith], the cytogeneticists were by and large 
entirely focused on delivering an efficient routine service, and seemed to have 
little feel for the great scientific excitement of human genetics at that period. 
We were not like that. The second purely political concern was, since there 
were large numbers of well-established cytogeneticists in senior professional 
positions, if we had thrown in our lot with them we would, of course, have 
been a very small minority. So, for all of those reasons, we opted to set up our 
own organization. 
Bobrow:  Succinct and true.
Macdonald:  I just brought along a few things. I did collate some information for 
our annual conference this year and I brought maybe some quirky bits of data 
and information about what happened. I have the first membership survey that 
was done in 1988; that’s probably three years after the suggestion of having the 
body formed. At that time there were 43 of us in the CMGS. Our ages ranged 
– nobody was above 45 years of age, over half of the people appear to have been 
under 25, with the next bracket probably 35 to 40.249 Interestingly, 38 of the 43 
members had no specialist training in molecular genetics at that time. Two years 
later, Andrew Read was elected Chair of the Society. I have the minutes of that 
249 See Appendix 3, page 96. 
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AGM.250 From that point we’d gone from 43 members to 186, so, very rapidly, 
the profession was expanding. In 1990, there were quite a few other important 
things that happened:  we put together a training board and we started to think 
about our A-grade scientists and our B-grade scientists, so that the 38 out of 43 
who had no specialist training was quickly altered and we brought training in 
as an important feature.251 That training board went from strength to strength 
and eventually we had national trainers and regional trainers, until everything 
changed in the last two or three years with Modernising Medical Careers.252 But 
from 1990, we’d recognized the importance of training. At the same time we 
also started our laboratory directory. Unfortunately I threw out the first two 
editions of that when I moved my office a couple of months ago. I have the third 
edition here, which is a lot more professional than the first two editions, but in 
that we began to list the disorders we all did within our laboratories, a kind of 
early UK Genetic Testing Network. We could see who did what and what level 
of testing was available. And we collected that data from 1989 onwards. The 
other thing we did, around the same time, was to start doing our best practice 
and our quality assurance and the first QA (quality assessment) scheme.253 We 
weren’t very good at putting the dates on things but Roger Mountford instigated 
the quality assurance scheme and we did it for cystic fibrosis where we had to 
type samples for the delta-F508 mutation.254 We did a pilot on DMD RFLP 
typing and we did a prenatal exclusion for Huntington’s disease in the very first 
of the QA schemes. I have a nice collection of the newsletters of the CMGS 
(The Probe), and I have some of the early ones here, including the one, where 
apparently Professor Read was unavailable for comment, that shows a certain 
250 Professor Andrew Read was elected Chairman of the CMGS after Professor Dame Kay Davies 
tendered her resignation in 1990. Minutes for the relevant AGM, 19 April 1990, will be deposited with 
the records of this seminar at the Wellcome Library, London, reference GC/253. 
251 For details of B-grade training see Appendix 3, pages 97–8. 
252 Modernising Medical Careers was a UK Department of Health programme introduced in 2003 to 
address problems with the postgraduate medical training system. See, for example, House of Commons 
Health Committee (2008). 
253 For further details of the Quality Assessment Scheme see Appendix 3, page 99. 
254 Dr Fiona Macdonald wrote: ‘Roger Mountford worked as a clinical scientist in the Manchester Regional 
Genetics service at that time. He sat on the CMGS executive and was responsible for establishing an 
external quality assessment group. He was Chair of the CMGS quality assurance sub-committee from 1993 
to 1994, then Scheme Organiser 1994 to 1997. He moved to the Liverpool lab in Sept 1995.’ Note on draft 
transcript, 6 September 2013. Mr Mountford is Head of Laboratory at Merseyside and Cheshire Regional 
Genetics Laboratory, Liverpool Women’s NHS Foundation Trust. 
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Colin Firth on the front cover in Pride and Prejudice I believe it was.255 So we 
began to put these newsletters together from 1990, the very first one when 
Andrew was Chair.256 These make interesting reading. They go back to explain 
how we could sometimes sort out our Southern blots or what quality problems 
people had in the labs, to some slightly more quirky issues, particularly from 
Lord Genome, who wrote certain articles every edition which weren’t always, 
they were slightly tongue in cheek, shall I say?257 I have some of those newsletters 
here. 
lister Cheese:  We can’t pass without mentioning the Genetics Interest Group 
(GIG), who have been a most responsible and forceful group in representing, 
one might say, everyone who was threatened or burdened by a genetic disorder 
regardless of its commonness or rarity.258 Under its aegis they brought together 
the shared concerns of many individual disease-focused charitable bodies. They 
are a force, a political force, and I think they have influenced very greatly the 
formulation of the policies that we now see.
Bobrow:  They are too numerous to mention, but an awful lot of patient 
organizations, single-disease charities who have worked, pressured and funded, 
some of them funded extensively, a lot of the work that we were talking about 
255 The actor Colin Firth played Mr Darcy in the BBC’s adaptation of Jane Austen’s novel Pride and 
Prejudice, broadcast in 1995. 
256 ‘A Message From Our New Chairman’ by Professor Andrew Read was included in the July 1990 edition 
of The Probe. See Appendix 3, page 95. Copies of some issues of The Probe newsletter will be deposited at 
the Wellcome Library with the records of this seminar, reference GC/253: July 1990; May and December 
1991; June 1993; February, August and December 1994; Autumn 1995 and Summer 1997. The newsletters 
include advertisements for professional training opportunities and career development funding, with reports 
from grant recipients on funded research trips; articles on professional networks’ development, affiliations 
and regulations; NHS policy issues; news of/reports from international conferences; arts and sports events 
listings; humorous cartoon strips; informal news on research and development of laboratory techniques 
from members; notices of the organization’s annual meeting and committee elections, and death notices, 
among other contents. 
257 Lord Genome is a pun on Lord Gnome, the fictitious proprietor of the popular UK news and current 
affairs magazine Private Eye, well known for its satirical humour. See, for example, Hislop (1985). 
258 Dr Ian Lister Cheese wrote: ‘The Genetics Interest Group (GIG), an umbrella organization set up 
to represent the common interests of societies for those threatened or burdened by a genetic disease, was 
formed in 1989. It has become an influential national voice.’ Note on draft transcript, 1 May 2013. ‘GIG 
was inaugurated on 22 April 1989 with the backing of 60 groups. … The first management council held 
its meetings at St Mary’s Hospital, London.’ Quoted from Genetic Interest Group (2006), pages 9–10. 
The Wellcome Trust was a key funding contributor to GIG, which in 2010 became Genetic Alliance UK. 
Clinical Molecular Genetics in the UK c.1975–c.2000
86
over that period of time. So we should note those and it was Bernadette who 
mentioned patients themselves and the pressure they put on for clinical stuff 
and we should just remember that there has been a lot of that, and very welcome 
it is too.259
sampson:  Just in relation to the Genetics Interest Group, I think we really 
should point out specifically Alastair Kent’s leadership role there and that the 
GIG is now the Genetic Alliance [UK], still headed by Alastair.260
Bobrow:  Quite so. It remains for me to thank the speakers; that’s you, and to 
thank our hosts for having me here, because I’ve enjoyed listening to you.
tansey:  It’s been a great privilege to hear all your stories today. I want to thank 
Martin because he has kept you all under control, even though he thought he 
didn’t have to, and he’s done the best job the Chairman does:  he gets us to the 
drinks at six o’clock. So thank you very much indeed Martin. 
259 See page xiii for a list of relevant single-disease charities and patient advocacy groups.
260 Alastair Kent is Director of Genetic Alliance UK, a consortium of more than 150 patient organizations 
representing those who are affected by genetic conditions. See http://www.geneticalliance.org.uk/
teammember_director.htm (visited 24 July 2013). 
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Appendix 1
delegates attending The Molecular Biology of Thalassaemia conference, 
organized by Bob Williamson, kolimbari, Crete, 1978261 
261 Identifications taken from key with original photograph.
delegates attending 
The Molecular Biology of 
Thalassaemia conference, 
organized by Bob Williamson, 
kolimbari, Crete, 1978
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standing
1 Emma Whitelaw
2 Francesco Ramirez
3 Koula Sofroniadou
4 Dina Politis
5 Lionella Camba
6 Yves Beuzard
7 Guglielmina Pepe
8 Michael Jenson
9 Bernadette Modell
10 Wilma Gabutti
11 Antigone Karoulis
12 Michel Goossens
13 Amalia Bosia
14 Michel Cohen-Solal
15 Mirijam Belhani
16 Marco Lucci
17 Roula Lagoyanni
18 Mauritzino Ferrari
19 Sergio Ottolenghi
20 M. Karagiorga-Lagana
21 Francesco Bernardi
22 Barbara Giglioni
23 Bruno Colombo
24 Stella Haralambidou
25 Sylvana Gargano
26 Anna Manitsa
27 Maria-Guilia Farace
28 Aris Antsaklis
29 George Chalavelakis
30 Thomas Zarvalis
31 Jules-Cassius De Linval
32 Francesco Conconi
33 Elizabeth Letsky
34 Nick Proudfoot
35 David Weatherall
36 Art Bank
37 George Maniatis
38 Nicholas Zeikos
seated
1 Douglas Higgs
2 Guy Trabuchet
3 Charles Coutelle
4 Sue Malcolm
5 Minas Hadjiminas
6 Toula Sofocleous
7 Aphrodite Anagnostou-
Loutradi
8 Abdoullah Kutlar
9 Mary Mouzouras
10 Apostolos Voutsadakis
11 Marios Matsakis
12 Mohammed Cherif 
Beldjord
13 Mike Angastiniotis
14 Tzwfia Henni
15 Graham Cowling
16 Anna Metaotou-
Mavrommati
17 Bill Wood
18 Lynn Pressley
19 Beppe Bandini
20 Irene Kontopoulou
21 Josee Pagnier
22 John Christakis
23 Nikos Zoumbos
24 Guiseppe Russo
25 Antonio Cao
26 Gino Schiliro
27 Anna Skalicka
28 Chaido Tsantali
29 Chintana Sirinavin
30 Vassilis Ladis
31 Gulzar Niazi
32 Boyd Webster
33 Gabriel Cividalli
34 Anita Li
35 Alma Marcolongo
36 Vasilios Berdoukas
37 Nick Anagnou
38 Martin Steinberg
39 R. Krishnamoorthy
40 Phillipa Darbre
41 Carla Perotta
42 Chris Ricketts
43 Beppe Saglio
44 Max Herzberg
45 Nica Cappelini
46 Regina Stathopoulou
47 Ray Dalgleish
48 Nicolas Constanzas
49 Willy Sciarratta
50 Cathy Anderson
51 French Anderson
52 Hashemi Nasab
53 Mohsen El-Hazmi
54 Joseph Tam
55 Luciano Vettore
56 Blanche Alter
57 Rich Propper
58 Laura del Senno
59 John Old
60 Bernie Forget
61 Jim Palis
62 Bob Williamson
63 Dimitris Loukopoulos
64 Bessie Aleporou-Marinou
65 Nancy Kunkle
66 Peter Little
67 Y.W. Kan
68 Panos Ioannou
And – Sharma, who is not in 
the photo because he took it.
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Appendix 2
extracts from the laboratory manual of the university of leiden 
postgraduate course in Restriction Fragment Length Polymorphisms and 
Human Genetics, 1982262
262 ‘Outline of Experiments’ is from manual’s introduction, pages 2–3; and, following this, ‘large scale isolation 
of plasmids (Leiden)’ is a sample experimental protocol from the manual, pages 51–2. This manual will be 
available, in full, in the Wellcome Library with the records of this Witness Seminar under reference GC/253.
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Appendix 3
archival material of the Clinical Molecular Genetics society263
263 This appendix includes: title page of the Society’s summer 1990 newsletter (this page); membership 
survey, 1998 (reproduced in part); a letter to members on professional qualifications and training c.1990; 
details of the Quality Assessment Scheme, 1991; and a sample page of the CMGS laboratory directory. 
Copies of The Probe will be deposited with the records of this meeting in the Wellcome Library, under 
reference GC/253. For further details of their contents see note 256.
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Professor egbert (Bert) Bakker 
PhD (b. 1951) studied chemistry 
in Delft (BSc), continuing his 
studies at Leiden University 
(1975–1976) where he was also a 
technician (1977–1989). During 
this period he worked closely 
with Professor Peter Pearson 
and pioneered molecular genetic 
techniques, which led to the first 
prenatal diagnosis of Duchenne 
muscular dystrophy (DMD) in 
1985. In 1989 he completed his 
doctoral research on DMD (Bakker 
(1989)) and, the same year, was 
awarded the Lustrum Prize by the 
Dutch Human Genetics Society. 
In 1990 he became Head of the 
DNA diagnostic section in Leiden 
University’s Clinical Genetics 
Centre and became Associate 
Professor at the Department of 
Human Genetics. In conjunction 
with these roles, he was Head of 
the Forensic DNA-Laboratory 
at Leiden (1994–2000). He was 
appointed Professor of Molecular 
Genetic Diagnosis at Leiden 
University Medical Center, where 
he is now Head of the Laboratory 
for Diagnostic Genome Analysis. 
Professor Martin Bobrow 
CBE FRCP FRCPath FRS 
FMedSci (b. 1938) came to 
Britain after graduating in South 
Africa. He worked in Edinburgh 
and Oxford and held Chairs of 
Medical Genetics in Amsterdam 
and Guy’s Hospital before 
becoming Professor of Medical 
Genetics in Cambridge in 1995. 
He has been on the council of the 
MRC, a governor of the Wellcome 
Trust, National Chairman of the 
Muscular Dystrophy Campaign, 
and Chairman of the Clinical 
Genetics Society. He has also held 
posts as Chairman of COMARE 
(Committee on Radiation in the 
Environment), ULTRA (Unrelated 
Living Transplant Regulating 
Authority), Deputy Chairman of 
the Nuffield Council on Bioethics 
and a member of the Human 
Genetics Advisory Commission.
Professor dame kay davies 
CBE DBE FMedSci FRS  
(b. 1951) studied at Somerville 
College and was Guy Newton 
Junior Research Fellow at Wolfson 
College, Oxford (1976–1978). 
From 1978 to 1980 she was Royal 
Society Postdoctoral Fellow at 
Biographical notes*
* Contributors are asked to supply details; other entries are compiled from conventional 
biographical sources.
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the Service de Biochimie, France, 
returning to the UK to become 
Cystic Fibrosis Research Fellow at 
St Mary’s Hospital Medical School 
(1980–1982). Senior Research 
Fellowships followed at the MRC 
(1982–1984) and, still within the 
MRC but based at the Nuffield 
Department of Clinical Medicine, 
at John Radcliffe Hospital, Oxford. 
She joined Oxford’s Institute of 
Molecular Medicine in 1989, 
remaining there until 1995 in an 
MRC external staff post. Within 
this period, from 1992 to 1994, 
she was also Research Director of 
the MRC Clinical Sciences Centre, 
Hammersmith Hospital. From 
1995 to 1998 she was Professor 
of Genetics at Keble College, 
Oxford. Also at the University of 
Oxford, in 1998 she was elected 
Dr Lee’s Professor of Anatomy. 
The following year she started 
the MRC Functional Genomics 
Unit at Oxford, of which she 
remains Director and leads the 
Neurological Disease Group. This 
group studies the pathogenesis of 
muscular dystrophy, and researches 
its potential treatments, as well as 
neurodegenerative and behavioural 
disorders. From 2008 to 2011 she 
was also Head of the Division of 
Medical Sciences of the University 
of Oxford’s Department of 
Physiology, Anatomy and Genetics, 
of which she is now Associate 
Head. She has conducted research 
into Duchenne muscular dystrophy 
for over 20 years and is currently 
working with colleagues on the 
development of therapies for this 
disorder. In October 2013 she was 
appointed Deputy Chairman of the 
Wellcome Trust.
dr rob elles
FRCPath (b. 1951) worked as a 
research technician at St Mary’s 
London helping to characterize 
probes for X-linked conditions 
from a DNA fragment library. In 
1983 he moved to Manchester 
University, completing a PhD 
while helping to build the 
molecular diagnostics laboratory 
aided by a DoH Special Medical 
Development award. In 2002 his 
laboratory was awarded a DoH 
contract to develop a National 
Genetics Reference Laboratory 
specializing in informatics and 
quality. He was Secretary of the 
Clinical Molecular Genetics Society 
in the 1990s, and was involved in 
training and professional standards 
and many areas of development of 
diagnostic genetics in the UK. In 
1998 he coordinated a European 
Commission research project that 
developed the European Molecular 
Genetics Quality Network. He was 
Co-chair of the expert group that 
developed guidelines for Quality 
Assurance in Molecular Genetic 
Testing adopted by the OECD. As 
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the Chairman of the British Society 
for Human Genetics, he gave 
evidence to the House of Lords 
enquiry on Genomic Medicine 
and contributed to the service 
configuration work-stream  
of the Human Genomics Strategy 
Group that reported in January 
2012. He retired as the Clinical 
Director of Genetic Medicine, 
Manchester, in 2013.
Professor Malcolm Ferguson-smith 
FRCPath FRCP FMedSci FRSE 
FRS (b. 1931) is Emeritus 
Professor of Pathology, University 
of Cambridge, UK. He graduated 
in medicine at Glasgow University 
in 1955 and, while undertaking 
postgraduate training there in 
pathology, was introduced to 
research on sex chromatin under 
Bernard Lennox. An interest in 
Klinefelter’s syndrome in 1957 
to 1958 led to his appointment 
as Fellow in Medicine at Johns 
Hopkins University, Baltimore, in 
1959 where he established the first 
chromosome diagnostic service in 
the USA and undertook cytogenetic 
research into Turner syndrome. 
Returning to Glasgow University 
in late 1961, he was appointed 
successively Lecturer, Senior 
Lecturer, Reader and Director of 
the West of Scotland Regional 
Genetics Service before becoming 
Burton Professor of Medical 
Genetics in 1973. In 1987 he was 
appointed Professor and Head of 
Pathology at Cambridge University 
and Director of the East Anglia 
Regional Genetics Service. Research 
interests include molecular 
cytogenetics, karyotype evolution, 
vertebrate sex determination and 
comparative genomics. In 1998, 
he moved to the Department of 
Veterinary Medicine to establish 
the Cambridge Resource Centre 
for Comparative Genomics. He is 
joint author of Essential Medical 
Genetics (See Tobias E, Connor M, 
Ferguson-Smith M. (2011)).
Professor Peter harper
Kt FRCP (b. 1939) graduated 
from Oxford University in 1961, 
qualifying in medicine in 1964. 
After a series of clinical posts, he 
trained in medical genetics at the 
Liverpool Institute for Medical 
Genetics under Cyril Clarke and 
at Johns Hopkins University, 
Baltimore, under Victor McKusick. 
He was Professor of Medical 
Genetics at the University of Wales’ 
College of Medicine, Cardiff, from 
1971 until his retirement in 2004, 
when he was appointed University 
Research Professor in Human 
Genetics, Cardiff University 
(Emeritus since 2008). As a policy 
adviser for the Chief Medical 
Officer, in 1996 he authored the 
government report Genetics and 
Cancer Services, more commonly 
known as ‘The Harper Report’. 
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He served on the UK’s Human 
Genetics Commission from 2000 
to 2004 and from 2004 to 2010 
with the Nuffield Council on 
Bioethics. He has been closely 
involved with the identification of 
the genes underlying Huntington’s 
disease and muscular dystrophies, 
and with their application to 
predictive genetic testing. He 
has also been responsible for the 
development of a general medical 
genetics service for Wales. His 
books include Practical Genetic 
Counselling (Harper (1981)), 
Landmarks in Medical Genetics 
(Harper (2004)), First Years of 
Human Chromosomes (Harper 
(2006)) and A Short History of 
Medical Genetics (Harper (2008)). 
For the past decade he has led 
an initiative, supported by the 
Wellcome Trust, to preserve 
and document the history of 
human and medical genetics 
(http://www.genmedhist.org; 
visited 8 November 2013). He 
is a consultant to the ‘Makers of 
Modern Biomedicine’ project 
for the History of Modern 
Biomedicine Research Group, 
Queen Mary, University of 
London. 
Professor rodney harris
CBE FRCP FRCPath (b. 1932) 
is Emeritus Professor of Medical 
Genetics at the University of 
Manchester, having been Professor 
of Medical Genetics from 1980 
to 1997. From 1982 to 1989 
he was Consultant Adviser in 
Medical Genetics to the Chief 
Medical Officer at the Department 
of Health. He was Chairman of 
the UK National Confidential 
Inquiry into Genetic Counselling 
from 1986 to 1990, Chairman of 
the Royal College of Physicians’ 
(London) Committee on Clinical 
Genetics and subsequently 
Chairman of the EU concerted 
Action on Genetic Services in 
Europe. He was also Coordinator 
of the EU-funded GenEd measure 
based at Manchester.
Professor Patricia Jacobs 
DSc FRS FRSE (b. 1934) 
graduated from St Andrews 
University with a BSc in Zoology 
in 1956. She spent a year in the 
USA as a graduate assistant, then 
returned as Scientist in the MRC 
Clinical Effects of Radiation 
Research Unit in Edinburgh. Her 
entire scientific life has been spent 
as a cytogeneticist, with a special 
interest in the epidemiology of 
human chromosome abnormalities, 
firstly under the mentorship of 
Professor Michael Court Brown 
and, from 1972 to 1985, in the 
University of Hawaii Medical 
School with her husband Professor 
Newton Morton. In Hawaii, her 
major interests were in mental 
retardation, with emphasis on 
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Fragile X, and the cytogenetic 
abnormalities associated with 
pregnancy loss. From 1985 to 
1987 she was Professor in the 
Department of Paediatrics at 
Cornell University Medical College 
in New York City. In 1988 she 
returned to the UK where she was 
Director of the Wessex Regional 
Genetics Laboratory in Salisbury 
until her retirement in 2001. From 
1988 she has been Professor of 
Human Genetics at the University 
of Southampton Medical School 
where she continues her interest 
in the epidemiology of human 
chromosome abnormalities.
Professor yuet Wai kan
FRCP FRS (b. 1936) was Associate 
Professor of Pediatrics at Harvard 
Medical School from 1970 to 1972 
and was Associate Professor of 
Medicine in the Departments of 
Medicine and Laboratory Medicine 
at the University of California, 
San Francisco from 1972 to 1977. 
Since 1977 he has been Professor of 
Laboratory Medicine and Medicine 
at the University of California.
Mr lazarus lazarou 
BSc DipRCPath (b. 1962) 
graduated from University College 
Cardiff in 1984 with a degree in 
Biochemistry. On graduating, 
he took up a research technician 
position in the Medical Genetics 
Department at the Welsh National 
School of Medicine, to set up 
a DNA bank and to map the 
adult polycystic kidney disease 
(ADPKD) gene. In 1987 he 
became Scientific Officer for 
the newly formed Molecular 
Genetics Diagnostic Laboratory 
at the University Hospital of 
Wales, where he remains. He has 
had interests in and published 
work on inherited conditions, in 
particular ADPKD and autosomal 
recessive polycystic kidney disease, 
Huntington’s disease, myotonic 
muscular dystrophy, cystic fibrosis, 
Fragile X syndrome (A, E and F), 
X-linked hypohidrotic ectodermal 
dysplasia, myotubular myopathy, 
Rett and Rett-like syndromes, 
lissencephaly and, more recently, 
has been involved with the delivery 
of stratified medicine analysis in 
lung, colorectal, skin and gastric 
cancer. In 1998 he became a 
diplomate of the Royal College of 
Pathologists and has served on the 
executive committee of the Clinical 
Molecular Genetics Society  
(1998–2001, 2007–2008).
dr ian lister Cheese
PhD FRCP FRCPH (b. 1936) 
read natural sciences followed by 
training in research (Professor 
W T J Morgan) and qualified in 
medicine in 1966 at Cambridge  
& St Thomas’s. He was a Medical 
Registrar at Radcliffe Infirmary, 
Oxford and then joined general 
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practice in Wantage, Oxfordshire. 
He was also a tutor in general 
practice, a trainer in a vocational 
training scheme, and served in 
NHS management in Oxfordshire. 
In 1984 he entered the senior civil 
service with appointments in the 
Department of Health and the 
Department of Education, in posts 
that included responsibilities for 
the fitness of teachers, hospital 
services for children and genetics 
services. He has been Secretary 
of both the Standing Medical 
Advisory Committee and the Gene 
Therapy Advisory Committee. He 
also served on the Royal College 
of Physicians’ Clinical Genetics 
Committee. Following notional 
retirement in 1996, he served as 
adviser to the DoH on matters 
relating to clinical governance and 
the working of the Abortion Act. 
He has undertaken policy work 
for the Royal College of Physicians 
and the Academy of Medical Royal 
Colleges, and served as a member 
of the editorial board that prepared 
the new Paediatric Formulary, and 
as a trustee to voluntary bodies 
concerned with the support of 
disabled children and their families.
dr Fiona Macdonald 
PhD (b. 1954) graduated from 
Edinburgh University and 
completed a PhD at Leicester 
University. After spending some 
time working in the Department of 
Surgery at Birmingham University 
on gastro-intestinal cancers 
she was appointed to head the 
Molecular Genetics Section of the 
Regional Genetics Laboratory at 
Birmingham Heartlands Hospital, 
establishing a service for inherited 
colorectal cancer as a priority. In 
1997, the two genetics laboratories 
in Birmingham merged on a single 
site and she headed the Molecular 
Genetics Laboratory within the 
merged lab. Her research interests 
are inherited cancer syndromes, 
development of molecular 
genetics-based methods for rapid 
prenatal diagnosis and translation 
of service for rare autosomal 
recessive conditions into the 
diagnostic services.
Professor sue Malcolm 
PhD FRCPath was educated at 
Somerville College, University 
of Oxford, and at the Beatson 
Institute, University of Glasgow. 
Since 2002, she has been Emerita 
Professor of Molecular Genetics 
at the Institute of Child Health, 
University College London. She is 
also faculty member of the Faculty 
of 1000 Ltd. Her blog Me and My 
Genes takes a ‘light-hearted look at 
how genes rule your life’ and can 
be viewed at http://blogs.ucl.ac.uk/
clinical-molecular-genetics/ (visited 
29 May 2013). 
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dr linda Meredith
PhD DipRCPath (b. 1955) studied 
at Cardiff University, graduating 
with a doctorate in biochemistry. 
She was a Scientific Officer at 
Cardiff University’s College of 
Medicine from 1980 to 1985, 
during which time she collaborated 
with the research team at St Mary’s 
Hospital (London) that localized 
the gene for Duchenne muscular 
dystrophy, and worked within the 
team that localized and cloned 
the gene for myotonic muscular 
dystrophy. From 1985 to 1988 
she was a Senior Scientific Officer 
at the All Wales Medical Genetics 
Service (AWMGS), where she 
piloted a molecular diagnostic 
service for Wales. She was Head of 
the molecular diagnostic section 
of the AWMGS from 1987 to 
2000, where she now works part-
time as Clinical Scientist and leads 
staff training and professional 
development programmes. 
dr helen Middleton-Price 
PhD FRCPath (b. 1955) graduated 
with a BA in psychology from the 
University of Durham in 1976 
and a BSc in biochemistry from 
the University of London in 1982. 
Following postgraduate research in 
neurochemistry at the Karl Marx 
Universität, Leipzig and at the 
Institute of Neurology, University of 
London, she embarked on her PhD 
in human genetics in 1985 at the 
Institute of Child Health (ICH), 
University of London. In 1989 she 
transferred to lead the Regional 
Clinical Molecular Genetics 
Laboratory at ICH/Great Ormond 
Street Hospital for Sick Children, 
with overall responsibility for the 
delivery of the laboratory service, 
and gained her MRCPath in 1994. 
In 1996 Helen joined the Science 
Museum in London as Biomedical 
Science Adviser in Genetics for the 
new Wellcome Wing exhibitions, 
which opened in June 2000. In 
2003 she was awarded FRCPath 
and in the same year she became 
Director of Nowgen, a centre of 
excellence in biomedical public 
engagement, patient-centred 
research, second-level education 
and professional training. Recently, 
Helen has collaborated with artists 
on projects relating to modern 
genetics, including with Tempered 
Body Dance Theatre on the 
production ‘It goes here now’.
Professor Bernadette Modell
PhD FRCP FRCOG (b. 1935) 
undertook her first degree in 
zoology, predominantly in genetics 
and embryology, Oxford, 1955; 
followed by her doctoral research in 
developmental biology, Cambridge, 
1959. She qualified in medicine 
at Cambridge and University 
College Hospital in 1964, aiming 
to investigate the application of 
genetic knowledge in medical 
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practice. She subsequently worked 
at University College London 
and University College London 
Hospitals until her retirement in 
2000, where her work focused on 
thalassaemia as an example of a 
common genetic disorder. She was 
involved in developing effective 
treatment for thalassaemia major 
and prevention of the disease 
through community information; 
population screening and genetic 
counselling; and methods for 
prenatal diagnosis – including 
the first trimester diagnosis by 
chorionic villus sampling and DNA 
analysis. In collaboration with the 
WHO she has helped to extend 
programmes for the treatment 
and prevention of haemoglobin 
disorders to many parts of the 
world. She is currently Emeritus 
Professor of Community Genetics 
at the UCL Centre for Health 
Informatics and Multiprofessional 
Education, where she works on the 
global epidemiology of congenital 
disorders, and developing 
informatics approaches to the 
provision of genetic information for 
communities. She is also Director 
of the WHO Collaborating 
Centre for Community Control of 
Hereditary Disorders.
dr John old
FRCPath (b. 1949) graduated 
from Liverpool University in 
1971 (BSc) and in 1974 with a 
PhD in biochemistry. He was a 
postdoctoral research scientist in 
Professor Sir David Weatherall’s 
laboratory at the Radcliffe 
Infirmary and the John Radcliffe 
Hospital in Oxford from 1974 
to 1981. He was then employed 
as a Clinical Scientist to run 
the newly established National 
Haemoglobinopathy Reference 
Service until his retirement 
in 2012. He is an Honorary 
Reader in Haematology, Oxford 
University. His research activities 
focused on the molecular basis 
of the haemoglobinopathies and 
the development of molecular 
diagnostic techniques for 
the detection and prenatal 
diagnosis of the thalassaemias 
and abnormal haemoglobins. 
He has collaborated with many 
international thalassaemia 
laboratories on identifying 
the mutations underlying the 
haemoglobinopathies, and helped 
to establish molecular diagnostic 
programmes for the prevention of 
thalassaemia in Cyprus and India. 
He has been actively involved with 
the development of the profession 
of clinical molecular genetics, 
helping with the establishment of 
the CMGS, the development of 
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examinations for membership of 
the Royal College of Pathologists, 
and the establishment of state 
registration for clinical molecular 
geneticists.
Professor Marcus Pembrey 
MD FRCP FRCPCH FRCOG 
FMedSci (b. 1943) trained in 
medical genetics in Liverpool 
(1969–1971) and Guy’s Hospital, 
London (1973–1978). In 1979 he 
moved to the Institute of Child 
Health, London, as Head of the 
Mothercare Unit of Paediatric 
Genetics, where he led a team 
that helped to introduce DNA 
testing into clinical genetics 
in the 1980s. He was also 
Consultant Clinical Geneticist at 
the Hospital for Sick Children, 
Great Ormond Street, London 
(1979–1998) and Consultant 
Adviser in Genetics to the Chief 
Medical Officer, Department of 
Health (1989–1998). He led the 
genetic component of the Avon 
Longitudinal Study of Parents 
and Children (ALSPAC) from 
1988. After early retirement from 
the ICH in 1998, he continued 
as Director of Genetics within 
ALSPAC, University of Bristol, 
until 2006. He continues to be 
Visiting Professor at the University 
of Bristol. He is the founding 
and current Chair of the Progress 
Educational Trust; publisher of 
BioNews (http://www.bionews.org.
uk/home; visited 12 December 
2013). 
Professor andrew read 
PhD FRCPath FMedSci  
(b. 1939) trained at Cambridge 
University as an organic chemist. 
After postdoctoral positions in 
the Max-Planck Institute for 
Medical Research, Heidelberg and 
University of Warwick he moved 
to Manchester University in 1967 
and joined the Medical Genetics 
Department there in 1977. Initially 
he worked on neural tube defects 
(NTD), including the vitamin 
trials that first showed vitamin 
supplementation could greatly 
reduce the incidence of NTDs, 
and on various computer projects. 
In 1982 he set up the molecular 
laboratory and spent many of 
the following years establishing 
molecular genetic services. He 
was Chairman of the CMGS and 
Founder Chairman of the British 
Society for Human Genetics. His 
research focused on mapping and 
identifying disease genes, especially 
for hereditary deafness.
Professor Julian sampson
DM FRCP FMedSci (b. 1959) 
is Clinical Professor of Medical 
Genetics and Head of the Institute 
of Medical Genetics at Cardiff 
University and the University 
Hospital of Wales. He graduated 
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in medicine from Nottingham 
University (1982) and trained in 
Medical Genetics at the Duncan 
Guthrie Institute, Glasgow with 
Professor Malcolm Ferguson-Smith  
and at the Institute of Medical 
Genetics, Cardiff, with Professor 
Peter Harper. His research interests 
in tuberous sclerosis have ranged 
from gene identification to clinical 
trials, and in colorectal cancer 
have included identification 
and characterization of a novel 
autosomal recessive form of 
polyposis colorectal cancer, 
MUTYH-associated polyposis 
(MAP).
dr rosalind skinner
MD FRCPE FFPH (b. 1946) 
qualified in medicine at the 
London Hospital Medical School 
in 1969. After a series of clinical 
posts in England, she went to the 
University Department of Human 
Genetics in Edinburgh to train 
in genetics with Alan Emery. As a 
member of the clinical academic 
staff of the department, she played 
a full role in the clinical genetics 
service and its neuromuscular 
genetics research activities until 
1983. After leaving the University, 
she retrained in Public Health 
and in 1988 joined the Scottish 
Health Department where she 
remained until her retirement in 
2010. During this time, she played 
a lead role in the creation and 
implementation of genetics policy 
and the development of NHS 
genetics services in Scotland. 
Professor sir edwin southern
Kt PhD FRS (b. 1938) was 
awarded his PhD from the 
Department of Chemistry, 
University of Glasgow in 1962. 
From 1963 to 1967 he was a 
Research Assistant at the ARC Low 
Temperature Research Station in 
Cambridge. Returning to Scotland, 
he was a Research Assistant at the 
MRC Mammalian Genome Unit 
in Edinburgh (1967–1980). He 
became Director of the MRC unit 
(1980–1985) and during this time 
he was also Deputy Director of the 
MRC’s Clinical and Population 
Cytogenetics Unit, where he 
pioneered human genome mapping 
with molecular methods. From 
1985 to 1991 he was Whitley 
Professor of Biochemistry at 
Oxford, Director of the CRC 
Chromosome Molecular Biology 
Research Group and Head of the 
Department of Biochemistry, now 
Emeritus Professor.
Professor tilli tansey
OBE PhD PhD DSc HonFRCP 
FMedSci (b. 1953) graduated in 
zoology from the University of 
Sheffield in 1974, and obtained her 
PhD in Octopus neurochemistry 
in 1978. She worked as a 
neuroscientist in the Stazione 
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Zoologica Naples, the Marine 
Laboratory in Plymouth, the MRC 
Brain Metabolism Unit, Edinburgh, 
and was a Multiple Sclerosis Society 
Research Fellow at St Thomas’ 
Hospital, London (1983–1986). 
After a short sabbatical break at 
the Wellcome Institute for the 
History of Medicine (WIHM), 
she took a second PhD in medical 
history on the career of Sir Henry 
Dale, and became a member of the 
academic staff of the WIHM, later 
the Wellcome Trust Centre for the 
History of Medicine at UCL. She 
became Professor of the History 
of Modern Medical Sciences 
at UCL in 2007 and moved to 
Queen Mary, University of London 
(QMUL), with the same title, in 
2010. With the late Sir Christopher 
Booth she created the History 
of Twentieth Century Medicine 
Group in the early 1990s, now the 
History of Modern Biomedicine 
Research Group at QMUL. 
Professor sir david Weatherall 
MD FRCP FRS FMedSci (b. 1933) 
qualified in medicine at Liverpool 
University in 1956 and, following 
periods in Liverpool, Baltimore 
and Oxford, became Emeritus 
Regius Professor of Medicine, 
University of Oxford in September 
2000 upon retirement. His major 
research contributions have been 
in the elucidation of the clinical 
and molecular basis and population 
genetics of the thalassaemias and 
the application of this information 
for the control and prevention 
of these diseases in developing 
countries. In 1989 he founded the 
Institute of Molecular Medicine 
in Oxford, which now bears his 
name. He has received a number of 
national and international awards 
and is an overseas member of the 
National Academy of Sciences, 
USA.
Professor robert (Bob) 
Williamson 
AO FRCP FRCPath FRS FMedSci 
(b. 1938) was awarded his PhD 
from University College London 
in 1963. From then until 1967 he 
was a lecturer at the University of 
Glasgow, then Senior Scientist in 
molecular biology at the Beatson 
Institute for Cancer Research, 
Glasgow (1967–1976). He 
became Professor of Molecular 
Genetics and Biochemistry at St 
Mary’s Hospital Medical School, 
University of London (1976–1995). 
From 1976 to 1991 he was also 
a member of the UK Genetic 
Manipulation Advice Committee. 
In 1995 he moved to Melbourne, 
Australia, to become Director 
of the Murdoch Institute and 
Professor of Medical Genetics at the 
University of Melbourne, until his 
retirement in 2004. He is Honorary 
Professor of Medical Genetics at the 
Murdoch Institute. Williamson’s 
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research has been instrumental in 
the identification and cloning of 
the genes for thalassaemia, cystic 
fibrosis, craniofacial abnormalities, 
heart disease and Alzheimer’s 
disease. 
Professor John yates
FRCP (b. 1948) graduated 
with a degree in physics from 
Oxford University in 1970 and 
subsequently studied medicine 
at University College Hospital, 
London, qualifying in 1977. He 
trained in paediatrics and then 
in medical genetics, initially in 
Edinburgh with Alan Emery and 
then in Glasgow with Malcolm 
Ferguson-Smith. He moved to an 
academic post at the University 
of Cambridge in 1987 where 
he subsequently became Reader 
(2001) and then Professor of 
Medical Genetics (2003). He 
was an Honorary Consultant 
at Addenbrooke’s Hospital, 
Cambridge and, for many years, 
was Clinical Director of the 
East Anglian Regional Genetics 
Service. His research has focused 
on the identification of human 
disease genes and their molecular 
pathology. He contributed to the 
mapping of the X chromosome 
and has carried out extensive 
genetic studies of the hereditary 
diseases X-linked ichthyosis (steroid 
sulphatase deficiency); retinoschisis; 
Emery-Dreifuss muscular 
dystrophy; Stickler syndrome, 
and tuberous sclerosis. He has 
also worked on the identification 
of genetic factors predisposing to 
age-related macular degeneration 
(AMD), the commonest 
cause of blindness in Western 
populations. Since his retirement 
from Cambridge in 2008 he has 
continued working on AMD at 
the Institute of Ophthalmology 
and is an Honorary Professor at 
University College London. 
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